Attached files

file filename
8-K - 8-K - ENDOLOGIX INC /DE/d372800d8k.htm
EX-10.13 - EX-10.13 - ENDOLOGIX INC /DE/d372800dex1013.htm
EX-10.12 - EX-10.12 - ENDOLOGIX INC /DE/d372800dex1012.htm
EX-10.11 - EX-10.11 - ENDOLOGIX INC /DE/d372800dex1011.htm
EX-10.10 - EX-10.10 - ENDOLOGIX INC /DE/d372800dex1010.htm
EX-10.9 - EX-10.9 - ENDOLOGIX INC /DE/d372800dex109.htm
EX-10.8 - EX-10.8 - ENDOLOGIX INC /DE/d372800dex108.htm
EX-10.7 - EX-10.7 - ENDOLOGIX INC /DE/d372800dex107.htm
EX-10.6 - EX-10.6 - ENDOLOGIX INC /DE/d372800dex106.htm
EX-10.5 - EX-10.5 - ENDOLOGIX INC /DE/d372800dex105.htm
EX-10.3 - EX-10.3 - ENDOLOGIX INC /DE/d372800dex103.htm
EX-10.2 - EX-10.2 - ENDOLOGIX INC /DE/d372800dex102.htm
EX-10.1 - EX-10.1 - ENDOLOGIX INC /DE/d372800dex101.htm
EX-4.11 - EX-4.11 - ENDOLOGIX INC /DE/d372800dex411.htm
EX-4.10 - EX-4.10 - ENDOLOGIX INC /DE/d372800dex410.htm
EX-4.9 - EX-4.9 - ENDOLOGIX INC /DE/d372800dex49.htm
EX-4.8 - EX-4.8 - ENDOLOGIX INC /DE/d372800dex48.htm
EX-4.7 - EX-4.7 - ENDOLOGIX INC /DE/d372800dex47.htm
EX-4.6 - EX-4.6 - ENDOLOGIX INC /DE/d372800dex46.htm
EX-4.5 - EX-4.5 - ENDOLOGIX INC /DE/d372800dex45.htm
EX-4.4 - EX-4.4 - ENDOLOGIX INC /DE/d372800dex44.htm
EX-4.3 - EX-4.3 - ENDOLOGIX INC /DE/d372800dex43.htm
EX-4.2 - EX-4.2 - ENDOLOGIX INC /DE/d372800dex42.htm
EX-4.1 - EX-4.1 - ENDOLOGIX INC /DE/d372800dex41.htm

Exhibit 10.4

AMENDED AND RESTATED

GUARANTY AND SECURITY AGREEMENT

dated as of August 9, 2018

by and among

Endologix, Inc.,

as Borrower,

the other Grantors and Guarantors party hereto from time to time

and

Deerfield Private Design Fund IV, L.P.,

as agent for itself and the other Secured Parties


AMENDED AND RESTATED

GUARANTY AND SECURITY AGREEMENT

This AMENDED AND RESTATED GUARANTY AND SECURITY AGREEMENT (this “Agreement”), dated as of August 9, 2018, by and among Endologix, Inc., a Delaware corporation (“Borrower”), CVD/RMS Acquisition Corp., a Delaware corporation (“CVD”), Nellix, Inc., a Delaware corporation (“Nellix”), TriVascular Technologies, Inc., a Delaware corporation (“TriVascular Technologies”), TriVascular, Inc., a California corporation (“TriVascular California”), Endologix Canada, LLC, a Delaware limited liability company (f/k/a TriVascular Canada, LLC) (“Endologix Canada”), TriVascular Sales LLC, a Texas limited liability company (“Sales”), RMS/Endologix Sideways Merger Corp., a Delaware corporation (“Sideways”), each other Person who becomes a party hereto pursuant to Section 8.15 (together with the Borrower, CVD, Nellix, TriVascular Technologies, TriVascular California, Endologix Canada, Sales and Sideways, the “Grantors” and each, a “Grantor”), each other Person signatory hereto as a “Guarantor” (as defined below) and Deerfield Private Design Fund IV, L.P., as Agent.

RECITALS

A. Borrower, CVD, Nellix, TriVascular Technologies, TriVascular California and Sales previously entered into a certain Guaranty and Security Agreement dated April 3, 2017 (as amended, restated, supplemented and otherwise modified from time to time prior to the effectiveness of the Facility Agreement (defined below) (including by that certain Joinder to Guaranty and Security Agreement, Facility Agreement and Intercreditor Agreement, dated as of May 18, 2017, by and among Sales, Sideways and Agent (the “Joinder”)), the “Existing Guaranty and Security Agreement”). Pursuant to the Existing Guaranty and Security Agreement and the Joinder, Borrower, the other Grantors and the other Guarantors, among other things, previously (i) agreed to jointly and severally guaranty the Guaranteed Obligations (as defined therein) and (ii) pledged and granted unto Agent, for the benefit of the Secured Parties, security interests and liens in the collateral described therein, in order to secure the Secured Obligations (as defined therein).

B. The Existing Guaranty and Security Agreement and the Joinder were entered into in connection with the Prior Facility Agreement (as defined in the Facility Agreement). The Prior Facility Agreement, among other things and in addition to the other Loan Documents (as defined in the Prior Facility Agreement, such documents are referred to herein as the “Existing Loan Documents”), prior to the time of the effectiveness of the Facility Agreement, evidences and governs certain Loans and Obligations (as both such terms are defined in the Prior Facility Agreement).

C. Borrower, the other Loan Parties, the Agent and the Lenders have agreed to certain amendments, restatements, amendments and restatements, supplements and other modifications to the terms of the Existing Loan Documents, and in connection therewith such Persons have amended and restated the Prior Facility Agreement in its entirety pursuant to the terms of the Facility Agreement.

D. Each Grantor will (a) derive substantial direct and indirect benefits from (i) the making of the extensions of credit under the Facility Agreement, (ii) the Agent and the Lenders permitting the Grantors party thereto to enter into the ABL Credit Facility and ABL Debt Documents on the terms and conditions set forth in the Facility Agreement and other Loan Documents and (iii) the amendments, restatements, amendments and restatements, supplements and modifications to the Existing Loan Documents and (b) continue to derive substantial direct and indirect benefits from any prior making of extensions of credit under the Prior Facility Agreement (which continue as Loans and Obligations under the Facility Agreement and the other Loan Documents).


E. As a further condition to the Agent and the Lenders agreeing to the amendments, restatements, amendments and restatements, supplements and modifications to the Existing Loan Documents, and continuing to extend the Loans and other Obligations under the Existing Loan Documents, as amended, restated, amended and restated, supplemented and otherwise modified pursuant to the Loan Documents, the Agent and Lenders are requiring that the parties hereto enter into this Agreement, and thereby amend and restate the Existing Guaranty and Security Agreement in its entirety as set forth herein.

F. In consideration of the premises and to induce the Lenders and Agent to enter into the Facility Agreement and the Loan Documents (including the amendment, restatements, amendments and restatements, supplements and modifications to the Existing Loan Documents) and to permit the Grantors party thereto to enter into the ABL Credit Facility and ABL Debt Documents on the terms and conditions set forth in the Facility Agreement and other Loan Documents and to induce the Lenders to continue to allow their respective extensions of credit and Loans to Borrower under the Facility Agreement to remain outstanding and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto do hereby amend and restate the Existing Guaranty and Security Agreement in its entirety as set forth herein, and hereby covenant and agree, as follows:

SECTION 1 DEFINITIONS.

1.1 Unless otherwise defined herein, terms defined in the Facility Agreement and used herein shall have the meanings given to them in the Facility Agreement, and the following terms are used herein as defined in the UCC (such meanings to be equally applicable to both the singular and plural forms of the terms defined): “accounts”, “certificated security”, “chattel paper”, “commercial tort claims”, “commodity contract”, “deposit accounts”, “documents”, “electronic chattel paper”, “equipment”, “farm products”, “fixture”, “general intangibles”, “goods”, “health care insurance receivables”, “instruments”, “inventory”, “leases”, “letter-of-credit rights”, “money”, “payment intangibles”, “product”, “record”, “securities account”, “security”, “supporting obligations”, and “tangible chattel paper”. It is hereby agreed that the term “instrument” shall not include checks received in the ordinary course of business.

1.2 Whenever used in this Agreement, the Exhibits or the Schedules attached hereto, unless the context otherwise requires, the following terms have the following meanings:

Agreement” has the meaning set forth in the preamble of this Agreement.

Collateral” means all of Grantors’ assets, whether now owned or hereafter created, acquired or arising, including without limitation, all of Grantors’ right, title and interest in and to the following:

(a) all goods, accounts (including health care insurance receivables), equipment, inventory, contract rights or rights to payment of money, leases, license agreements and other licenses, franchise agreements, general intangibles, commercial tort claims (including any Identified Claims), documents, instruments (including any promissory notes) (and any distribution of property made on, in respect of or in exchange for such instruments from time to time), chattel paper (whether tangible chattel paper or electronic), cash, Cash Equivalents, deposit accounts, Intellectual Property, Intellectual Property Licenses, securities accounts, fixtures, letter-of-credit rights (whether or not the letter of credit is evidenced by a writing), securities, all other Pledged Collateral and Pledged Investment Property (including any distribution of property made on, in respect of or in exchange for such Pledged Collateral and/or Pledged Investment Property from time to time) and all supporting obligations related to any of the foregoing, and financial assets, wherever located;

 

2


(b) all books and records relating to any of the foregoing;

(c) all property of any Grantor held by any Secured Party, including all property of every description, in the custody of or in transit to such Secured Party for any purpose, including safekeeping, collection or pledge, for the account of such Grantor or as to which such Grantor may have any right or power, including but not limited to cash; and

(d) any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, Proceeds and insurance Proceeds of any or all of the foregoing.

Where the context requires, terms relating to the Collateral or any part thereof, when used in relation to a Grantor, shall refer to such Grantor’s Collateral or the relevant part thereof. Notwithstanding the foregoing, “Collateral” shall not include Excluded Property; provided, however, that if and when any assets cease to be Excluded Property, the term “Collateral” shall include such assets and a Lien on and security interest in such assets shall be deemed granted therein pursuant to Section 3.1 hereof.

Copyrights” means any and all rights in any works of authorship, including (A) copyrights and moral rights, (B) copyright registrations and recordings thereof and all applications in connection therewith including those listed on Schedule 8, (C) income, license fees, royalties, damages, and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past, present, or future infringements thereof, (D) the right to sue for past, present, and future infringements thereof, and (E) all of each Grantor’s rights corresponding thereto throughout the world.

Facility Agreement” means the Amended and Restated Facility Agreement of even date herewith by and among Borrower, the other Loan Parties party thereto from time to time, Agent and Lenders, as amended, supplemented, restated or otherwise modified from time to time.

Fraudulent Transfer Laws” has the meaning set forth in Section 2.6 hereof.

Grantor” has the meaning set forth in the preamble of this Agreement.

Guaranteed Obligations” means all obligations of each Guarantor under the Loan Documents and all other Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment).

Guarantors” means Borrower, CVD, Nellix, TriVascular Technologies, TriVascular, Endologix Canada, Sales, Sideways and any other Person who becomes a party to this Agreement pursuant to Section 8.15.

Identified Claims” means the commercial tort claims described on Schedule 5, as such schedule shall be supplemented from time to time in accordance with the terms and conditions of this Agreement.

Intellectual Property License” means, with respect to any Grantor (the “Specified Party”), (A) any licenses or other similar rights provided to the Specified Party in or with respect to Intellectual Property owned or controlled by any other Person, and (B) any licenses or other similar rights provided to any other Person in or with respect to Intellectual Property owned or controlled by the Specified Party, in each case, including (1) any software license agreements, (2) the license agreements listed on Schedule 9, and (3) the right to use any of the licenses or other similar rights described in this definition in connection with the enforcement of any Secured Party’s rights under the Loan Documents.

 

3


Issuers” means the collective reference to each issuer of Pledged Collateral and Pledged Investment Property.

Paid in Full” and “Payment in Full” each means (a) with respect to Guaranteed Obligations, all Guaranteed Obligations have been repaid in full in cash (other than (i) any unasserted contingent indemnification obligations and (ii) any Obligations under any Warrant and the Registration Rights Agreement that are not due or payable at the time when all such other Guaranteed Obligations are repaid in full in cash) and (b) with respect to Secured Obligations, all Secured Obligations have been repaid in full in cash (other than (i) any unasserted contingent indemnification obligations and (ii) any Obligations under any Warrant and the Registration Rights Agreement that are not due or payable at the time when all such other Secured Obligations are repaid in full in cash); provided that the foregoing shall be subject to any reinstatement pursuant to (and the other provisions set forth in) Section 8.18 hereof.

Patents” means patents and patent applications, including (A) the patents and patent applications listed on Schedule 10, (B) all continuations, divisionals, continuations-in-part, re-examinations, reissues, and renewals thereof and improvements thereon, (C) all income, royalties, damages and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past, present, or future infringements thereof, (D) the right to sue for past, present, and future infringements thereof, and (E) all of each Grantor’s rights corresponding thereto throughout the world.

Pledged Collateral” means, collectively, the Pledged Equity and the Pledged Debt Instruments.

Pledged Debt Instruments” means all right, title and interest of any Grantor in instruments evidencing any Indebtedness owed to such Grantor or other obligations owed to such Grantor, including all Indebtedness described on Schedule 1, issued by the obligors named therein. Pledged Debt Instruments excludes any Excluded Property.

Pledged Equity” means collectively, all Pledged Interests and Pledged Stock.

Pledged Interests” shall mean, with respect to each limited liability company, partnership or other organization listed on Schedule 1, (i) the Stock in such limited liability company, partnership or other organization owned by a Grantor and listed on Schedule 1, and the certificates, if any, representing such interests and any interest of such Grantor, as applicable, on the books and records of such limited liability company, partnership or other organization or on the books and records of any securities intermediary pertaining to such interests, (ii) the Stock of any other Person whose Stock is at any time hereafter issued or granted to, or held by any Grantor, and (iii) all dividends, distributions, cash, warrants, rights, options, instruments, securities and other property or Proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all interests set forth in the preceding clauses (i) and (ii). Pledged Interests excludes any Excluded Property.

Pledged Investment Property” means the collective reference to (i) all “investment property” as such term is defined in Section 9-102(a)(49) of the UCC and (ii) all “financial assets” as such term is defined in Section 8-102(a)(9) of the UCC, other than any Pledged Equity or Pledged Debt Instruments. Pledged Investment Property excludes any Excluded Property.

Pledged Stock” shall mean, with respect to each corporation listed on Schedule 1, the Stock of such corporation owned by a Grantor and listed on Schedule 1, and the certificates, if any, representing such shares and any interest of such Grantor, as applicable, in the entries on the books of the issuer of such shares or on the books of any securities intermediary pertaining to such shares and the Stock of any other Person whose Stock is at any time hereafter issued to or granted to or held by any Grantor, and all dividends,

 

4


distributions, cash, warrants, rights, options, instruments, securities and other property or Proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of such shares. Pledged Stock excludes any Excluded Property.

Proceeds” means all “proceeds” as such term is defined in Section 9-102(a)(64) of the UCC and, in any event, shall include all dividends or other income from the Pledged Investment Property, collections thereon or distributions or payments with respect thereto.

Receivable” means any right to payment for goods sold or leased or for services rendered, whether or not such right is evidenced by an instrument or chattel paper and whether or not it has been earned by performance (including any accounts).

Secured Obligations” means the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment).

Trademarks” means any and all trademarks, trade names, registered trademarks, trademark applications, service marks, registered service marks and service mark applications, including (A) the trade names, registered trademarks, trademark applications, registered service marks and service mark applications listed on Schedule 11, (B) all renewals thereof, (C) all income, royalties, damages and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past or future infringements or dilutions thereof, (D) the right to sue for past, present and future infringements and dilutions thereof, (E) the goodwill of each Grantor’s business symbolized by the foregoing or connected therewith, and (F) all of each Grantor’s rights corresponding thereto throughout the world.

Transferred Guarantor” has the meaning set forth in Section 8.16(c).

SECTION 2 GUARANTY.

2.1 Guaranty.

(a) To induce Lenders to make the Loans and each other Secured Party to make credit available to or for the benefit of one or more Grantors and for the applicable Secured Parties to enter into the Loan Documents, each of the Guarantors hereby, jointly and severally, absolutely, unconditionally and irrevocably, as a primary obligor and not only a surety, guarantees to Agent and the other Secured Parties and their respective successors and permitted assigns, the prompt and complete payment and performance by Borrower and each other Grantor, as applicable, of the Guaranteed Obligations when due (whether at the stated maturity or earlier, by reason of acceleration, any mandatory prepayment required pursuant to the terms of the Financing Agreement or otherwise).

(b) This guaranty includes all present and future Guaranteed Obligations including any under transactions continuing, compromising, extending, increasing, modifying, releasing, or renewing the Guaranteed Obligations, changing the interest rate, payment terms, or other terms and conditions thereof, or creating new or additional Guaranteed Obligations after prior Guaranteed Obligations have been satisfied in whole or in part. To the maximum extent permitted by law, each Guarantor hereby waives any right to revoke this guaranty as to future Guaranteed Obligations. If such a revocation is effective notwithstanding the foregoing waiver, each Guarantor acknowledges and agrees that (i) no such revocation shall be effective until written notice thereof has been received by Agent, (ii) no such revocation shall apply to any Guaranteed Obligations in existence on the date of receipt by Agent of such written notice (including any subsequent continuation, extension, or renewal thereof, or change in the interest rate, payment terms, or other terms and conditions thereof), (iii) no such revocation shall apply to any Guaranteed Obligations

 

5


made or created after such date to the extent made or created pursuant to a legally binding commitment of any Lender in existence on the date of such revocation, (iv) no payment by any Guarantor, Borrower, or from any other source, prior to the date of Agent’s receipt of written notice of such revocation shall reduce the maximum obligation of such Guarantor hereunder, and (v) any payment by Borrower or from any source other than such Guarantor subsequent to the date of such revocation shall first be applied to that portion of the Guaranteed Obligations as to which the revocation is effective and which are not, therefore, Guaranteed hereunder, and to the extent so applied shall not reduce the maximum obligation of such Guarantor hereunder. This guaranty shall be binding upon each Guarantor, its successors and assigns and inure to the benefit of and be enforceable by Agent (for the benefit of the Secured Parties) and its successors, transferees, or assigns.

(c) The guaranty contained in this Section 2 is a guaranty of payment and not of collection and shall remain in full force and effect until all of the Guaranteed Obligations shall have been Paid in Full.

(d) No payment made by Borrower, any of the Guarantors, any other guarantor or any other Person, or received or collected by Agent or the other Secured Parties from Borrower, any of the Guarantors, any other guarantor or any other Person, as applicable, by virtue of any action or proceeding or any set-off or appropriation or application at any time or from time to time in reduction of or in payment of the Guaranteed Obligations shall be deemed to modify, reduce, release or otherwise affect the Liability of any Guarantor hereunder which Guarantor shall, notwithstanding any such payment (other than any payment received or collected from such Guarantor in respect of the Guaranteed Obligations), remain liable for the Guaranteed Obligations until the Guaranteed Obligations are Paid in Full.

2.2 No Subrogation. Notwithstanding any payment made by any Guarantor hereunder or any set-off or application of funds of any Guarantor by Agent or any other Secured Party, no Guarantor shall be entitled to be subrogated to any of the rights of Agent or any other Secured Party against Borrower or any Guarantor or any collateral security or guaranty or right of offset held by Agent or any other Secured Party for the payment of the Guaranteed Obligations, nor shall any Guarantor seek or be entitled to seek any contribution or reimbursement from Borrower or any Guarantor in respect of payments made by such Guarantor hereunder, until all of the Guaranteed Obligations are Paid in Full. If any amount shall be paid to any Guarantor on account of such subrogation rights at any time when all of the Guaranteed Obligations shall not have been Paid in Full, such amount shall be held by such Guarantor in trust for Agent and the other Secured Parties, segregated from other funds of such Guarantor, and shall, forthwith upon receipt by such Guarantor, be turned over to Agent (for the benefit of the Secured Parties) in the exact form received by such Guarantor (duly indorsed by such Guarantor to Agent), to be applied against the Guaranteed Obligations, whether matured or unmatured, as set forth in Section 6.5 hereof.

2.3 Amendments, etc. with respect to the Guaranteed Obligations.

(a) Each Guarantor shall remain obligated hereunder, without any reservation of rights against any Guarantor and without notice to or further assent by any Guarantor, notwithstanding the fact that: (i) any demand for payment of any of the Guaranteed Obligations made by Agent or the other Secured Parties may be rescinded by Agent or the other Secured Parties and any of the Guaranteed Obligations continued, (ii) the Guaranteed Obligations, or the Liability of any other Person upon or for any part thereof, or any collateral security or guaranty therefor or right of offset with respect thereto, may, from time to time, in whole or in part, be renewed, extended, amended, modified, accelerated, compromised, waived, surrendered or released by Agent or any other Secured Party, or (iii) any of the Facility Agreement or the other Loan Documents or any other documents executed and delivered in connection therewith may be amended, modified, supplemented or terminated, in whole or in part, as Agent or any other Secured Party may deem advisable from time to time. Agent and the other Secured Parties shall have no obligation

 

6


to protect, secure, perfect or insure any Lien at any time held by them as security for the Guaranteed Obligations or for the guaranty contained in this Section 2 or any property subject thereto.

(b) Agent or any other Secured Party may, from time to time, in their reasonable discretion and without notice to or demand upon the Guarantors (or any of them), take any or all of the following actions, without discharging or otherwise affecting the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) of any Guarantor hereunder and without incurring any Liability hereunder: (i) receive, take and hold additional Collateral to secure any of the Guaranteed Obligations or any obligation hereunder, (ii) retain or obtain the primary or secondary obligation of any obligor or obligors, in addition to the undersigned, with respect to any of the Guaranteed Obligations, (iii) extend or renew any of the Guaranteed Obligations for one or more periods (whether or not longer than the original period), alter or exchange any of the Guaranteed Obligations or otherwise modify, amend, supplement or otherwise change any Guaranteed Obligation or any Loan Document (including accelerating or otherwise changing the time of payment), or release or compromise any obligation of any of the undersigned hereunder or any obligation of any nature of any other obligor with respect to any of the Guaranteed Obligations or otherwise in connection with the Loan Documents, (iv) release any guaranty or right of offset or their security interest in, or surrender, release or permit any substitution or exchange for, all or any part of any personal property securing any of the Guaranteed Obligations or any obligation hereunder, or extend or renew for one or more periods (whether or not longer than the original period) or release, compromise, alter or exchange any obligations of any nature of any obligor with respect to any such personal property, (v) resort to the undersigned (or any of them) for payment of any of the Guaranteed Obligations when due, whether or not Agent or any other Secured Party shall have resorted to any personal property securing any of the Guaranteed Obligations or any obligation hereunder or shall have proceeded against any other of the undersigned or any other obligor primarily or secondarily obligated with respect to any of the Guaranteed Obligations, (vi) apply to the Guaranteed Obligations any sums by whomever paid or however realized to any Guaranteed Obligation as set forth in Section 6.5 hereof, (vii) refund at any time any payment received by any Secured Party in respect of any Guaranteed Obligation, (viii) sell, exchange, enforce, waive, substitute, liquidate, terminate, release, abandon, fail to perfect, subordinate, accept, substitute, surrender, exchange, affect, impair or otherwise alter or release any Collateral for any Guaranteed Obligation or any other guaranty therefor in any manner, (ix) otherwise deal in any manner with Borrower or any other Guarantor, maker or endorser of any Guaranteed Obligation or any part thereof, and/or (x) settle, release, compromise, collect or otherwise liquidate the Guaranteed Obligations.

2.4 Waivers. To the extent permitted by Applicable Law, each Guarantor hereby unconditionally and irrevocably waives any and all notice of the creation, renewal, extension or accrual of any of the Guaranteed Obligations and notice of or proof of reliance by Agent or any other Secured Party upon the guaranty contained in this Section 2 or acceptance of the guaranty contained in this Section 2. The Guaranteed Obligations, and any of them, shall conclusively be deemed to have been created, contracted or incurred, or renewed, extended, amended or waived, in reliance upon the guaranty contained in this Section 2, and all dealings between Borrower and any of the Guarantors, on the one hand, and Agent and the other Secured Parties, on the other hand, likewise shall be conclusively presumed to have been had or consummated in reliance upon the guaranty contained in this Section 2. To the extent permitted by Applicable Law, each Guarantor hereby unconditionally and irrevocably waives and agrees not to assert any claim, defense, setoff or counterclaim based on (i) diligence, promptness, presentment, protest, requirements for any demand for payment or performance and protest and notice of protest, requirements for any notice of default, dishonor or nonpayment and all other notices whatsoever to or upon Borrower or any of the Guarantors with respect to the Guaranteed Obligations or any part thereof, (ii) notice of the existence or creation or non-payment of all or any of the Guaranteed Obligations, (iii) all diligence in collection or protection of or realization upon any Guaranteed Obligations or any security for or guaranty of any Guaranteed Obligations, (iv) any presentment, demand, protest or further notice or other formality or

 

7


requirements of any kind with respect to any Guaranteed Obligation (including any accrued but unpaid interest thereon) becoming immediately due and payable, and (v) any defense arising by reason of a disability or other defense of Borrower or any Guarantor. No obligation of any Guarantor hereunder shall be discharged other than by Payment in Full in cash of the Guaranteed Obligations. Each Guarantor further waives any right such Guarantor may have under any Applicable Law to require any Secured Party to seek recourse first against Borrower or any other Person, or to realize upon any Collateral for any of the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment), as a condition precedent to enforcing such Guarantor’s Liability and obligations under this Guaranty.

2.5 Payments. Each Guarantor hereby guaranties that payments hereunder will be paid to Agent and the other Secured Parties without set-off or counterclaim in Dollars in accordance with Section 2.4 of the Facility Agreement.

2.6 Limitation of Guaranty. Any term or provision of this Agreement or any other Loan Document to the contrary notwithstanding, the maximum aggregate amount for which any Guarantor shall be liable hereunder shall not exceed the maximum amount for which such Guarantor can be liable without rendering this Agreement or any other Loan Document, as it relates to such Guarantor, subject to avoidance under Applicable Laws relating to fraudulent conveyance or fraudulent transfer (including the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act and Section 548 of title 11 of the United States Code or any applicable provisions of comparable Applicable Laws) (collectively, “Fraudulent Transfer Laws”). Any analysis of the provisions of this Agreement for purposes of Fraudulent Transfer Laws shall take into account the right of contribution established in Section 2.7 hereof and, for purposes of such analysis, give effect to any discharge of intercompany debt as a result of any payment made under this Agreement.

2.7 Contribution. To the extent that any Guarantor shall be required hereunder to pay any portion of any Guaranteed Obligation exceeding the greater of (i) the amount of the value actually received by such Guarantor and its Subsidiaries from the Loans and other Obligations and (ii) the amount such Guarantor would otherwise have paid if such Guarantor had paid the aggregate amount of the Guaranteed Obligations (excluding the amount thereof repaid by the Borrower and any other Guarantor that is a direct or indirect parent entity of the Borrower) in the same proportion as such Guarantor’s net worth on the date enforcement is sought hereunder bears to the aggregate net worth of all the Guarantors on such date, then such Guarantor shall be reimbursed by such other Guarantors for the amount of such excess, pro rata, based on the respective net worth of such other Guarantors on such date.

2.8 Guaranty Absolute and Unconditional. Each Guarantor hereby waives and agrees not to assert any defense, whether arising in connection with or in respect of any of the following or otherwise, and hereby agrees that its obligations under this Agreement are irrevocable, absolute and unconditional and shall not be discharged as a result of or otherwise affected by any of the following (which may not be pleaded and evidence of which may not be introduced in any proceeding with respect to this Agreement) to the fullest extent not prohibited by Applicable Law:

(a) the invalidity or unenforceability of any obligation of Borrower or any Guarantor under any Loan Document or any other agreement or instrument relating thereto (including any amendment, consent or waiver thereto), or any security for, or other guaranty of, any Guaranteed Obligation or any part thereof, or the lack of perfection or continuing perfection or failure of priority of any security for the Guaranteed Obligations or any part thereof;

(b) the absence of (i) any attempt to collect any Guaranteed Obligation or any part thereof from Borrower or any Guarantor or other action to enforce the same or (ii) any action to enforce any Loan Document or any Lien thereunder;

 

8


(c) the failure by any Person to take any steps to perfect and maintain any Lien on, or to preserve any rights with respect to, any Collateral;

(d) any workout, insolvency, bankruptcy proceeding, reorganization, arrangement, liquidation or dissolution by or against Borrower, any Guarantor or any of Borrower’s Subsidiaries or any procedure, agreement, order, stipulation, election, action or omission thereunder, including any discharge or disallowance of, or bar or stay against collecting, any Guaranteed Obligation (or any interest thereon) in or as a result of any such proceeding;

(e) any foreclosure, whether or not through judicial sale, and any other sale or other disposition of any Collateral or any election following the occurrence of an Event of Default by any Secured Party to proceed separately against any Collateral in accordance with such Secured Party’s rights under any Applicable Law; or

(f) any other defense, setoff, counterclaim or any other circumstance that might otherwise constitute a legal or equitable discharge of Borrower, any Guarantor or any Subsidiary of Borrower, in each case other than the Payment in Full in cash of the Guaranteed Obligations.

2.9 Reliance. Each Guarantor hereby assumes responsibility for keeping itself informed of the financial condition of Borrower, each Guarantor and any other guarantor, maker or endorser of any Guaranteed Obligation or any part thereof, and of all other circumstances bearing upon the risk of nonpayment of any Guaranteed Obligation or any part thereof that diligent inquiry would reveal, and each Guarantor hereby agrees that no Secured Party shall have any duty to advise any Guarantor of information known to it regarding such condition or any such circumstances. In the event any Secured Party, in its sole discretion, undertakes at any time or from time to time to provide any such information to any Guarantor, such Secured Party shall be under no obligation to (i) undertake any investigation not a part of its regular business routine, (ii) disclose any information that such Secured Party, pursuant to accepted or reasonable commercial finance or banking practices, wishes to maintain confidential, or (iii) make any future disclosures of such information or any other information to any Guarantor.

SECTION 3 GRANT OF SECURITY INTEREST.

3.1 Grant. Each Grantor hereby collaterally assigns and grants to Agent, for the benefit of the Secured Parties, a Lien on and security interest in all of its Collateral, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Secured Obligations. Notwithstanding the foregoing, no Lien or security interest is hereby granted on any Excluded Property. Each Grantor hereby represents and warrants as of (i) the Agreement Date, (ii) the date of each amendment, consent or waiver of this Agreement or the Facility Agreement executed by any Grantor and (iii) solely with respect to any new Grantor that joins this Agreement after the Agreement Date, on the date such new Grantor joins this Agreement, that the Excluded Property, when taken as a whole, is not material to the business operations or financial condition of the Grantors, taken as a whole.

SECTION 4 REPRESENTATIONS AND WARRANTIES.

To induce Agent and Lenders to enter into the Facility Agreement and to induce Lenders to make extensions of credit to Borrower thereunder, each Grantor jointly and severally hereby represents and warrants to Agent and the other Secured Parties that the following are true, correct and complete, in each case to the extent and in the manner set forth herein, on the Agreement Date and as of (i) the Agreement Date, (ii) the date of each amendment, consent or waiver of this Agreement or the Facility Agreement

 

9


executed by any Grantor and (iii) solely with respect to any new Grantor that joins this Agreement after the Agreement Date, on the date such new Grantor joins this Agreement:

4.1 Title; No Other Liens. Except for the Lien granted to Agent pursuant to this Agreement and other Permitted Liens, such Grantor owns, or has rights or the power to transfer rights in, each item of the Collateral free and clear of any and all Liens of others. Such Grantor (i) is the record and beneficial owner of the Collateral pledged by it hereunder constituting instruments or certificates and (ii) has rights in or the power to transfer each other item of Collateral in which a Lien is granted by it hereunder, free and clear of any other Lien (other than Permitted Liens). No effective financing statement or other public notice with respect to all or any part of the Collateral is on file or of record in any public office, except filings evidencing Permitted Liens.

4.2 Perfected Liens. The security interests granted in the Collateral pursuant to this Agreement (i) will constitute valid and continuing perfected security interests in all of the Grantors’ rights in the Collateral in favor of Agent as collateral security for the Secured Obligations, enforceable in accordance with the terms hereof, except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally, upon (A) in the case of all Collateral in which a security interest may be perfected by filing a financing statement under the UCC, completion of the filings and other actions specified on Schedule 2 (which filings and other documents referred to on Schedule 2 have been delivered to Agent in completed form), (B) with respect to any deposit account or securities account, the execution of Control Agreements, (C) in the case of all Copyrights, Trademarks and Patents for which UCC filings are insufficient, all appropriate filings having been made with the applicable Intellectual Property registries, including but not limited to the United States Copyright Office or the United States Patent and Trademark Office, as applicable, (D) in the case of letter-of-credit rights that are not supporting obligations of Collateral, the execution of a contractual obligation granting control to Agent over such letter-of-credit rights and (E) in the case of electronic chattel paper with payment or amounts owing thereon in excess of $250,000 in the aggregate, the completion of all steps necessary to grant control to Agent over such electronic chattel paper; and (ii) shall be prior to all other Liens on the Collateral except for Permitted Priority Liens, upon (A) in the case of all Pledged Collateral and Pledged Investment Property, the delivery thereof to Agent (for the benefit of the Secured Parties) of such Pledged Collateral and Pledged Investment Property consisting of instruments and certificates, in each case properly endorsed for transfer to Agent (for the benefit of the Secured Parties) or in blank, (B) in the case of all Pledged Investment Property not in certificated form and deposit accounts, the execution of Control Agreements with respect to such Pledged Investment Property and deposit accounts and (C) in the case of all other instruments and tangible chattel paper that has aggregate payments or amounts owing thereunder in excess of $250,000 in the aggregate that are not Pledged Collateral or Pledged Investment Property, the delivery thereof to Agent (for the benefit of the Secured Parties) of such instruments and tangible chattel paper. Except as set forth in this Section 4.2 or as otherwise provided in the Facility Agreement, all actions by each Grantor necessary or otherwise requested by Agent to perfect the Liens granted hereunder on the Collateral have been duly taken.

4.3 Grantor Information. On the Agreement Date, Schedule 3 sets forth (i) each Grantor’s and each Guarantor’s jurisdiction of organization, (ii) the location of each Grantor’s and each Guarantor’s chief executive office, (iii) each Grantor’s and each Guarantor’s exact legal name as it appears on its organizational documents and (iv) each Grantor’s organizational identification number (to the extent a Grantor or Guarantor is organized in a jurisdiction which assigns such numbers) and federal employer identification number.

4.4 Collateral Locations. On the Agreement Date, Schedule 4 sets forth (i) each place of business of each Grantor and each Guarantor (including its chief executive office), (ii) all locations where any material portion of inventory and equipment owned by each Grantor is kept (other than

 

10


(A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Facility Agreement), (iii) all locations where each Grantor’s books and records concerning the Collateral are kept and (iv) whether each such Collateral location and place of business (including each Grantor’s chief executive office) is owned or leased (and if leased, specifies the complete name and notice address of each lessor) or otherwise occupied (and if otherwise occupied, describes the nature of such occupation). On the Agreement Date, no Collateral (other than (A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Facility Agreement) is located outside the United States or in the possession of any lessor, bailee, warehouseman or consignee, except as indicated on Schedule 4.

4.5 Certain Property. None of the Collateral constitutes, or is the Proceeds of, (i) farm products, (ii) as-extracted collateral, (iii) timber to be cut or (iv) vessels, aircraft or any other personal property subject to any certificate of title or other registration statute of the United States, any State or other jurisdiction, except for motor vehicles owned by the Grantors and used by employees of the Grantors in the Ordinary Course of Business.

4.6 Pledged Collateral and Pledged Investment Property.

(a) The Pledged Collateral pledged by each Grantor hereunder is listed on Schedule 1 and, with respect to the Pledged Equity, constitutes all the issued and outstanding equity interests of each Issuer owned by such Grantor as set forth on Schedule 1. None of the Pledged Equity is a certificated security or otherwise represented or evidenced by any certificate other than the Pledged Equity in Nellix, Inc., CVD/RMS Acquisition Corp., RMS/Endologix Sideways Merger Corp., TriVascular, Inc. and TriVascular Technologies, Inc, and no foreign Issuer has certificated its Stock nor is any Grantor (or any representative, agent or any other Related Party of any Grantor) holding any certificate of Stock of any foreign Issuer.

(b) All of the Pledged Equity has been duly authorized and validly issued and, in the case of shares of capital stock and membership interests, is fully paid and nonassessable.

(c) Each of the Pledged Equity, Pledged Debt Instruments and Pledged Investment Property constitutes the legal, valid and binding obligation of the obligor with respect thereto, enforceable in accordance with its terms, except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally.

(d) Schedule 1A lists all Pledged Investment Property owned by each Grantor. Each Grantor is the record and beneficial owner of, and has good and valid title to, the Pledged Investment Property pledged by it hereunder, free of any and all Liens or options in favor of, or claims of, any other Person, except Permitted Liens.

(e) All Pledged Collateral (other than uncertificated Pledged Equity) and all Pledged Investment Property consisting of instruments and certificates has been delivered to Agent (for the benefit of the Secured Parties) in accordance with Section 5.1 hereof to the extent required thereby.

(f) Upon the occurrence and during the continuance of an Event of Default, Agent shall be entitled to exercise all of the rights of the Grantor granting the security interest in any Pledged Equity, and a transferee or assignee of such Pledged Equity shall become a holder of such Pledged Equity to the same extent as such Grantor and be entitled to participate in the management of the Issuer of such

 

11


Pledged Equity, and, subject to Agent’s exercise of remedies pursuant to Section 6 hereof, upon the transfer of the entire interest of such Grantor, such Grantor shall, by operation of law, cease to be a holder of such Pledged Equity.

4.7 Receivables.

(a) No amount over $250,000 in the aggregate payable to a Grantor under or in connection with any account is evidenced by any instrument or chattel paper which, to the extent required hereunder, has not been delivered to Agent (for the benefit of the Secured Parties), properly endorsed for transfer.

(b) No obligor on any Receivable in excess of $250,000 in the aggregate is a Governmental Authority, unless any assignment of claims act or law has been complied with for the benefit of Agent.

4.8 Facility Agreement. Each Grantor and each Guarantor makes each of the representations and warranties made by Borrower in Section 3.1 of the Facility Agreement to the extent applicable to it on the date such Grantor or Guarantor becomes a party hereto (which representations and warranties shall be deemed to be re-made (i) as of the date of each amendment, consent or waiver of this Agreement or the Facility Agreement executed by any Grantor and (iii) solely with respect to any new Grantor that joins this Agreement after the Agreement Date, on the date such new Grantor joins this Agreement). Such representations and warranties shall be incorporated herein by this reference as if fully set forth herein.

4.9 Commercial Tort Claims. The only commercial tort claims that any Grantor is asserting or intends to assert in which the potential recovery exceeds $250,000 in the aggregate are those listed on Schedule 5, as may be supplemented from time to time by delivery thereof to Agent, which sets forth such information separately for each Grantor.

4.10 Enforcement. No material permit, notice to or filing with any Governmental Authority or any other Person or any material consent from any Person is required for the exercise by Agent of its rights (including voting rights) provided for in this Agreement or the enforcement of remedies in respect of the Collateral pursuant to this Agreement, including the transfer of any Collateral, except (i) as may be required in connection with the disposition of any portion of the Pledged Collateral by laws affecting the offering and sale of securities generally, (ii) any approvals that may be required to be obtained from any bailees or landlords to collect the Collateral, (iii) permits or consents which have been obtained and notices or filings which have been made, and (iv) any requirements set forth in any assignment of claims act and laws.

4.11 Accounts. Set forth on Schedule 6 (as such Schedule may be expressly updated from time to time to reflect changes resulting from transactions permitted under the Loan Documents) is a listing of all of Grantors’ and their Subsidiaries’ deposit accounts and securities accounts, including, with respect to each bank or securities intermediary (a) the name and address of such Person, and (b) the account numbers of the deposit accounts or securities accounts maintained with such Person.

4.12 Real Estate. Schedule 7 sets forth all Real Estate owned by any of the Grantors as of the Agreement Date.

4.13 Intellectual Property. As of the Agreement Date: (i) Schedule 8 provides a complete and correct list of all registered Copyrights owned by any Grantor and all other Copyrights owned by any Grantor and material to the conduct of the business of any Grantor; (ii) Schedule 9 provides a

 

12


complete and correct list of all Intellectual Property Licenses (other than license agreements for commercially available off-the-shelf software that is generally available to the public which have been licensed to a Grantor pursuant to end-user licenses) entered into by any Grantor that are material to the business of such Grantor, including any Intellectual Property Licenses that relate to Intellectual Property that is incorporated in any Inventory, software, or other product marketed, sold, licensed, or distributed by such Grantor; (iii) Schedule 10 provides a complete and correct list of all Patents owned by any Grantor; and (iv) Schedule 11 provides a complete and correct list of all registered Trademarks owned by any Grantor and all other Trademarks owned by any Grantor and material to the conduct of the business of any Grantor.

SECTION 5 COVENANTS.

Each Grantor covenants and agrees with Agent that, from and after the date of this Agreement until the Secured Obligations and the Guaranteed Obligations, as applicable, shall have been Paid in Full:

5.1 Delivery of Instruments, Certificated Securities and Chattel Paper.

(a) Such Grantor shall (i) deliver to Agent (for the benefit of the Secured Parties), in suitable form for transfer and in form and substance reasonably satisfactory to Agent, (A) all certificated Pledged Equity, together with stock powers or other suitable instruments for transfer, executed in blank, (B) all Pledged Debt Instruments and (C) all certificates and instruments evidencing Pledged Investment Property and (ii) to the extent required by Section 5.1(k) of the Facility Agreement, maintain all other Pledged Investment Property in an account that is subject to a Control Agreement. No foreign Issuer shall issue certificates of its Stock unless the foregoing provisions of this paragraph are complied with.

(b) If any amount in excess of $250,000 in the aggregate payable under or in connection with any Collateral owned by such Grantor shall be or become evidenced by an instrument or tangible chattel paper other than such instrument delivered in accordance with this Section 5.1 and in the possession of Agent, such Grantor shall notify Agent, and upon the written request of Agent, mark all such instruments and tangible chattel paper with the following legend: “This writing and the obligations evidenced or secured hereby are subject to the security interest of Deerfield Private Design Fund IV, L.P., as Agent” and, at the written request of Agent, shall promptly deliver such instrument or tangible chattel paper to Agent (for the benefit of the Secured Parties), duly indorsed in a manner reasonably satisfactory to Agent.

(c) Such Grantor shall not grant “control” (within the meaning of such term under Article 9-106 of the UCC) over any Pledged Collateral or Pledged Investment Property to any Person other than Agent (for the benefit of the Secured Parties) or, to the extent permitted under (and subject to the terms of) the Intercreditor Agreement and subject to the terms of Section 8.21, the ABL Agent.

(d) If such Grantor is or becomes the beneficiary of a letter of credit that is (i) not a supporting obligation of any Collateral and (ii) in excess of $250,000 in the aggregate, such Grantor shall promptly, and in any event within five (5) Business Days after becoming a beneficiary, notify Agent thereof and shall use commercially reasonable efforts to enter into a contractual arrangement reasonably requested by the Agent with respect to the letter-of-credit rights under such letter of credit. Such contractual arrangement shall assign such letter-of-credit rights to Agent and such assignment shall be sufficient to grant control for the purposes of Section 9-107 of the UCC (or any similar section under any equivalent UCC). Such contractual arrangement shall also direct all payments thereunder to an account subject to a Control Agreement. The provisions of the contractual arrangement shall be in form and substance reasonably satisfactory to Agent.

 

13


(e) If any amount in excess of $250,000 in the aggregate payable under or in connection with any Collateral owned by such Grantor shall be or become evidenced by electronic chattel paper, such Grantor shall take all commercially reasonable steps necessary to grant Agent control of all such electronic chattel paper for the purposes of Section 9-105 of the UCC (or any similar section under any equivalent UCC) and all “transferable records” as defined in each of the Uniform Electronic Transactions Act and the Electronic Signatures in Global and National Commerce Act.

(f) In the event that an Event of Default shall have occurred and be continuing, upon the request of Agent, any instrument, certificated security or chattel paper not theretofore delivered to Agent and at such time being held by such Grantor shall be promptly (and, in any event, within five (5) Business Days) delivered to Agent (for the benefit of the Secured Parties), duly indorsed in a manner satisfactory to Agent, to be held as Collateral pursuant to this Agreement and in the case of electronic chattel paper, such Grantor shall cause Agent to have control thereof within the meaning set forth in Section 9-105 of the UCC. In the event that an Event of Default shall have occurred and be continuing, Agent shall have the right, at any time in its discretion and without notice to any Grantor, to (i) transfer to or to register in its name or in the name of its nominees any Pledged Collateral or any Pledged Investment Property and (ii) exchange any certificate or instrument representing or evidencing any Pledged Collateral or any Pledged Investment Property for certificates or instruments of smaller or larger denominations.

5.2 Maintenance of Perfected Security Interest; Further Documentation.

(a) Such Grantor shall maintain the security interests created by this Agreement as perfected security interests (to the extent such security interests can be perfected by the filing of UCC financing statements (and, with respect to commercial tort claims, to the extent any commercial tort claims are sufficiently identified herein)) having at least the priority described in Section 4.2 hereof, and shall defend such security interests against the claims and demands of all Persons whomsoever (other than holders of Permitted Liens).

(b) Subject to Section 5.1(q) of the Facility Agreement, such Grantor will furnish to Agent from time to time statements and schedules further identifying and describing the assets and property of such Grantor and such other reports in connection therewith as Agent may reasonably request, all in reasonable detail in form and substance reasonably satisfactory to Agent.

(c) At any time and from time to time, upon the written request of Agent, and at Grantor’s sole expense, such Grantor will, for the purpose of obtaining or preserving the full benefits of this Agreement and of the rights and powers herein granted, promptly and duly execute and deliver, and have recorded, such further instruments and documents and take such further actions as Agent may reasonably request, including (i) filing or authorizing the filing of any financing or continuation statements under the UCC (or other similar laws) in effect in any jurisdiction with respect to the security interests created hereby; (ii) in the case of Pledged Collateral, Pledged Investment Property and any other relevant Collateral, taking any such reasonably requested actions necessary to enable Agent (on behalf of the Secured Parties) to obtain “control” (within the meaning of the applicable UCC) with respect to such Pledged Collateral, Pledged Investment Property and other Collateral to the extent required to be pledged hereunder; (iii) if requested by Agent, delivering, to the extent permitted by Applicable Law, any original motor vehicle certificates of title for vehicles in the aggregate with a fair market value in excess of $250,000 received by such Grantor from the applicable secretary of state or other Governmental Authority after information reflecting Agent’s security interest has been recorded in such motor vehicles to the extent required to be pledged thereunder; (iv) use of commercially reasonable efforts to secure all approvals necessary or appropriate for the assignment to or the benefit of Agent of any contractual obligation held by such Grantor and to enforce the security interests hereunder; and (v) subject to Section 5.1(k) of the Facility Agreement, executing and delivering any Control Agreements with respect to deposit, securities, commodity and

 

14


similar accounts.

(d) Such Grantor shall not use or permit any Collateral to be used unlawfully or in violation of any provision of any Loan Document or any policy of insurance covering the Collateral.

5.3 Changes in Locations, Name, etc. Such Grantor shall not, except upon 10 Business Days’ prior written notice to Agent (or such lesser notice as Agent may agree to in writing in its sole discretion) and delivery to Agent of (i) all additional financing statements and other documents reasonably requested by Agent as to the validity, perfection and priority of the security interests provided for herein and (ii) if applicable, a written supplement to Schedule 4 showing any additional location at which inventory or equipment shall be kept (other than (A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Facility Agreement):

(a) permit any of the inventory or equipment comprising Collateral to be kept at a location subject to the possession or control of any warehouse, consignee, bailee, or any of the Grantors’ agents or processors other than those listed on Schedule 4, other than (i) the inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (ii) de minimis amounts of inventory with sales personnel and at medical facilities or (iii) otherwise disposed of in a transaction permitted by the Facility Agreement;

(b) change its jurisdiction of organization or the location of its chief executive office from that specified on Schedule 3 or in any subsequent notice delivered pursuant to this Section 5.3; or

(c) change its name, organizational identification number (if any), identity or corporate structure, except as permitted by Section 5.2(i) of the Facility Agreement upon prior written notice thereof to the Agent.

5.4 Notices. Such Grantor will advise Agent in writing promptly, in reasonable detail, of:

(a) any Lien (other than Permitted Liens) on any of the Collateral; and

(b) the occurrence of any other event which would reasonably be expected to have a Material Adverse Effect on the Collateral or on the Liens created hereby.

5.5 Pledged Investment Property and Pledged Collateral.

(a) If such Grantor shall become entitled to receive or shall receive any certificate, option or rights in respect of the Stock of any Issuer, whether in addition to, in substitution of, as a conversion of, or in exchange for, any of the Pledged Equity, or otherwise in respect thereof, such Stock shall be Pledged Equity (to the extent consistent with the percentage of such Grantor’s Stock in such Issuer pledged hereunder, as set forth on Schedule 1) and such Grantor shall accept the same as the agent of Agent, hold the same in trust for Agent (for the benefit of the Secured Parties) and deliver the same forthwith to Agent (for the benefit of the Secured Parties) in the exact form received, duly indorsed by such Grantor to Agent (for the benefit of the Secured Parties), if required by Agent, together with an undated instrument of transfer covering such certificate duly executed in blank by such Grantor and with, if Agent so request, signature guarantied, to be held by Agent (for the benefit of the Secured Parties), subject to the terms hereof, as additional Collateral for the Secured Obligations.

 

15


(b) Upon the occurrence and during the continuance of an Event of Default and the request of Agent, (i) any sums paid upon or in respect of the Pledged Collateral or Pledged Investment Property upon the liquidation or dissolution of any Issuer shall be paid over to Agent (for the benefit of the Secured Parties) to be held by it hereunder as additional Collateral for the Secured Obligations, and (ii) in case any distribution of capital shall be made on or in respect of the Pledged Collateral, or any property shall be distributed upon or with respect to the Pledged Collateral, pursuant to the recapitalization or reclassification of the capital of any Issuer or pursuant to the reorganization thereof, the property so distributed shall, unless otherwise subject to a perfected Lien in favor of Agent, be delivered to Agent (for the benefit of the Secured Parties) to be held by it hereunder as additional Collateral for the Secured Obligations. Upon the occurrence and during the continuance of an Event of Default, if any sums of money or property so paid or distributed in respect of the Pledged Investment Property shall be received by a Grantor, such Grantor shall, at the request of Agent and until such money or property is paid or delivered to the applicable Secured Parties, hold such money or property in trust for Agent (for the benefit of the Secured Parties), segregated from other funds of such Grantor, as additional Collateral for the Secured Obligations.

(c) Without the prior written consent of Agent, no Grantor will (i) vote to enable, or take any other action, to permit any Issuer to issue any Stock of any nature or to issue any other securities or interests convertible into or granting the right to purchase or exchange for any Stock of any nature of any Issuer, except, in each case, as permitted by the Facility Agreement, (ii) sell, assign, transfer, exchange, or otherwise dispose of, or grant any option with respect to, the Pledged Investment Property or Proceeds thereof other than any such action which is permitted by the Facility Agreement, (iii) create, incur or permit to exist any Lien or option in favor of, or any claim of any Person with respect to, any of the Pledged Investment Property or Proceeds thereof, or any interest therein, except for Permitted Liens, or (iv) enter into any agreement or undertaking restricting the right or ability of such Grantor or Agent to sell, assign or transfer any of the Pledged Investment Property or Proceeds thereof, except with respect to Permitted Liens and any such action which is permitted by the Facility Agreement.

(d) In the case of each Grantor which is an Issuer, such Issuer agrees that (i) it will be bound by the terms of this Agreement relating to the Pledged Equity issued by it and will comply with such terms insofar as such terms are applicable to it, (ii) it will notify Agent promptly in writing of the occurrence of any of the events described in Sections 5.5(a) and 5.5(b) hereof with respect to the Pledged Equity issued by it and (iii) the terms of Sections 6.3(c) and 6.7 hereof shall apply to such Grantor with respect to all actions that may be required of it pursuant to Section 6.3(c) or 6.7 hereof regarding the Pledged Equity issued by it.

5.6 Receivables. Other than in the Ordinary Course of Business consistent with its past practice, such Grantor will not (i) grant any extension of the time of payment of any Receivable, (ii) compromise or settle any Receivable for less than the full amount thereof, (iii) release, wholly or partially, any Person liable for the payment of any Receivable, (iv) allow any credit or discount whatsoever on any Receivable or (v) amend, supplement or modify any Receivable in any manner that would reasonably be expected to adversely affect the value thereof, in each case, unless taking the foregoing actions would not reasonably be expected, individually or in the aggregate, to cause a Material Adverse Effect.

5.7 Intellectual Property. Except as permitted by the Facility Agreement, or except, in each case, where the failure to do so could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, provided that no such Material Adverse Effect qualifier should apply to Section 5.7(h) hereof:

(a) Upon the request of Agent, in order to facilitate filings with the United States Patent and Trademark Office and the United States Copyright Office, each Grantor shall execute and

 

16


deliver to Agent one or more Copyright Security Agreements, Trademark Security Agreements, or Patent Security Agreements to further evidence Agent’s Lien on such Grantor’s Patents, Trademarks, or Copyrights, and the General Intangibles of such Grantor relating thereto or represented thereby.

(b) Such Grantor (either itself or through licensees) will (i) continue to use each Trademark (owned by such Grantor), in order to maintain such Trademark in full force and effect free from any claim of abandonment for non-use, (ii) maintain as in the past the quality of products and services offered under such Trademark, (iii) use, and cause its licensees and sublicensees to use, such Trademark with the appropriate notice of registration and all other notices and legends required by Applicable Law, (iv) not adopt or use any mark which is confusingly similar or a colorable imitation of such Trademark unless Agent shall obtain a perfected security interest in such Trademark pursuant to this Agreement and (v) not (and not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby such Trademark (or any goodwill associated therewith) may become destroyed, harmed, invalidated or impaired in any way.

(c) Each Grantor (either itself or through licensees) will not do any act, or omit to do any act, whereby as a result of such act or omission, any Patent owned by such Grantor may become unenforceable, invalidated, forfeited, abandoned or dedicated to the public, will employ, and cause its licensees and sublicensees to employ, each such Patent with the appropriate notice of registration and all other notices and legends required by Applicable Law, and will take commercially reasonable steps to establish and preserve the Patents in any patentable invention under Applicable Law.

(d) Each Grantor (either itself or through licensees) (i) will employ, and cause its licensees and sublicensees to employ, each Copyright owned by such Grantor with the appropriate notice of registration and all other notices and legends required by Applicable Law, and (ii) will not (and will not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby such Copyrights may become invalidated or otherwise impaired, and (iii) will not (either itself or through licensees or sublicensees) do any act whereby any such Copyrights may fall into the public domain.

(e) Each Grantor (either itself or through licensees or sublicensees) will not (and will not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby any trade secret may become unenforceable under any Applicable Law and each Grantor shall take reasonable steps to maintain the confidentiality of, and otherwise protect and enforce its rights in, the Intellectual Property that is necessary in or material to the conduct of such Grantor’s business, including, as applicable (A) protecting the secrecy and confidentiality of its confidential information and trade secrets by having and enforcing a policy requiring all current employees, consultants, licensees, vendors and contractors with access to such information to execute appropriate confidentiality agreements; (B) taking actions reasonably necessary to ensure that no trade secret falls into the public domain due to any action of any Grantor; and (C) protecting the secrecy and confidentiality of the source code of all software programs and applications of which it is the owner or licensee by having and enforcing a policy requiring any licensees (or sublicensees) of such source code to enter into license agreements with commercially reasonable use and non-disclosure restrictions.

(f) Such Grantor (either itself or through licensees or sublicensees) will not do any act that infringes, misappropriates, dilutes, violates or otherwise impairs the Intellectual Property or intellectual property rights of any other Person.

(g) Such Grantor will notify Agent promptly if it knows, or has reason to know, that any application or registration relating to any Intellectual Property owned by such Grantor may become unenforceable, invalidated, forfeited, abandoned or dedicated to the public, or of any determination or development (including the institution of, or any such determination or development in, any proceeding in

 

17


the United States Patent and Trademark Office, the United States Copyright Office or any court or tribunal in any country) regarding such Grantor’s ownership of, or the validity of, any such Intellectual Property or such Grantor’s right to register the same or to own and maintain the same.

(h) At the time of delivery of any Perfection Certificate required by Section 5.1(t) of the Facility Agreement, each Grantor will notify Agent of applications filed for the registration of any Intellectual Property with the United States Patent and Trademark Office, the United States Copyright Office or any similar office or agency in any other country or any political subdivision thereof. Upon the request of Agent, within five (5) Business Days, such Grantor shall execute and deliver, and have recorded, any and all agreements, instruments, documents, and papers as Agent may request to evidence Agent’s security interest in any Intellectual Property owned by such Grantor, including any Copyright, Patent or Trademark and the goodwill and general intangibles of such Grantor relating thereto or represented thereby.

(i) Such Grantor will take all actions that are necessary or reasonably requested by Agent to maintain and pursue each application (and to obtain the relevant registration or recordation) and to maintain each registration and recordation of all Intellectual Property owned by it.

(j) In the event that any Intellectual Property owned by a Grantor is, to its knowledge, infringed upon or misappropriated or diluted by a third party, such Grantor shall, subject to Section 5.1(q) of the Facility Agreement, (i) take such actions as such Grantor shall reasonably deem appropriate under the circumstances to protect such Intellectual Property and (ii) promptly notify Agent after it learns thereof and sue for infringement, misappropriation or dilution, to seek injunctive relief where appropriate and to recover any and all damages for such infringement, misappropriation or dilution.

(k) Each Grantor shall require all employees, consultants, and contractors of such Grantor who are involved in the creation or development of any Intellectual Property for such Grantor to sign agreements that presently assigned all Intellectual Property created or developed for the Grantor to such Grantor, and obligate such employee, consulting or contractor to hold all confidential information of the Grantor (or of any other Person and held by the Grantor) in confidence.

(l) Grantors acknowledge and agree that no Secured Party shall have any duties with respect to any Intellectual Property or Intellectual Property Licenses of any Grantor. Without limiting the generality of this Section 5.7(l), Grantors acknowledge and agree that no Secured Party shall be under any obligation to take any steps necessary to preserve rights in the Collateral consisting of Intellectual Property or Intellectual Property Licenses against any other Person, but any Secured Party may do so at its option from and after the occurrence and during the continuance of an Event of Default, and all expenses incurred in connection therewith (including reasonable fees and expenses of attorneys and other professionals) shall be for the sole account of Borrower and the other Grantors.

5.8 [Reserved].

5.9 Other Matters.

(a) Each Grantor authorizes Agent and its Affiliates directors, partners, officers, employees, agents, counsel and advisors to, at any time and from time to time, file or record financing statements, continuation statements, amendments thereto, and other filing or recording documents or instruments with respect to any Collateral in such forms and in such offices as Agent or such other Person reasonably determines appropriate to perfect, or continue or maintain perfection of, the security interests of Agent under this Agreement, and such statements, amendments, documents, and instruments may describe the Collateral covered thereby as “all assets of the debtor” of each Grantor, or words of similar effect and may contain any other information required pursuant to the UCC for the sufficiency of filing office

 

18


acceptance of any financing statement, continuation statement or amendment, and each Grantor agrees to furnish any such information to Agent promptly upon Agent’s reasonable request. Any such financing statement, continuation statement or amendment may be signed by Agent on behalf of any Grantor and may be filed at any time in any jurisdiction. A copy of this Agreement shall be sufficient as a financing statement or other filing or recording document or instrument for filing or recording in any jurisdiction. Such Grantor also hereby ratifies its authorization for Agent to have filed any initial financing statement or amendment thereto under the UCC (or other similar laws) in effect in any jurisdiction if filed prior to the date hereof. To the extent permitted by law, each Grantor hereby (i) waives any right under the UCC or any other Applicable Law to receive notice and/or copies of any filed or recorded financing statements, amendments thereto, continuations thereof or termination statements and (ii) releases and excuses each Secured Party from any obligation under the UCC or any other Applicable Law to provide notice or a copy of any such filed or recorded documents. As this Agreement constitutes an amendment and restatement of the Existing Guaranty and Security Agreement, the parties to this Agreement do hereby acknowledge and agree that those financing statements currently on record naming the applicable Grantors as “Debtor” and the Agent as “Secured Party”, shall continue in full force and effect (as amended, if applicable) and shall continue to perfect the security interests and Liens granted under the Existing Guaranty and Security Agreement and reaffirmed, ratified and re-granted under this Agreement.

(b) Each Grantor shall, at any time and from time and to time, take such steps as the Agent may reasonably request for Agent to insure the continued perfection and priority of Agent’s security interest in any of the Collateral and of the preservation of its rights therein.

(c) If any Grantor shall at any time, acquire a commercial tort claim as set forth in Section 4.9 hereof, such Grantor shall promptly notify Agent thereof in writing and supplement Schedule 5, therein providing a reasonable description and summary thereof, and upon delivery thereof to Agent, such Grantor shall be deemed to thereby grant to Agent (and such Grantor hereby grants to Agent) a Lien in and to such commercial tort claim and all Proceeds thereof, all upon the terms of and governed by this Agreement, and such Grantor shall execute and deliver to Agent, in each case in form and substance reasonably satisfactory to Agent, any document, and take all other action, deemed by Agent to be reasonably necessary or appropriate for Agent to obtain, for the benefit of the Secured Parties, a perfected security interest in all such commercial tort claims. Any supplement to Schedule 5 delivered pursuant to this Section 5.9(c) shall, after the receipt thereof by Agent, become part of Schedule 5 for all purposes hereunder other than in respect of representations and warranties made prior to the date of such receipt.

5.10 Facility Agreement. Each of the Grantors covenants that it will, and, if necessary, will cause or enable Borrower to, fully comply with each of the covenants and other agreements set forth in the Facility Agreement.

5.11 Agent May Purchase Insurance. If a Grantor at any time or times hereafter shall fail to obtain, maintain or provide to Agent evidence of any of the policies of insurance or other items required under Section 5.1(e) of the Facility Agreement or to pay any premium relating thereto, then Agent, without waiving or releasing any obligation or default by such Grantor hereunder, may (but shall be under no obligation to) obtain and maintain such policies of insurance and pay such premiums and take such other actions with respect thereto as Agent deems advisable upon notice to such Grantor. Such insurance, if obtained by Agent, may, but need not, protect such Grantor’s interests or pay any claim made by or against such Grantor with respect to the Collateral. Such insurance may be more expensive than the cost of insurance such Grantor may be able to obtain on its own and may be cancelled only upon such Grantor providing evidence that it has obtained the insurance as required above. All sums disbursed by Agent in connection with any such actions shall constitute Secured Obligations and Guaranteed Obligations payable upon demand.

 

19


5.12 Further Assurances.

(a) Each Grantor agrees that from time to time, at its own expense, such Grantor will promptly execute and deliver all further instruments and documents, and take all further action, that Agent may reasonably request, in order to perfect and protect the security interest and Lien granted hereby, to create, perfect or protect the security interest and Lien purported to be granted hereby or to enable Agent to exercise and enforce its rights and remedies hereunder with respect to any of the Collateral.

(b) Grantor acknowledges that it is not authorized to file any financing statement or amendment or termination statement with respect to any financing statement filed in connection with this Agreement, the other Loan Documents or the Existing Loan Documents without the prior written consent of Agent, subject to such Grantor’s rights under Section 9-509(d)(2) of the UCC.

SECTION 6 REMEDIAL PROVISIONS.

6.1 Certain Matters Relating to Receivables. Subject to, in each case, the terms of the Intercreditor Agreement (to the extent applicable):

(a) At any time and from time to time after the occurrence and during the continuance of an Event of Default, Agent shall have the right to make test verifications of the Receivables in any manner and through any medium that it reasonably considers advisable, and each Grantor shall furnish all such assistance and information as Agent may reasonably require in connection with such test verifications. At any time and from time to time after the occurrence and during the continuance of an Event of Default, upon request of the Agent and at the expense of the relevant Grantor, such Grantor shall cause independent public accountants or others satisfactory to Agent to furnish to Agent reports showing reconciliations, agings and test verifications of, and trial balances for, the Receivables.

(b) If requested by Agent at any time after the occurrence and during the continuance of an Event of Default, any payments of Receivables, when collected by any Grantor, (i) shall be forthwith (and, in any event, within two (2) Business Days) deposited by such Grantor in the exact form received, duly indorsed by such Grantor to Agent (for the benefit of the Secured Parties) and upon notice to such Grantor, in a collateral account maintained under the sole dominion and control of Agent, subject to withdrawal by Agent as provided in Section 6.4 hereof, and (ii) until so turned over, shall be held by such Grantor in trust for Agent (for the benefit of the Secured Parties), segregated from other funds of such Grantor. Each such deposit of Proceeds of Receivables shall be accompanied by a report identifying in reasonable detail the nature and source of the payments included in the deposit.

(c) At any time and from time to time after the occurrence and during the continuance of an Event of Default, at the request of Agent, each Grantor shall deliver to Agent all original and other documents evidencing, and relating to, the agreements and transactions which gave rise to the Receivables, including all original orders, invoices and shipping receipts and notify account debtors that the accounts or general intangibles that are Collateral have been collaterally assigned to Agent and that payments in respect thereof shall be made directly to Agent.

(d) Each Grantor hereby irrevocably authorizes and empowers Agent, in Agent’s sole discretion, at any time after the occurrence and during the continuance of an Event of Default, without notice to such Grantor: (i) to limit or terminate the ability of a Grantor to collect its Receivables or any thereof; to assert, either directly or on behalf of such Grantor, any claim such Grantor may from time to time have against account debtors and to otherwise enforce such Grantor’s rights against such account debtors; (ii) to receive and collect any and all damages, awards and other monies resulting therefrom and to apply the same to the Secured Obligations as set forth in Section 6.5 hereof; and (iii) in its own name or in the

 

20


name of others, to communicate with account debtors to verify with them to Agent’s reasonable satisfaction the existence, amount and terms of any account or amounts due under any general intangible that is Collateral.

6.2 Communications with Obligors; Grantors Remain Liable.

(a) Agent in its own name or in the name of others may at any time after the occurrence and during the continuance of an Event of Default communicate with obligors under the Receivables to verify with them to Agent’s satisfaction the existence, amount and terms of any Receivables

(b) Subject to the terms of the Intercreditor Agreement (to the extent applicable), upon the request of Agent at any time after the occurrence and during the continuance of an Event of Default, each Grantor shall notify obligors on the Receivables that the Receivables have been assigned to Agent and that payments in respect thereof shall be made directly to Agent.

(c) Anything herein to the contrary notwithstanding, each Grantor shall remain liable in respect of each of the Receivables to observe and perform all the conditions and obligations to be observed and performed by it thereunder, all in accordance with the terms of any agreement giving rise thereto. No Secured Party shall have any obligation or Liability under any Receivable (or any agreement giving rise thereto) by reason of or arising out of any Loan Document or the receipt by Agent or any other Secured Party of any payment relating thereto, nor shall any Secured Party be obligated in any manner to perform any of the obligations of any Grantor under or pursuant to any Receivable (or any agreement giving rise thereto), to make any payment, to make any inquiry as to the nature or the sufficiency of any payment received by it or as to the sufficiency of any performance by any party thereunder, to present or file any claim, to take any action to enforce any performance or to collect the payment of any amounts which may have been assigned to it or to which it may be entitled at any time or times.

6.3 Pledged Investment Property and Pledged Collateral.

(a) Unless an Event of Default shall have occurred and be continuing and until Agent has notified Borrower otherwise, each Grantor shall be permitted to receive all cash dividends and distributions paid in respect of the Pledged Collateral and all payments made in respect of the Pledged Investment Property, to the extent permitted in the Facility Agreement, and to exercise all voting and other rights with respect to the Pledged Collateral and Pledged Investment Property; provided, that no vote shall be cast or other right exercised or action taken that could be reasonably likely to materially impair the Collateral or which would be inconsistent with or result in any violation of any provision of the Facility Agreement, this Agreement or any other Loan Document.

(b) If an Event of Default shall occur and be continuing: (i) Agent shall have the right to receive any and all cash dividends and distributions, payments or other Proceeds paid in respect of the Pledged Collateral and Pledged Investment Property and make application thereof to the Secured Obligations as set forth in Section 6.5 hereof, (ii) Agent shall have the right to cause any or all of the Pledged Collateral and Pledged Investment Property to be registered in the name of Agent or its nominee and (iii) Agent or its nominee may exercise (x) all voting, consent, corporate and other rights pertaining to such Pledged Collateral and Pledged Investment Property at any meeting of shareholders, partners or members, as the case may be, of the relevant Issuer or Issuers or otherwise (or by written consent) and (y) any and all rights of conversion, exchange and subscription and any other rights, privileges or options pertaining to such Pledged Collateral and Pledged Investment Property as if it were the absolute owner thereof (including the right to exchange at its discretion any and all of the Pledged Collateral and Pledged Investment Property upon the merger, amalgamation, consolidation, reorganization, recapitalization or other fundamental change in the corporate or other structure of any Issuer, or upon the exercise by any

 

21


Grantor or Agent of any right, privilege or option pertaining to such Pledged Collateral and Pledged Investment Property, and in connection therewith, the right to deposit and deliver any and all of the Pledged Collateral and Pledged Investment Property with any committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions as Agent may determine), all without Liability other than to the extent such Liability is a result of its own willful misconduct or gross negligence as determined by a court of competent jurisdiction in a final non-appealable order or to account for property actually received by it, but Agent shall have no duty to any Grantor to exercise any such right, privilege or option and shall not be responsible for any failure to do so or delay in so doing.

(c) Each Grantor hereby expressly and irrevocably authorizes and instructs, without any further instructions from such Grantor, each Issuer of the Pledged Collateral and Pledged Investment Property pledged by such Grantor hereunder to (i) comply with any instruction received by it from Agent in writing that (x) states that an Event of Default has occurred and is continuing and (y) is otherwise in accordance with the terms of this Agreement, and each Grantor agrees that each Issuer shall be fully protected in so complying and (ii) unless otherwise permitted under the Loan Documents, pay any dividends, distributions or other payments with respect to the Pledged Collateral and Pledged Investment Property directly to Agent.

(d) In order to permit Agent to exercise the voting and other consensual rights that it is entitled to exercise pursuant hereto and to receive all dividends and other distributions that it is entitled to receive hereunder, (i) during the existence of an Event of Default, each Grantor shall promptly execute and deliver (or cause to be executed and delivered) to Agent all such proxies, dividend payment orders and other instruments as Agent may from time to time reasonably request and (ii) without limiting the effect of clause (i) above, such Grantor hereby grants to Agent an irrevocable proxy to vote all or any part of the Pledged Collateral and the Pledged Investment Property and to exercise all other rights, powers, privileges and remedies to which a holder of the Pledged Collateral or the Pledged Investment Property, as applicable, would be entitled (including giving or withholding written consents of shareholders, partners or members, as the case may be, calling special meetings of shareholders, partners or members, as the case may be, and voting at such meetings), which proxy shall be effective, automatically and without the necessity of any action (including any transfer of any Pledged Collateral or Pledged Investment Property on the record books of the Issuer thereof) by any other person (including the Issuer of such Pledged Collateral or Pledged Investment Property, as applicable, or any officer or agent thereof) solely during the continuance of an Event of Default and which proxy shall only terminate upon the Payment in Full in cash of the Secured Obligations or upon an express waiver in writing by Agent and the Required Lenders of the underlying Event of Default in accordance with the terms of the Facility Agreement.

6.4 Proceeds to be Turned Over to Agent. In addition to the rights of Agent specified in Section 6.1 hereof with respect to payments of Receivables, if an Event of Default shall occur and be continuing and Agent has notified Borrower of the Grantors’ obligations under this Section 6.4, all Proceeds received by any Grantor consisting of cash, checks and other cash equivalent items shall be held by such Grantor in trust for Agent (for the benefit of the Secured Parties), segregated from other funds of such Grantor, and shall, upon written request of Agent, forthwith upon receipt by such Grantor, be turned over to Agent in the exact form received by such Grantor (duly indorsed by such Grantor to Agent, if required). Subject to the terms of the Intercreditor Agreement (if applicable), all Proceeds received by Agent under this Section 6.4 shall be held by Agent in a collateral account maintained under its sole dominion and control. All Proceeds, while held by Agent (for the benefit of the Secured Parties) in any collateral account (or by such Grantor in trust for Agent (for the benefit of the Secured Parties)) established pursuant hereto, shall continue to be held as collateral security for the Secured Obligations and shall not constitute payment thereof until applied as provided in Section 6.5 hereof.

6.5 Application of Proceeds. Agent may apply all or any part of Proceeds from the

 

22


sale of, or other realization upon, all or any part of the Collateral (after deducting all reasonable and documented external attorneys’ and other fees and out-of-pocket costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any Collateral or in any way relating to the Collateral or the rights of Agent and any other Secured Party hereunder) in payment of the Secured Obligations in such order as the Agent shall determine in its discretion, and may pay any other amount required by any Applicable Law. Any balance of such Proceeds remaining after the Secured Obligations and the Guaranteed Obligations (as applicable) shall have been Paid in Full shall be paid over to the applicable Grantor or to whomsoever may be lawfully entitled to receive the same. The parties hereto understand and agree that the exercise of remedies hereunder with respect to accounts arising under any Third Party Payor program may be subject to Applicable Law.

6.6 UCC and Other Remedies. If an Event of Default shall occur and be continuing, Agent may exercise, in addition to all other rights and remedies granted to them in this Agreement and in any other instrument or agreement securing, evidencing or relating to the Secured Obligations, all rights and remedies of a secured party under the UCC or any other Applicable Law. Without limiting the generality of the foregoing, Agent, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon any Grantor or any other Person (all and each of which demands, defenses (other than defense of payment), advertisements and notices are hereby waived), may in such circumstances forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof, and/or may forthwith sell, lease, assign, give options to purchase, or otherwise dispose of and deliver the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s board or office of Agent or elsewhere upon such terms and conditions as they may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery with assumption of any credit risk. Agent shall have the right upon any such public sale or sales, and, to the extent permitted by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption in any Grantor, which right or equity is hereby waived and released. Each Grantor further agrees, at Agent’s request, to assemble the Collateral and make it available to Agent at places which Agent shall reasonably select, whether at such Grantor’s premises or elsewhere in connection with the exercise of Agent’s remedies hereunder. Agent shall apply the net Proceeds of any action taken by it pursuant to this Section 6.6, after deducting all reasonable documented out-of-pocket costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any of the Collateral or in any way relating to the Collateral or the rights of Agent hereunder, to the payment in whole or in part of the Secured Obligations, as set forth in Section 6.5 hereof. To the extent permitted by Applicable Law, each Grantor waives all claims, damages and demands it may acquire against Agent arising out of the exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of Collateral shall be required by law, such notice shall be deemed reasonable and proper if given at least 10 calendar days before such sale or other disposition. Agent shall not be obligated to make any sale of Collateral regardless of notification of sale having been given. Agent may adjourn any public sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. Each Grantor agrees that (A) the internet shall constitute a “place” for purposes of Section 9-610(b) of the UCC and (B) to the extent notification of sale shall be required by law, notification by mail of the URL where a sale will occur and the time when a sale will commence at least ten (10) days prior to the sale shall constitute a reasonable notification for purposes of Section 9-611(b) of the UCC. Each Grantor agrees that any sale of Collateral to a licensor pursuant to the terms of a license agreement between such licensor and a Grantor is sufficient to constitute a commercially reasonable sale (including as to method, terms, manner, and time) within the meaning of Section 9-610 of the UCC.

6.7 Private Sale. Each Grantor recognizes that Agent may be unable to effect a public sale of any or all the Pledged Collateral and Pledged Investment Property, by reason of certain prohibitions

 

23


contained in the Securities Act and applicable state or foreign securities laws or otherwise, or may otherwise determine that a public sale is impracticable, not desirable or not commercially reasonable, and, accordingly, and may resort to one or more private sales thereof to a restricted group of purchasers that will be obliged to agree, among other things, to acquire such securities for their own account for investment and not with a view to the distribution or resale thereof. Each Grantor acknowledges and agrees that any such private sale may result in prices and other terms less favorable than if such sale were a public sale and, notwithstanding such circumstances, agrees that any such private sale shall be deemed to have been made in a commercially reasonable manner. Agent shall be under no obligation to delay a sale of any of the Pledged Collateral or Pledged Investment Property for the period of time necessary to permit the Issuer thereof to register such securities or other interests for public sale under the Securities Act, or under applicable state or foreign securities laws, even if such Issuer would agree to do so.

Each Grantor agrees to use its commercially reasonable efforts to do or cause to be done all such other acts as may be necessary to make such sale or sales of all or any portion of the Pledged Collateral and Pledged Investment Property pursuant to this Section 6.7 and Section 6.11 hereof valid and binding and in compliance with Applicable Law. Each Grantor further agrees that a breach of any of the covenants contained herein will cause irreparable injury to Agent and the other Secured Parties, that Agent and the other Secured Parties have no adequate remedy at law in respect of such breach and, as a consequence, that each and every covenant contained herein shall be specifically enforceable against such Grantor (except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally), and such Grantor hereby waives and agrees not to assert any defenses against an action for specific performance of such covenants. Until all of the Secured Obligations and all of the Guaranteed Obligations are Paid in Full, each Grantor postpones until such date any and all rights of contribution or subrogation upon the sale or disposition of all or any portion of the Pledged Collateral and Pledged Investment Property by Agent.

6.8 Deficiency. Each Grantor shall remain liable for any deficiency if the Proceeds of any sale or other disposition of any Collateral are insufficient to Pay in Full the Secured Obligations and the fees and disbursements of any attorneys employed by Agent or any other Secured Party to collect such deficiency.

6.9 Licenses. Solely for the purpose of enabling Agent (for the benefit of the Secured Parties) to exercise rights and remedies following and during the continuation of an Event of Default (including in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, sell, assign, convey, transfer or grant options to purchase any Collateral), each Grantor hereby grants to Agent, for the benefit of the Secured Parties, (i) an irrevocable, nonexclusive license (exercisable without payment of royalty or other compensation to such Grantor) including in such license the right to use, practice, license or sublicense any Intellectual Property now owned or hereafter acquired by such Grantor, and wherever the same may be located, and including in such license access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof, and (ii) an irrevocable license (without payment of rent or other compensation to such Grantor) to use, operate and occupy all Real Estate owned, operated, leased, subleased or otherwise occupied by such Grantor; provided, in each case, that no such licenses shall be granted with respect to any Excluded Property.

6.10 Reserved.

6.11 Disposition of Collateral. Without limiting the generality of the foregoing, to the fullest extent not prohibited by Applicable Law, Agent may, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon any Grantor or any other Person (all and each of which demands, defenses,

 

24


advertisements and notices are hereby waived), upon the occurrence and during the continuance of any Event of Default (personally or through its agents or attorneys), (i) enter upon the premises where any Collateral is located, without any obligation to pay rent, through self-help, without judicial process, without first obtaining a final judgment or giving any Grantor or any other Person notice or opportunity for a hearing on Agent’s claim or action, (ii) collect, receive, appropriate and realize upon any Collateral and (iii) sell, assign, convey, transfer, grant option or options to purchase and deliver any Collateral (and enter into contractual obligations to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s board or office of any Secured Party or elsewhere upon such terms and conditions as it may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery without assumption of any credit risk. Agent shall have the right, upon any such public sale or sales and, to the extent permitted by the UCC and other Applicable Law, upon any such private sale, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption of any Grantor, which right or equity is hereby waived and released.

6.12 Management of the Collateral. Each Grantor further agrees, that, upon the occurrence and during the continuance of any Event of Default and to the fullest extent not prohibited by Applicable Law and, in each case, subject to the terms of the Intercreditor Agreement (if applicable), (i) at Agent’s written request, it shall assemble the Collateral and make it available to Agent at places that Agent shall reasonably select, whether at such Grantor’s premises or elsewhere, (ii) without limiting the foregoing, Agent also has the right to require that each Grantor store and keep any Collateral pending further action by Agent and, while any such Collateral is so stored or kept, provide such guards and maintenance services as shall be necessary to protect the same and to preserve and maintain such Collateral in good condition, (iii) until Agent is able to sell, assign, convey or transfer any Collateral, Agent shall have the right to hold or use such Collateral to the extent that it deems appropriate for the purpose of preserving the Collateral or its value or for any other purpose deemed appropriate by Agent, and (iv) Agent may, if it so elects, seek the appointment of a receiver or keeper to take possession of any Collateral and to enforce any of Agent’s remedies (for the benefit of the Secured Parties), with respect to such appointment without prior notice or hearing as to such appointment. Agent shall not have any obligation to any Grantor to maintain or preserve the rights of any Grantor as against third parties with respect to any Collateral while such Collateral is in the possession of Agent.

6.13 Direct Obligation. Neither Agent nor any other Secured Party shall be required to make any demand upon, or pursue or exhaust any right or remedy against, any Grantor, any other Guarantor, any other Loan Party or any other Person with respect to the payment of the Secured Obligations or the Guaranteed Obligations or to pursue or exhaust any right or remedy with respect to any Collateral therefor or any direct or indirect guaranty thereof. All of the rights and remedies of Agent and any other Secured Party under any Loan Document shall be cumulative, may be exercised individually or concurrently and not exclusive of any other rights or remedies provided by any Applicable Law. To the extent it may lawfully do so, each Grantor absolutely and irrevocably waives and relinquishes the benefit and advantage of, and covenants not to assert against Agent or any other Secured Party, any valuation, stay, appraisement, extension, redemption or similar laws and any and all rights or defenses it may have as a surety, now or hereafter existing, arising out of the exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of any Collateral shall be required by law, such notice shall be deemed reasonable and proper if given at least ten (10) calendar days before such sale or other disposition.

6.14 Commercially Reasonable. To the extent that any Applicable Law impose duties on Agent to exercise remedies in a commercially reasonable manner, each Grantor acknowledges and agrees that it is not commercially unreasonable for Agent to do any of the following:

(a) fail to incur significant costs, expenses or other Liabilities reasonably deemed as such by Agent to prepare any Collateral for disposition or otherwise to complete raw material or work in

 

25


process into finished goods or other finished products for disposition;

(b) fail to obtain permits, or other consents, for access to any Collateral to sell or for the collection or sale of any Collateral, or, if not required by other Applicable Law, fail to obtain Permits or other consents for the collection or disposition of any Collateral;

(c) fail to exercise remedies against account debtors or other Persons obligated on any Collateral or to remove Liens on any Collateral or to remove any adverse claims against any Collateral;

(d) advertise dispositions of any Collateral through publications or media of general circulation, whether or not such Collateral is of a specialized nature, or to contact other Persons, whether or not in the same business as any Grantor, for expressions of interest in acquiring any such Collateral;

(e) exercise collection remedies against account debtors and other Persons obligated on any Collateral, directly or through the use of collection agencies or other collection specialists, hire one or more professional auctioneers to assist in the disposition of any Collateral, whether or not such Collateral is of a specialized nature, or, to the extent deemed appropriate by Agent, obtain the services of other brokers, investment bankers, consultants and other professionals to assist Agent in the collection or disposition of any Collateral, or utilize Internet sites that provide for the auction of assets of the types included in the Collateral or that have the reasonable capacity of doing so, or that match buyers and sellers of assets to dispose of any Collateral;

(f) dispose of assets in wholesale rather than retail markets;

(g) disclaim disposition warranties, such as title, possession or quiet enjoyment; or

(h) purchase insurance or credit enhancements to insure Agent against risks of loss, collection or disposition of any Collateral or to provide to Agent a guaranteed return from the collection or disposition of any Collateral.

Each Grantor acknowledges that the purpose of this Section 6.14 is to provide a non-exhaustive list of actions or omissions that are commercially reasonable when exercising remedies against any Collateral and that other actions or omissions by any Secured Party shall not be deemed commercially unreasonable solely on account of not being indicated in this Section 6.14. Without limitation upon the foregoing, nothing contained in this Section 6.14 shall be construed to grant any rights to any Grantor or to impose any duties on Agent or any other Secured Party that would not have been granted or imposed by this Agreement or by Applicable Law in the absence of this Section 6.14.

SECTION 7 AGENT.

7.1 Agent’s Appointment as Attorney-in-Fact.

(a) Each Grantor hereby irrevocably constitutes and appoints Agent and any Affiliates, directors, partners, officers, employees, agents, counsel and advisors thereof, with full power of substitution, as its true and lawful attorney-in-fact with full power and authority in the place and stead of such Grantor and in the name of such Grantor or in its own name, for the purpose of carrying out the terms of the Loan Documents, to, upon the occurrence and during the continuance of an Event of Default, take any appropriate action and to execute any document or instrument that may be necessary or desirable to accomplish the purposes of the Loan Documents, and, without limiting the generality of the foregoing, each Grantor hereby gives Agent and its Affiliates, directors, partners, officers, employees, agents, counsel and advisors the power and right, on behalf of such Grantor, without notice to or assent by such Grantor, to do

 

26


any of the following when an Event of Default has occurred and is continuing (subject, as applicable, to compliance by Agent with Applicable Law with respect to Accounts arising under any Third Party Payor programs):

(i) in the name of such Grantor, in its own name or otherwise, take possession of and indorse and collect any check, draft, note, acceptance or other instrument for the payment of moneys due under any account or general intangible that is Collateral or with respect to any other Collateral and file any claim or take any other action or proceeding in any court of law or equity or otherwise deemed appropriate by Agent for the purpose of collecting any such moneys due under any account or general intangible that is Collateral or with respect to any other Collateral whenever payable;

(ii) in the case of any Intellectual Property owned by and, in the case of Copyrights, exclusively licensed to such Grantor (to the extent not constituting Excluded Property and to the extent permitted under the applicable Intellectual Property), execute, deliver and have recorded any document that Agent may request in accordance with this Agreement to evidence, effect, publicize or record Agent’s security interest in such Intellectual Property and the goodwill and general intangibles of such Grantor relating thereto or represented thereby;

(iii) pay or discharge taxes and Liens levied or placed on or threatened against any Collateral, effect any repair or pay any insurance called for by the terms of the Facility Agreement (including all or any part of the premiums therefor and the costs thereof);

(iv) execute, in connection with any sale provided for in Section 6.7 or Section 6.11 hereof, any document to effect or otherwise necessary or appropriate in relation to evidence the sale of any Collateral; or

(v) (A) direct any party liable for any payment under any Collateral to make payment of any moneys due or to become due thereunder directly to Agent or as Agent shall direct, (B) ask or demand for, and collect and receive payment of and receipt for, any moneys, claims and other amounts due or to become due at any time in respect of or arising out of any Collateral, (C) sign and indorse any invoice, freight or express bill, bill of lading, storage or warehouse receipt, draft against debtors, assignment, verification, notice and other document in connection with any Collateral, (D) commence and prosecute any suit, action or proceeding at law or in equity in any court of competent jurisdiction to collect any Collateral and to enforce any other right in respect of any Collateral, (E) defend any actions, suits, proceedings, audits, claims, demands, orders or disputes brought against such Grantor with respect to any Collateral, (F) settle, compromise or adjust any such actions, suits, proceedings, audits, claims, demands, orders or disputes that are related to Collateral and, in connection therewith, give such discharges or releases as Agent may deem appropriate, (G) assign any Intellectual Property owned by any Grantor or any Intellectual Property Licenses of any Grantor where such Grantor is the licensor thereunder (to the extent not constituting Excluded Property and to the extent permitted under the applicable Intellectual Property or Intellectual Property License, as applicable) throughout the world on such terms and conditions and in such manner as Agent shall in its sole discretion determine (except, with respect to Trademarks, subject to reasonable quality control in favor of such Grantor), including the execution and filing of any document necessary to effectuate or record such assignment, or (H) generally, sell, assign, convey, transfer or grant a Lien on, make any Contractual Obligation with respect to and otherwise deal with, any Collateral as fully and completely as though Agent were the absolute owner thereof for all purposes and do, at Agent’s option, at any time or from time to time, all acts and things that Agent deems necessary to protect, preserve or realize upon any Collateral

 

27


and the Secured Parties’ security interests therein and to effect the intent of the Loan Documents, all as fully and effectively as such Grantor might do;

(vi) if any Grantor fails to perform or comply with any Contractual Obligation contained herein, then during the existence of an Event of Default, Agent, at its option, but without any obligation so to do, may perform or comply, or otherwise cause performance or compliance, with such Contractual Obligation;

(vii) receive and open all mail addressed to any Grantor and to notify postal authorities to change the address for the delivery of mail to such Grantor to that of Agent; or

(viii) use any Intellectual Property or Intellectual Property Licenses of such Grantor, including but not limited to any labels, Patents, Trademarks, trade names, URLs, domain names, industrial designs, Copyrights, or advertising matter, in preparing for sale, advertising for sale, or selling Inventory or other Collateral and to collect any amounts due under Accounts, contracts or negotiable Collateral of such Grantor.

(b) The expenses of Agent incurred in connection with actions undertaken as provided in this Section 7.1, together with, during the existence of an Event of Default as set forth in Section 2.7(b) of the Facility Agreement, interest thereon at a rate set forth in Section 2.7(b) of the Facility Agreement, from the date of payment by Agent to the date reimbursed by the relevant Grantor, shall be payable by such Grantor to Agent on written demand by Agent to Borrower.

(c) Each Grantor hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue of, and in accordance with, this Section 7.1. All powers, authorizations and agencies contained in this Agreement are coupled with an interest and are irrevocable until this Agreement is terminated and the security interests created hereby are released.

7.2 Authority of Agent. Each Grantor acknowledges that the rights and responsibilities of Agent under this Agreement with respect to any action taken by Agent or the exercise or non-exercise by Agent of any option, voting right, request, judgment or other right or remedy provided for herein or resulting or arising out of this Agreement shall, as between Agent and the other Secured Parties, be governed by the Facility Agreement and by such other agreements with respect thereto as may exist from time to time among them, but, as between Agent and any Grantor, Agent shall be conclusively presumed to be acting as agent for the Secured Parties with full and valid authority so to act or refrain from acting, and no Grantor shall be under any obligation or entitlement to make any inquiry respecting such authority.

7.3 Duty; Obligations and Liabilities.

(a) Agent’s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in its possession shall be to deal with it in the same manner as Agent deals with similar property for its own account. The powers conferred on Agent hereunder are solely to protect Agent’s interest in the Collateral and shall not impose any duty upon Agent to exercise any such powers. Agent shall be accountable only for amounts that it receives as a result of the exercise of such powers, and neither it nor any of its Affiliates, directors, partners, officers, employees, agents, counsel or advisors shall be responsible to any Grantor for any act or failure to act hereunder, except for their own gross negligence, bad faith or willful misconduct, in each case, as determined by a court of competent jurisdiction in a final non-appealable order. In addition, Agent shall not be liable or responsible for any loss or damage to any Collateral, or for any diminution in the value thereof, by reason of the act or omission of any warehousemen, carrier, forwarding agency, consignee or other bailee if such Person has been selected by Agent in good faith.

 

28


(b) No Secured Party and no Affiliates, directors, partners, officers, employees, agents, counsel or advisors thereof shall be liable for failure to demand, collect or realize upon any Collateral or for any delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or any other Person or to take any other action whatsoever with regard to any Collateral. The powers conferred on Agent hereunder shall not impose any duty upon any other Secured Party to exercise any such powers. The other Secured Parties shall be accountable only for amounts that they actually receive as a result of the exercise of such powers, and neither they nor any of their respective officers, directors, employees or agents shall be responsible to any Grantor for any act or failure to act hereunder, except for their own gross negligence or willful misconduct as determined by a court of competent jurisdiction in a final non-appealable order.

SECTION 8 MISCELLANEOUS.

8.1 Amendments in Writing. The provisions of this Agreement may be waived, modified, supplemented or amended only by an instrument in writing signed by Borrower and Agent; provided, however, that annexes and schedules, as applicable, to this Agreement may be supplemented or modified (but no existing provisions may be modified and no Collateral may be released, except with respect to the removal of items on the schedules in connection with a sale or other Disposition of Collateral, a merger or Acquisition, in each case, that is permitted under the Facility Agreement) as set forth in Section 5 and Section 8.15 hereof. Notwithstanding anything to the contrary in the first sentence of this Section 8.1, any time period for performance under this Agreement may be extended, at any time, by Agent in its sole discretion.

8.2 Notices. All notices, requests and demands to or upon Agent or any Guarantor or Grantor hereunder shall be addressed to such party and effected in the manner provided for in Section 6.1 of the Facility Agreement and each Guarantor and Grantor hereby appoints the Borrower as its agent to receive notices hereunder.

8.3 Indemnification by Grantors. Each Grantor and each Guarantor agrees to jointly and severally indemnify, pay, and hold Agent, the other Secured Parties and the Secured Parties’ Affiliates, officers, directors, employees, agents, and attorneys (the “Indemnitees”) harmless against losses and Liabilities to the extent set forth in Section 6.11 of the Facility Agreement, the terms of which are incorporated herein by reference as though set forth fully herein. The provisions in this Section 8.3 shall survive Payment in Full of all Secured Obligations and of all Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement.

8.4 Enforcement Expenses.

(a) The terms of Section 6.3 of the Facility Agreement with respect to costs and expenses are incorporated herein by reference, mutatis mutandis, and the parties hereto agree to such terms.

(b) The agreements in this Section 8.4 shall survive Payment in Full of all Secured Obligations and the Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement.

8.5 Nature of Remedies. All Secured Obligations and Guaranteed Obligations of each Grantor and rights of Agent and the other Secured Parties expressed herein or in any other Loan Document shall be in addition to and not in limitation of those provided by Applicable Law. No failure to exercise and no delay in exercising, on the part of Agent or the other Secured Parties, any right, remedy, power or privilege hereunder, shall operate as a waiver thereof; nor shall any single or partial exercise of any right,

 

29


remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

8.6 Counterparts; Effectiveness. This Agreement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

8.7 Severability. If any provision of this Agreement or any of the other Loan Documents shall be invalid, illegal or unenforceable in any respect under any law, the validity, legality and enforceability of the remaining provisions hereof or thereof shall not in any way be affected or impaired thereby. The parties hereto shall endeavor in good faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provision.

8.8 Entire Agreement. This Agreement contains the entire understanding of the parties hereto with respect to the matters covered hereby and supersedes any and all other written and oral communications, negotiations, commitments and writings with respect thereto. All Exhibits, Schedules and Annexes referred to herein are incorporated in this Agreement by reference and constitute a part of this Agreement. If any provision contained in this Agreement conflicts with any provision of the Facility Agreement, then with regard to such conflicting provisions, the Facility Agreement shall govern and control.

8.9 Successors; Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns, except, notwithstanding anything to the contrary in this Agreement or any other Loan Document, that Grantors and Guarantors may not assign their rights or obligations hereunder and any such purported, prohibited or attempted assignment shall be void ab initio.

8.10 Applicable Law. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN SUCH STATE.

8.11 Consent to Jurisdiction. EACH PARTY AGREES THAT ALL LEGAL PROCEEDINGS CONCERNING THE INTERPRETATIONS, ENFORCEMENT AND DEFENSE OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT AND, UNLESS OTHERWISE EXPRESSLY STATED THEREIN, THE OTHER LOAN DOCUMENTS (WHETHER BROUGHT AGAINST A PARTY HERETO OR ITS RESPECTIVE AFFILIATES, DIRECTORS, OFFICERS, SHAREHOLDERS, EMPLOYEES OR AGENTS) SHALL BE COMMENCED EXCLUSIVELY IN THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER THE OTHER LOAN DOCUMENTS OR IN CONNECTION HEREWITH OR WITH THE OTHER LOAN DOCUMENTS OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, OR THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER OR IS AN INCONVENIENT VENUE FOR SUCH PROCEEDING.

 

30


EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.

8.12 Waiver of Jury Trial. THE PARTIES HERETO, TO THE EXTENT PERMITTED BY LAW, WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING ARISING OUT OF, IN CONNECTION WITH OR RELATING TO, THIS AGREEMENT, THE OTHER LOAN DOCUMENTS AND ANY TRANSACTION CONTEMPLATED HEREBY AND THEREBY. THIS WAIVER APPLIES TO ANY ACTION, SUIT OR PROCEEDING WHETHER SOUNDING IN TORT, CONTRACT OR OTHERWISE. EACH PARTY HERETO (A) CERTIFIES THAT NO OTHER PARTY AND NO AGENT, REPRESENTATIVE OR OTHER PERSON AFFILIATED WITH OR RELATED TO ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THE LOAN DOCUMENTS, AS APPLICABLE, BY THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.12.

8.13 Set-off. Each Grantor agrees that Agent and the other Secured Parties have all rights of set-off and bankers’ lien provided by Applicable Law, and in addition thereto, each Grantor agrees that at any time any Event of Default exists, Agent and the other Secured Parties may apply to the payment of any Secured Obligations and the Guaranteed Obligations as set forth in Section 6.5 hereof, whether or not then due, any and all balances, credits, deposits, accounts or moneys of such Grantor then or thereafter with the Secured Parties.

8.14 Acknowledgements. Each Grantor and each Guarantor hereby acknowledges that:

(a) it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Loan Documents to which it is a party;

(b) Neither Agent nor any other Secured Party have any fiduciary relationship with or duty to any Grantor or Guarantor arising out of or in connection with this Agreement or any of the other Loan Documents, and the relationship between the Grantors and Guarantors, on the one hand, and Agent and the other Secured Parties, on the other hand, in connection herewith or therewith is solely that of debtor and creditor; and

(c) no joint venture is created hereby or by the other Loan Documents or otherwise exists by virtue of the transactions contemplated hereby among the Grantors, Guarantors and the Secured Parties.

8.15 Additional Grantors/Guarantors. The Grantors shall cause each Person, upon becoming a Subsidiary of a Grantor (other than any Excluded Subsidiary) or upon becoming a Subsidiary, limited liability company, other entity or other Person for which any Grantor divides or splits itself into (or that receives any assets or property of such Grantor from any such division or split), to guaranty Borrower’s and the other Grantors’ performance of the Secured Obligations and the Guaranteed Obligations and grant to Agent, for the benefit of the Secured Parties, a security interest in the personal property of such Person (to

 

31


the extent such personal property would constitute Collateral) to secure the Secured Obligations, its performance under the Facility Agreement and the other Loan Documents to the extent a party thereto and Borrower’s, each Guarantor’s and the other Grantors’ performance of the Secured Obligations by becoming a party to this Agreement. Upon execution and delivery by such Person of a joinder agreement in the form of Annex I hereto, such Person shall become a Grantor and Guarantor for all purposes of this Agreement.

8.16 Releases.

(a) At such time as the Secured Obligations have been Paid in Full, the Collateral shall be automatically released from the Liens created hereby and this Agreement shall automatically terminate (other than those provisions expressly surviving the Payment in Full of the Secured Obligations or the Guaranteed Obligations), all without delivery of any instrument or performance of any act by any party, and all rights to the Collateral shall automatically revert to the Grantors. At such time as the Guaranteed Obligations have been Paid in Full, subject to Section 8.18, the guarantees provided in Section 2 and the remainder of this Agreement shall automatically terminate (other than those provisions expressly surviving the Payment in Full of the Secured Obligations or the Guaranteed Obligations, including those specific provisions of Section 8 hereof expressly surviving Payment in Full of the Secured Obligations or the Guaranteed Obligations). At the request and sole expense of any Grantor following any such Payment in Full of the Secured Obligations, Agent shall promptly deliver to the Grantors any Collateral held by Agent hereunder, and execute and deliver to the Grantors such documents as the Grantors shall reasonably request in writing to evidence the termination and release of the Liens in the Collateral. At the request and sole expense of any Grantor following any such Payment in Full of the Guaranteed Obligations, Agent shall execute and deliver to the Grantors such documents as the Grantors shall reasonably request in writing to evidence the termination of the guarantees provided in Section 2.

(b) If any of the Collateral shall be sold, transferred or otherwise disposed of by any Grantor in a transaction permitted by the Facility Agreement or with the written consent of Agent and the Required Lenders, then Agent, at the reasonable written request and sole expense of such Grantor, shall execute and deliver to such Grantor all releases or other documents reasonably necessary for the release of the Liens created hereby on such Collateral; provided that Borrower shall have delivered to Agent, with reasonable notice prior to the date of the proposed release, a written request for release identifying the relevant Grantor, together with a certification by Borrower stating that such transaction is in compliance with the Facility Agreement and the other Loan Documents (including the relevant provision of the Loan Documents pursuant to which such transfer or other disposition is permitted, together with any additional evidence reasonably requested by Agent).

(c) If, in compliance with the terms and provisions of the Loan Documents, (i) all or substantially all of the Stock of any Guarantor is sold or otherwise transferred to a Person or Persons none of which is a Loan Party in a transaction permitted under the Loan Documents or with the written consent of Agent and the Required Lenders or (ii) any Guarantor becomes an Excluded Subsidiary as a result of a transaction permitted under the Loan Documents (any such Guarantor, and any Guarantor referred to in clause (i), a “Transferred Guarantor”), such Transferred Guarantor shall, upon the consummation of such sale or transfer or other transaction, be automatically released from its obligations under this Agreement (including under this Section 8.16) and the other Loan Documents, including its obligations to pledge and grant any Collateral owned by it and, in the case of a sale of all or substantially all of the Stock of the Transferred Guarantor, the pledge of such Stock to the Agent hereunder shall be automatically released, and, so long as the Borrower shall have provided the Agent such certifications or documents as the Agent shall reasonably request, the Agent, at the sole expense of the Grantors, shall take such actions as are reasonably necessary and requested by the Grantors in writing to effect each release described in this Section 8.16.

 

32


8.17 Obligations and Liens Absolute and Unconditional. Each Grantor and each Guarantor understands and agrees that the obligations of each Grantor under this Agreement shall be construed as continuing, absolute and unconditional without regard to (i) the validity or enforceability of any Loan Document, any of the Secured Obligations or any other collateral security therefor or guaranty or right of offset with respect thereto at any time or from time to time held by Agent or any other Secured Party, (ii) any defense, set-off or counterclaim (other than a defense of payment or performance) which may at any time be available to or be asserted by any Grantor, Guarantor or any other Person against Agent or any other Secured Party, or (iii) any other circumstance whatsoever (with or without notice to or knowledge of any Grantor or Guarantor) which constitutes, or might be construed to constitute, an equitable or legal discharge of any Grantor or Guarantor for the Secured Obligations or the Guaranteed Obligations, in bankruptcy or in any other instance. When making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Grantor or Guarantor, Agent and any other Secured Party may, but shall be under no obligation to, make a similar demand on or otherwise pursue such rights and remedies as they may have against any other Grantor or Guarantor or any other Person or against any collateral security for the Secured Obligations or guaranty for the Guaranteed Obligations or any right of offset with respect thereto, and any failure by Agent or any other Secured Party to make any such demand, to pursue such other rights or remedies or to collect any payments from any other Grantor or Guarantor or any other Person or to realize upon any such collateral security or guaranty or to exercise any such right of offset, or any release of any other Grantor or Guarantor or any other Person or any such collateral security, guaranty or right of offset, shall not relieve any Grantor or Guarantor of any obligation or Liability hereunder, and shall not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of Agent or any other Secured Party against any Grantor or Guarantor. For the purposes hereof “demand” shall include the commencement and continuance of any legal proceedings.

8.18 Reinstatement. Each Grantor and Guarantor agrees that, if any payment made by any Loan Party or other Person and applied to the Secured Obligations or the Guaranteed Obligations is at any time annulled, avoided, set aside, rescinded, invalidated, declared to be fraudulent or preferential or otherwise required to be refunded or repaid, or the Proceeds of any Collateral are required to be returned by any Secured Party to such Loan Party, its estate, trustee, receiver or any other party, including any Grantor or Guarantor, under any applicable bankruptcy law, state or federal law, common law or equitable cause, then, to the extent such payment or repayment is annulled, avoided, set aside, rescinded, invalidated, refunded, repaid or returned, any Lien or other Collateral securing such liability with respect to the Secured Obligations and any guarantee herein securing the Guaranteed Obligations shall be and remain in full force and effect, as fully as if such payment had never been made. If, prior to any of the foregoing, (i) any Lien or other Collateral securing such Grantor’s Secured Obligations or Guarantor’s Guaranteed Obligations shall have been released or terminated by virtue of the foregoing or (ii) any provision of the guaranty hereunder shall have been terminated, cancelled or surrendered in connection with the foregoing payment, such Lien, other Collateral, guaranty or other provision shall be reinstated in full force and effect and such prior release, termination, cancellation or surrender shall not diminish, release, discharge, impair or otherwise affect the obligations of any such Grantor in respect of any Lien or other Collateral securing, or any such Guarantor in respect of any guaranty guaranteeing such obligation or the amount of such payment. This Section 8.18 shall survive the termination of this Agreement pursuant to Section 8.16 or otherwise. The provisions in this Section 8.18 shall survive Payment in Full of all Secured Obligations and of all Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement.

8.19 Independent Obligations. The obligations of each Grantor and each Guarantor hereunder are independent of and separate from the Secured Obligations and the Guaranteed Obligations. During the continuance of any Event of Default, Agent may, at its sole election, proceed directly and at once, without notice, against any Grantor, any Guarantor and any Collateral to collect and recover the full amount of any Secured Obligation or Guaranteed Obligation (as applicable) then due, without first

 

33


proceeding against any other Grantor, any Guarantor, any other Loan Party or any other Collateral or any guaranty and without first joining any other Grantor, any other Guarantor or any other Loan Party in any proceeding.

8.20 No Waiver by Course of Conduct. No Secured Party shall by any act (except by a written signed instrument by the required Persons pursuant to Section 8.1 hereof and Section 6.6 of the Facility Agreement), delay, indulgence, omission or otherwise be deemed to have waived any right or remedy hereunder or to have acquiesced in any Default or Event of Default. No failure to exercise, nor any delay in exercising, on the part of any Secured Party, any right, power or privilege hereunder or under any other Loan Document shall operate as a waiver thereof. No single or partial exercise of any right, power or privilege hereunder or under any other Loan Document shall preclude any other or further exercise thereof or the exercise of any other right, power or privilege. A waiver by any Secured Party of any right or remedy hereunder or any other Loan Document on any one occasion shall not be construed as a bar to any right or remedy that such Secured Party would otherwise have on any future occasion.

8.21 Intercreditor Agreement. This Agreement is subject, in the manner and the extent, to the terms set forth in the Intercreditor Agreement. Any Collateral held by (or in the possession or control of) the ABL Agent (or its agents or bailees) shall be held as agent and bailee for security and Lien perfection purposes in favor of Agent (for the benefit of the Secured Parties) in accordance with the terms of the Intercreditor Agreement and the Loan Documents.

8.22 Relation to Other Loan Documents. The provisions of this Agreement shall be read and construed with the other Loan Documents referred to below in the manner so indicated. The provisions of any Copyright Security Agreement(s), Trademark Security Agreement(s), and Patent Security Agreement(s) are supplemental to the provisions of this Agreement, and nothing contained in any Copyright Security Agreement(s), Trademark Security Agreement(s), or Patent Security Agreement(s) shall limit any of the rights or remedies of Agent hereunder. In the event of any conflict between any provision in this Agreement and a provision in a Copyright Security Agreement, Trademark Security Agreement or Patent Security Agreement, such provision of this Agreement shall control.

8.23 Amendment and Restatement; Continuation of Obligations and Liens; No Novation.

(a) This Agreement does not extinguish the outstanding obligations of the Grantors evidenced by the Existing Guaranty and Security Agreement or discharge or release any Lien or security interest or any other security under the Existing Loan Documents or the Loan Documents, all of which obligations, Liens and security interests continue under this Agreement and the other Loan Documents (in each case, as expanded, increased and enlarged hereby, as applicable). Nothing herein contained shall be construed as a substitution or novation of the original obligations or other obligations (including, without limitation, any “Guaranteed Obligations” or “Secured Obligations”) under the Existing Guaranty and Security Agreement, which shall remain in full force and effect, except as amended hereby and by the other Loan Documents, and shall continue at all times under this Agreement, as amended hereby and thereby.

(b) All of the security interests, Liens and collateral granted under the Existing Guaranty and Security Agreement are hereby reaffirmed, ratified and confirmed in all respects and all parties hereto agree that such security interests, Liens and collateral continue under this Agreement.

(c) Each Grantor acknowledges and confirms that, as of the Agreement Date, it has no defense, set off, claim or counterclaim arising on or prior to the Agreement Date against any of the Secured Parties with regard to the indebtedness, liabilities and obligations created under the Existing Guaranty and Security Agreement and the Liens and security interests granted pursuant to the Existing Loan Documents

 

34


to secure the indebtedness, liabilities and obligations (including, without limitation, the “Guaranteed Obligations”, the “Secured Obligations” and the “Obligations,” as applicable) of the Grantors to the Secured Parties under the Existing Guaranty and Security Agreement, as amended and restated hereby, and that the term “Obligations” as used in the Loan Documents (or any other term used therein to describe or refer to the indebtedness, liabilities and obligations of the Grantors to the Secured Parties) includes, without limitation, the indebtedness, liabilities and obligations of the Guarantors under this Agreement, as the same further may be amended, modified, supplemented and/or restated from time to time. The Loan Documents and all agreements, instruments and documents executed or delivered in connection with any of the foregoing shall each be deemed to be amended to the extent necessary to give effect to the provisions of this Section 8.23. From and after the date hereof, all references in the Loan Documents to the “Guaranty and Security Agreement” shall be deemed to refer to this Agreement. From and after the date hereof, all references in the Loan Documents to (i) a “Guarantor” or the “Guarantors” shall be deemed to refer to the defined terms “Guarantor” or the “Guarantors” (as applicable) under this Agreement, (ii) the “Guaranteed Obligations” shall be deemed to refer to the defined term “Guaranteed Obligations” under this Agreement and (iii) the “Secured Obligations” shall be deemed to refer to the defined term “Secured Obligations” under this Agreement. Cross-references in the Loan Documents to particular section numbers in the Existing Guaranty and Security Agreement shall be deemed to be cross-references to the corresponding sections, as applicable, of this Agreement.

(d) The provisions of Sections 6.29, 6.30 and 6.31 of the Facility Agreement are incorporated herein mutatis mutandis.

[SIGNATURE PAGES FOLLOW]

 

35


IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.

 

GRANTORS AND GUARANTORS:     ENDOLOGIX, INC.,
      a Delaware corporation,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer
      CVD/RMS ACQUISITION CORP.,
      a Delaware corporation,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary
      NELLIX, INC.,
      a Delaware corporation,
as Grantor and Guarantor
      By:  

/s/ Vaseem, Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary
      TRIVASCULAR TECHNOLOGIES, INC.,
      a Delaware corporation,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary

 

 

[Signature Page to Amended and Restated Guaranty and Security Agreement]


GRANTORS AND GUARANTORS
CONTINUED:
    TRIVASCULAR, INC.,
      a California corporation,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary
      ENDOLOGIX CANADA, LLC,
      a Delaware limited liability company,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary
      TRIVASCULAR SALES LLC,
      a Texas limited liability company,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary
      RMS/ENDOLOGIX SIDEWAYS MERGER CORP.,
      a Delaware corporation,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary

 

 

[Signature Page to Amended and Restated Guaranty and Security Agreement]


AGENT:    

DEERFIELD PRIVATE DESIGN FUND IV, L.P.,

as Agent

      By: Deerfield Mgmt IV, L.P., General Partner
      By: J.E. Flynn Capital IV, LLC, General Partner
      By:  

/s/ David J. Clark                                        

      Name:   David J. Clark
      Title:   Authorized Signatory

 

 

[Signature Page to Amended and Restated Guaranty and Security Agreement]


ANNEX I

FORM OF JOINDER TO GUARANTY AND SECURITY AGREEMENT

This JOINDER AGREEMENT (this “Agreement”) dated as of [            ], 20[        ] is executed by the undersigned in favor of Deerfield Private Design Fund IV, L.P., as Agent, for the benefit of the Secured Parties in connection with that certain Amended and Restated Guaranty and Security Agreement dated as of August 9, 2018, by and among Agent and the Guarantors and Grantors party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Guaranty and Security Agreement”). Capitalized terms not otherwise defined herein are being used herein as defined in the Guaranty and Security Agreement, or if not defined therein, in the Facility Agreement (as defined therein).

Each Person signatory hereto is required to execute this Agreement pursuant to Section 8.15 of the Guaranty and Security Agreement.

In consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each such Person hereby agrees as follows:

1. Each such Person assumes all the obligations of a Grantor and a Guarantor under the Guaranty and Security Agreement and agrees that such Person is a Grantor and a Guarantor and bound as a Grantor and a Guarantor under the terms of the Guaranty and Security Agreement, as if it had been an original signatory to such agreement. In furtherance of the foregoing, such Person hereby mortgages, pledges, assigns, hypothecates and transfers to Agent, for the benefit of the Secured Parties, and hereby grants to Agent, for the benefit of the Secured Parties, a Lien on and security interest in all of its Collateral, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Secured Obligations. For the avoidance of doubt, the Collateral does not include any Excluded Property.

2. Schedules 1, 1A, 2, 3, 4, 5, 6, 7, 8, 9 and 10 of the Guaranty and Security Agreement are hereby amended to add the information relating to each such Person set out on Schedules 1, 1A, 2, 3, 4, 5, 6, 7, 8, 9 and 10, respectively, hereof. Each such Person hereby makes to Agent and the other Secured Parties the representations and warranties set forth in the Guaranty and Security Agreement applicable to such Person and the applicable Collateral and confirms that such representations and warranties are true and correct in all material respects (without duplication of any materiality qualifier) as of the date hereof after giving effect to such amendment to such Schedules (except to the extent stated to relate to a specific earlier date, in which case, as of such earlier date).

3. In furtherance of its obligations under Section 5.2 of the Guaranty and Security Agreement, each such Person agrees to deliver to Agent appropriately complete UCC financing statements naming such Person as debtor and Agent as secured party, and describing its Collateral and such other documentation as Agent (or its successors or assigns) may require to evidence, protect and perfect the Liens created by the Guaranty and Security Agreement, as modified hereby. Each such Person acknowledges the authorizations given to Agent and its Related Parties and their counsel under the Section 5.9 of the Guaranty and Security Agreement and otherwise.

4. Each such Person’s address for notices under the Guaranty and Security Agreement shall be the address of the Borrower set forth in the Facility Agreement and each such Person hereby appoints the Borrower as its agent to receive notices hereunder.


5. Agent acknowledges that upon the effectiveness of this Agreement, the undersigned shall have the rights of a Grantor and Guarantor under the Guaranty and Security Agreement.

6. This Agreement shall be deemed to be part of, and a modification to, the Guaranty and Security Agreement and shall be governed by all the terms and provisions of the Guaranty and Security Agreement, with respect to the modifications intended to be made to such agreement, which terms are incorporated herein by reference, are ratified and confirmed and shall continue in full force and effect as valid and binding agreements of each such person or entity enforceable against such Person, except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally. Each such Person hereby waives notice of Agent’s acceptance of this Agreement. Each such Person will deliver an executed original of this Agreement to Agent. This Agreement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

 

 

[remainder of page intentionally left blank]


IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.

 

[add signature block for each new Grantor]

[                                         ],

a [                        ], as a Grantor and Guarantor

By:  

 

Name:  

 

Acknowledged and agreed to as of the year and date first written above:
AGENT:
DEERFIELD PRIVATE DESIGN FUND IV, L.P., as Agent
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By:  

                                  

Name:   James E. Flynn
Title:   President


SCHEDULE 1

PLEDGED EQUITY AND PLEDGED DEBT INSTRUMENTS

Pledged Equity:

 

Grantor
(owner of
Record of
such Pledged
Equity)

  

Issuer

  

Par Value

  

No. of
Shares,
Units or
Interests
Owned

  

Total
Shares,
Units or
Interests
Authorized
and
Outstanding

  

Percentage
of Shares, Units or
Interests Owned

  

Certificate
(Indicate
No.)

Endologix, Inc.    Nellix, Inc.    $0.001    100 Shares    1,000 Shares Authorized; 100 Shares Outstanding    100%    65
Endologix, Inc.    CVD/RMS Acquisition Corp.    $0.001    100 Shares    100 Shares Authorized and Outstanding    100%    4
Endologix, Inc.    RMS/Endologix Sideways Merger Corp.    $0.001    100 Shares    100 Shares Authorized and Outstanding    100%    Com-1
Endologix, Inc.    TriVascular Technologies, Inc.    $0.001    100 Shares    1,000 Shares Authorized; 100 Shares Outstanding    100%    60
Endologix, Inc.    ELGX International Holdings GP    N.A.    Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests    100%    N.A.
Endologix, Inc.    Endologix Bermuda L.P.    N.A.    Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests    99%    N.A.


Grantor
(owner of
Record of
such Pledged
Equity)

  

Issuer

  

Par Value

  

No. of
Shares,
Units or
Interests
Owned

  

Total
Shares,
Units or
Interests
Authorized
and
Outstanding

  

Percentage
of Shares, Units or
Interests Owned

  

Certificate

(Indicate
No.)

ELGX International Holdings GP    Endologix Bermuda L.P.    N.A.    Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests    1%    N.A.
Endologix, Inc.    Endologix Singapore Private Limited    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
Endologix, Inc.    Endologix New Zealand Co.    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
Endologix, Inc.    ELGX South Korea Ltd    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
TriVascular Technologies, Inc.    TriVascular,Inc.    $0.01    100 Shares    100 Shares Authorized and Outstanding    100%    CS-4
TriVascular, Inc.    TriVascular Sales LLC    N.A.    1,000 Units of Membership Interests    1,000 Units of Membership Interests    100%    N.A.
TriVascular, Inc.    TriVascular
Germany
GmbH
   N.A.    Unspecified number of Company Interests    Unspecified number of Company Interests    100%    N.A.
TriVascular, Inc.    TriVascular
Switzerland
Sarl
   N.A.    Unspecified number of Company Interests    Unspecified number of Company Interests    100%    N.A.
TriVascular,    Endologix    N.A.    1,000 Units of Membership    1,000 Units of    100%    N.A.


Grantor
(owner of
Record of
such Pledged
Equity)

  

Issuer

  

Par
Value

  

No. of
Shares,
Units or
Interests
Owned

  

Total
Shares,
Units or
Interests
Authorized
and
Outstanding

  

Percentage
of Shares, Units or
Interests Owned

  

Certificate
(Indicate
No.)

Inc.    Canada, LLC       Interests    Membership Interests      
TriVascular, Inc.    TriVascular, Inc.
Italia Sarl
   N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
Endologix Bermuda L.P.    Endologix International Holdings B.V.    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
Endologix International Holdings B.V.    Endologix Poland spolkda z ograniczona odpowiedzialnoscia    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
Endologix International Holdings B.V.    Endologix Italia Sarl    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
Endologix International Holdings B.V.    Endologix International B.V.    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.

Pledged Debt Instruments:

 

Grantor (owner
of Record of such
Pledged Debt
Instrument)

  

Issuer

  

Description of Debt

  

Final
Maturity

  

Principal
Amount

  

Certificate
(Indicate
No.)

N.A.               


SCHEDULE 1A

PLEDGED INVESTMENT PROPERTY

 

Name of Issuer

  

Description and Value of Security

  

Loan Party/Subsidiary

Cianna Medical, Inc.    8,677 Shares of Series A Preferred Stock    Endologix, Inc.

See Schedule 1.


SCHEDULE 2

FILINGS AND PERFECTION

To be attached.


FIRST SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT

This FIRST SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT (this “Supplement”) made as of August 9, 2018, by Endologix, Inc., a Delaware corporation (“Endologix” or “Borrower”), and TriVascular, Inc., a Delaware corporation (“TriVascular”; TriVascular and Endologix are each individually a “Grantor” and collectively “Grantors”), in favor of Deerfield Private Design Fund IV, L.P., in its capacity as Agent for the Secured Parties (each as defined in the Facility Agreement referenced below) (in such capacity, “Grantee”):

W I T N E S S E T H

WHEREAS, Borrower, the other Loan Parties (including TriVascular) from time to time party thereto, the financial institutions from time to time party thereto as Lenders and Grantee have entered into that certain Amended and Restated Facility Agreement dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Facility Agreement”), pursuant to which Grantee and the Lenders have agreed, subject to the terms and conditions thereof, to make certain loans to, and other credit accommodations in favor of, Borrower (collectively, the “Loans”).

WHEREAS, pursuant to the terms of that certain Amended and Restated Guaranty and Security Agreement dated as of the date hereof, by and among Grantee, Grantors and the other Loan Parties from time to time party thereto (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Guaranty and Security Agreement”), Grantors have granted to Grantee, for its benefit and the benefit of the other Secured Parties, a security interest and Lien upon substantially all assets (including the Collateral) of Grantors, including all right, title and interest of Grantors in, to and under all now owned and hereafter acquired (a) trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, trade dress, service marks, logos and other source or business identifiers of each Grantor, and all goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith, whether in the United States Patent and Trademark Office or in any similar office or agency of the United States, any state thereof or any other country or any political subdivision thereof, or otherwise, and all common-law rights related thereto, and (b) the right to obtain all renewals thereof (all of the foregoing in clauses (a) and (b), collectively, together with “Trademarks” as defined in the Guaranty and Security Agreement, “Trademarks”), together with the goodwill of the business symbolized by Grantors’ Trademarks, and all income, royalties, damages and payments with respect to the foregoing, to secure the payment of all Secured Obligations, in each case other than Excluded Property.

WHEREAS, Grantors and Grantee are parties to that certain Trademark Security Agreement, dated April 3, 2017 (as the same heretofore may have been and hereafter may be amended, restated, supplemented or otherwise modified from time to time, the “Trademark Security Agreement”).


NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantors agree to supplement the Trademark Security Agreement as follows:

(e) Incorporation of Facility Agreement, Guaranty and Security Agreement and Trademark Security Agreement. The representations and warranties contained in the Facility Agreement, the Guaranty and Security Agreement and the Trademark Security Agreement to the extent applicable to Grantors are hereby incorporated herein in their entirety by this reference thereto. The provisions of Sections 1.2 and 6.4 of the Facility Agreement are incorporated herein by reference thereto mutatis mutandis. Unless otherwise noted herein, all capitalized terms used herein but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Guaranty and Security Agreement, or if not defined therein, in the Facility Agreement. In the event of a conflict between a provision of the Guaranty and Security Agreement and a provision of this Supplement (or the Trademark Security Agreement as amended and/or supplemented by this Supplement), the provision of the Guaranty and Security Agreement shall control.

(f) Grant and Reaffirmation of Grant of Security Interests. To secure the payment of the Secured Obligations, Grantors hereby grant to Grantee, for its benefit and the benefit of the other Secured Parties, and hereby reaffirm their prior grant pursuant to the Guaranty and Security Agreement and the Trademark Security Agreement of, a continuing Lien on and security interest in Grantors’ entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the “Trademark Collateral”), whether now owned or existing or hereafter created, acquired or arising:

each Trademark listed on Schedule A annexed hereto and all other Trademarks, together with any reissues, continuations or extensions thereof, all of the goodwill of the business connected with the use of, and symbolized by, each such Trademark, and all proceeds and products with respect to the foregoing; and

all income, royalties, damages and payments relating to the foregoing, including without limitation, damages payable with respect to any claim by Grantors against third parties for past, present or future (i) infringement or dilution of each such Trademark, or (ii) injury to the goodwill associated with each such Trademark, and all proceeds and products with respect to the foregoing.

Notwithstanding the foregoing, no Trademark Collateral shall include any Excluded Property.

(g) Incorporation of the Trademark Security Agreement. The terms and provisions of the Trademark Security Agreement are hereby incorporated by reference, and this Supplement shall be considered an amendment and supplement to and part of the Trademark Security Agreement, all of the provisions of which Trademark Security Agreement are and remain in full force and effect. Any reference after the date hereof in any Loan Document to the Trademark Security Agreement shall be a reference to the Trademark Security Agreement as amended and supplemented by this Supplement.

(h) Reaffirmation of Obligations. Each Grantor hereby reaffirms its obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Trademark Security Agreement, the Guaranty and Security Agreement and all other Loan Documents. Each Grantor hereby further ratifies and reaffirms the validity and enforceability of all of the Liens and security interests heretofore granted, pursuant to and in connection with the Trademark Security Agreement, the Security Agreement or any other Loan Document, to Grantee


(for the benefit of the Secured Parties), as collateral security for the obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Loan Documents in accordance with their respective terms, and acknowledges that all of such Liens and security interests, and all Collateral (including, without limitation, the Trademark Collateral (as defined in the Trademark Security Agreement)) heretofore pledged as security for such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)), continue to be and remain collateral for such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) from and after the date hereof.

(i) Ratification. Each Grantor hereby restates, ratifies and reaffirms each and every term and condition set forth in the Trademark Security Agreement effective as of the date hereof and as amended hereby.

(j) Governing Law. This Supplement is governed by and construed and enforced in accordance with the laws of the State of New York applicable to contracts made and to be performed in such State.

(k) Counterparts. This Supplement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

[Signature Page Follows]


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

ENDOLOGIX, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer

First Supplement to Trademark Security Agreement


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

TRIVASCULAR, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

First Supplement to Trademark Security Agreement


Agreed and accepted as of

the date first written above:

DEERFIELD PRIVATE DESIGN FUND IV, L.P., as Agent and Grantee
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By: /s/ David J. Clark                                    
Name: David J. Clark
Title: Authorized Signatory

First Supplement to Trademark Security Agreement


SCHEDULE A

 

Mark

  

Application No.

  

Application Date

  

Registration No.

  

Registration

Date

  

Status of

Mark

  

Owner/

Applicant

DURAPLY    86362822    8/11/14    5433696    3/27/18    Registered    Endologix, Inc.
EVAS FORWARD    86116940    11/12/13    5306786    10/10/17    Registered    Endologix, Inc.
VELA    85857988    2/22/13    5296578    9/26/17    Registered    Endologix, Inc.
ANGIOTIP    85767055    10/30/12    5205176    5/16/17    Registered    Endologix, Inc.
ACTIVESEAL    85518608    1/17/12    5396605    2/6/18    Registered    Endologix, Inc.
OVATION ALTO    86047894    8/26/13    5195890    5/2/17    Registered    TriVascular, Inc.
DESIGN ONLY    86854470    12/18/18    N/A    N/A   

Published (Pending) –

Intent to Use

   Endologix, Inc.
ALLEGRO    86758465    9/16/15    N/A    N/A   

Published (Pending) –

Intent to Use

   TriVascular, Inc.
VERTA    87116482    7/26/16    N/A    N/A   

Pending

(Intent to use)

   Endologix, Inc.

 

 

First Supplement to Trademark Security Agreement


FIRST SUPPLEMENT TO PATENT SECURITY AGREEMENT

This FIRST SUPPLEMENT TO PATENT SECURITY AGREEMENT (this “Supplement”) made as of August 9, 2018, by Endologix, Inc., a Delaware corporation (“Endologix” or “Borrower”), Nellix, Inc., a Delaware corporation (“Nellix”), TriVascular, Inc., a Delaware corporation (“TriVascular”; TriVascular, Endologix and Nellix are each individually a “Grantor” and collectively “Grantors”), in favor of Deerfield Private Design Fund IV, L.P., in its capacity as Agent for the Secured Parties (each as defined in the Facility Agreement referenced below) (in such capacity, “Grantee”):

W I T N E S S E T H

WHEREAS, Borrower, the other Loan Parties (including Nellix and TriVascular) from time to time party thereto, the financial institutions from time to time party thereto as Lenders and Grantee have entered into that certain Amended and Restated Facility Agreement dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Facility Agreement”), pursuant to which Grantee and the Lenders have agreed, subject to the terms and conditions thereof, to make certain loans to, and other credit accommodations in favor of, Borrower (collectively, the “Loans”).

WHEREAS, pursuant to the terms of that certain Amended and Restated Guaranty and Security Agreement dated as of the date hereof, by and among Grantee, Grantors and the other Loan Parties from time to time party thereto (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Guaranty and Security Agreement”), Grantors have granted to Grantee, for its benefit and the benefit of the other Secured Parties, a security interest and Lien upon substantially all assets (including the Collateral) of Grantors, including all right, title and interest of Grantors in, to and under all now owned and hereafter acquired (a) letters patent of the United States or any political subdivision thereof of each Grantor, all reissues and extensions thereof and all goodwill associated therewith, (b) applications for letters patent of the United States and all divisions of each Grantor, continuations and continuations-in-part thereof and (c) rights to, and the rights to obtain any reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of all the foregoing (all of the foregoing in clauses (a), (b) and (c), collectively, together with all “Patents” as defined in the Guaranty and Security Agreement, “Patents”), together with the goodwill of the business symbolized by Grantors’ Patents, and all income, royalties, damages and payments with respect to the foregoing, to secure the payment of all Secured Obligations, in each case other than Excluded Property.

WHEREAS, Grantors and Grantee are parties to a certain Patent Security Agreement dated April 3, 2017 (as the same heretofore may have been and hereafter may be amended, restated, supplemented or otherwise modified from time to time, the “Patent Security Agreement”).

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantors agree to supplement the Patent Security Agreement as follows:


1. Incorporation of Facility Agreement, Guaranty and Security Agreement and Patent Security Agreement. The representations and warranties contained in the Facility Agreement, the Guaranty and Security Agreement and the Patent Security Agreement to the extent applicable to Grantors are hereby incorporated herein in their entirety by this reference thereto. The provisions of Sections 1.2 and 6.4 of the Facility Agreement are incorporated herein by reference thereto mutatis mutandis. Unless otherwise noted herein, all capitalized terms used herein but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Guaranty and Security Agreement, or if not defined therein, in the Facility Agreement. In the event of a conflict between a provision of the Guaranty and Security Agreement and a provision of this Supplement (or the Patent Security Agreement as amended and/or supplemented by this Supplement), the provision of the Guaranty and Security Agreement shall control.

2. Grant and Reaffirmation of Grant of Security Interests. To secure the payment of the Secured Obligations, Grantors grant to Grantee, for its benefit and the benefit of the other Secured Parties, and hereby reaffirm their prior grant pursuant to the Guaranty and Security Agreement and the Patent Security Agreement of, a continuing Lien on and security interest in Grantors’ entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the “Patent Collateral”), whether now owned or existing or hereafter created, acquired or arising:

(a) each Patent listed on Schedule A annexed hereto and all other Patents, together with any reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions thereof, all of the goodwill of the business connected with the use of, and symbolized by, each such Patent, and all proceeds and products with respect to the foregoing; and

(b) all income, royalties, damages and payments at any time due or payable or asserted under and with respect to the foregoing, including without limitation, damages payable with respect to any claim by Grantors against third parties for past, present or future (i) infringement or dilution of each such Patent, or (ii) injury to the goodwill associated with each such Patent, and all proceeds and products with respect to the foregoing.

Notwithstanding the foregoing, no Patent Collateral shall include any Excluded Property.

3. Incorporation of the Patent Security Agreement. The terms and provisions of the Patent Security Agreement are hereby incorporated by reference and this Supplement shall be considered an amendment and supplement to and part of the Patent Security Agreement, all of the provisions of which Patent Security Agreement are and remain in full force and effect. Any reference after the date hereof in any Loan Document to the Patent Security Agreement shall be a reference to the Patent Security Agreement as amended and supplemented by this Supplement.

4. Reaffirmation of Obligations. Each Grantor hereby reaffirms its obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Patent Security Agreement, the Guaranty and Security Agreement and all other Loan Documents. Each Grantor hereby further ratifies and reaffirms the validity and enforceability of all of the Liens and security interests


heretofore granted, pursuant to and in connection with the Patent Security Agreement, the Security Agreement or any other Loan Document, to Grantee (for the benefit of the Secured Parties), as collateral security for the obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Loan Documents in accordance with their respective terms, and acknowledges that all of such Liens and security interests, and all Collateral (including, without limitation, the Patent Collateral (as defined in the Patent Security Agreement)) heretofore pledged as security for such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)), continue to be and remain collateral for such obligations (including, without limitation, the Obligations(including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) from and after the date hereof.

5. Ratification. Each Grantor hereby restates, ratifies and reaffirms each and every term and condition set forth in the Patent Security Agreement effective as of the date hereof and as amended hereby.

6. Governing Law. This Supplement is governed by and construed and enforced in accordance with the laws of the State of New York applicable to contracts made and to be performed in such State.

7. Counterparts. This Supplement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

[Signature Page Follows]


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

ENDOLOGIX, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer

 

First Supplement to Patent Security Agreement


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

NELLIX, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

 

First Supplement to Patent Security Agreement


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

TRIVASCULAR, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

 

First Supplement to Patent Security Agreement


Agreed and Accepted
As of the Date First Written Above:
DEERFIELD PRIVATE DESIGN FUND IV, L.P., as Agent and Grantee as Agent
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory

 

First Supplement to Patent Security Agreement


SCHEDULE A

 

Description/Title

  

Application
No.

  

Application
Date

  

Patent No.

  

Registration
Date

  

Owner/

Applicant

Bifurcated vascular graft
deployment device
   09505038    2/16/00    6210422    4/3/01    Endologix, Inc.
Method of deploying
bifurcated vascular graft
   09086247    5/28/98    6156063    12/5/00    Endologix, Inc.
Bifurcated vascular graft
deployment device
   08802478    2/20/97    6090128    7/18/00    Endologix, Inc.
Inflatable implant    12628623    12/1/09    N/A    N/A    Trivascular, Inc.
Ptfe layers and methods of
manufacturing
   12250946    10/14/08    N/A    N/A    Trivascular, Inc.
Ptfe layers and methods of
manufacturing
   12250915    10/14/08    N/A    N/A    Trivascular, Inc.
Hybrid modular
endovascular graft
   11097718    4/1/05    N/A    N/A    Trivascular, Inc.
Non-degradable low
swelling, water soluble
radiopaque hydrogel polymer
   11097467    4/1/05    N/A    N/A    Trivascular, Inc.
Delivery system and method
for bifurcated graft
   11205793    8/15/05    N/A    N/A    Trivascular, Inc.
Methods, compositions
and devices for embolizing body
lumens
   11031311    1/7/05    N/A    N/A    Trivascular, Inc.
Endoluminal prosthesis
endoleak management
   10691849    10/22/03    N/A    N/A    Trivascular, Inc.
Layered endovascular graft    10803153    3/17/04    N/A    N/A    Trivascular, Inc.
Delivery system and method
for bifurcated graft
   10686863    10/16/03    N/A    N/A    Trivascular, Inc.
Inflatable intraluminal graft    10289137    11/5/02    N/A    N/A    Trivascular, Inc.
Endovascular graft    10289136    11/5/02    N/A    N/A    Trivascular, Inc.
Advanced endovascular graft    10091641    3/5/02    N/A    N/A    Trivascular, Inc.

 

 

 

First Supplement to Patent Security Agreement


Description/Title

  

Application
No.

  

Application
Date

  

Patent No.

  

Registration
Date

  

Owner/

Applicant

Delivery system and method
for bifurcated graft
   10122474    4/11/02    N/A    N/A    Trivascular, Inc.
Layered endovascular graft    09970576    10/3/01    N/A    N/A    Trivascular, Inc.
Dual inflatable arterial
prosthesis
   15540246    6/27/17    N/A    N/A    Endologix, Inc.
Catheter system and methods
of using same
   15632064    6/23/17    N/A    N/A    Endologix, Inc.
Catheter system and methods
of using same
   15639028    6/30/17    N/A    N/A    Endologix, Inc.
Apparatus and method of
placement of a graft or graft
system
   15610242    5/31/17    N/A    N/A    Endologix, Inc.
Stent graft delivery system    15676869    8/14/17    N/A    N/A    Nellix, Inc.        
Endovascular graft    15686214    8/25/17    N/A    N/A    TriVascular, Inc.
Advanced endovascular graft    15686218    8/25/17    N/A    N/A    TriVascular, Inc.
Endovascular graft for
aneurysms involving major
branch vessels
   15638559    6/30/17    N/A    N/A    TriVascular, Inc.
Systems and methods for
guidewire crossover for
bifurcated
   15491074    4/19/17    N/A    N/A    TriVascular, Inc.
Low profile stent graft and
delivery system
   15263469    9/13/16    N/A    N/A    TriVascular, Inc.
Endoluminal prosthesis
systems and methods
   15737223    12/15/17    N/A    N/A    Endologix, Inc.
Endovascular graft systems
and methods for deployment
in main and branch arteries
   65/529663    7/7/17    N/A    N/A    Endologix, Inc.
Stent grants and methods of
enhancing flexibility of stent
grafts by thermal pleating
   65/532737    7/14/17    N/A    N/A    Endologix, Inc.
Endoluminal device and
polymer
   62/575827    10/23/17    N/A    N/A    Endologix, Inc.

 

 

First Supplement to Patent Security Agreement


Description/Title

  

Application
No.

  

Application
Date

  

Patent
No.

  

Registration
Date

  

Owner/

Applicant

Systems and Methods with
Stents and Filling Structure
   62/382207    8/31/16    N/A    N/A    Endologix, Inc.
STENTS, GRAFTS,
DELIVERY SYSTEMS,
AND METHODS
   62/481560    4/4/17    N/A    N/A    Endologix, Inc.
ENDOVASCULAR
SYSTEMS, DEVICES,
AND METHODS
ALLOWING FOR BRANCH DEVICE
PLACEMENT IN POCKET
OF MAIN GRAFT
   62/489213    4/24/17    N/A    N/A    Endologix, Inc.
ENDOVASCULAR GRAFT
SYSTEMS AND
METHODS FOR
DEPLOYMENT IN MAIN AND
BRANCH ARTERIES
   62/529669    7/7/17    N/A    N/A    Endologix, Inc.

STENT GRAFTS AND
METHODS OF ENHANCING
FLEXIBILITY OF STENT GRAFTS BY THERMAL

PLEATING

   62/532737    7/14/17    N/A    N/A    Endologix, Inc.
STENT GRAFT    15/911629    3/5/18    N/A    N/A    Endologix, Inc.
INTERNAL ILIAC
PRESERVATION
DEVICES AND METHODS
   15/965649    4/__/18    N/A    N/A    Endologix, Inc.
MODULATION OF
INFLAMMATORY
RESPONSE FOLLOWING ENDOVASCULAR
TREATMENT
   62/661569    4/23/18    N/A    N/A    Endologix, Inc.
ADVANCED KINK
RESISTANT STENT
GRAFT
   16/005269    6/11/18    N/A    N/A    Endologix, Inc.
LOW PROFILE STENT
GRAFT AND DELIVERY
SYSTEM
   15/985572    5/21/18    N/A    N/A    Endologix, Inc.

 

 

First Supplement to Patent Security Agreement


Description/Title

  

Application
No.

  

Application
Date

  

Patent No.

  

Registration
Date

  

Owner/

Applicant

SYSTEMS AND
METHODS WITH STENT
AND FILLING
STRUCTURE
   15/774511    8/30/17    N/A    N/A    Endologix, Inc.
LONGITUDINALLY
EXTENDABLE STENT
GRAFT SYSTEMS AND
METHODS
   15/774548    1/23/18    N/A    N/A    Endologix, Inc.
GRAFT SYSTEMS
HAVING FILLING
STRUCTURES
SUPPORTED BY
SCAFFOLDS AND
METHODS FOR THEIR
USE
   16/035497    7/13/18    N/A    N/A    Endologix, Inc.
PRE-FIXATION DEVICE
FOR NELLIX AND OTHER
EVAS DEVICES
   62/678956    5/31/18    N/A    N/A    Endologix, Inc.
SYSTEMS AND
METHODS WITH
FENESTRATED GRAFT
AND FILLING
STRUCTURE
   16/066595       N/A    N/A    Endologix, Inc.
MODULATION OF
INFLAMMATORY
RESPONSE FOLLOWING
ENDOVASCULAR
TREATMENT
   62/661569    4/23/18    N/A    N/A    Endologix, Inc.
ENDOLUMINAL DEVICE
AND POLYMER
   62/575827    10/23/17    N/A    N/A    Endologix, Inc.
Implantable vascular graft    12/860280    8/20/10    20100318174       Endologix, Inc.
Endoluminal vascular
prosthesis
   11/623679    1/16/07    2007012412       Endologix, Inc.
Delivery catheter for
endovascular device
   13/835491    3/15/13    9498363    11/22/16    Trivascular, Inc.
Stent-graft with improved
flexibility
   15568834    10/24/17    N/A    N/A    TriVascular, Inc.

 

 

First Supplement to Patent Security Agreement


Description/Title

  

Application
No.

  

Application
Date

  

Patent No.

  

Registration
Date

  

Owner/

Applicant

System and methods of
Endovasular Aneurysm
Treatment
   14682414    8/21/17    N/A    N/A    Nellix, Inc.
Stent graft systems with
restraints in circumferential
channels and methods thereof
   62/678961    5/31/18    N/A    N/A    Endologix, Inc.
Percutaneous method and
device to treat dissections
   15/429090    2/9/17    N/A    N/A    Endologix, Inc.
Endovascular delivery
system with an improved radiopague
marker scheme
   16/049560    7/30/18    N/A    N/A    Nellix, Inc.

 

 

First Supplement to Patent Security Agreement


SCHEDULE 3

GRANTOR INFORMATION

 

GRANTOR
(exact legal name)

  

STATE/
COUNTRY
OF
ORGANIZATION

  

FEDERAL
EMPLOYER
IDENTIFICATION
NUMBER

  

CHIEF EXECUTIVE
OFFICE

   ORGANIZATIONAL
IDENTIFICATION
NUMBER
Endologix, Inc.    Delaware    68-0328265    2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.
   2338745
CVD/RMS Acquisition Corp.    Delaware    33-0928438    2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.
   2955166
RMS/Endologix Sideways Merger Corp    Delaware    03-0512974    2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.
   3530477
Nellix, Inc.    Delaware    94-3398416    2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.
   3359980
TriVascular Technologies, Inc.    Delaware    87-0807313    3910 Brickway Blvd.,
County of Santa Rosa,
Sonoma, CA 95403 U.S.A.
   4387054
TriVascular, Inc.    California    68-0402620    3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.
   C2065374
Endologix
Canada, LLC
   Delaware    47-2442872    3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.
   5647226
TriVascular Sales LLC    Texas    46-0859179    3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.
   801644988


SCHEDULE 4

PLACES OF BUSINESS / LOCATION OF COLLATERAL

 

Grantor

  

Location

  

Specify
Whether
Location
Has
(i) Inventory
and/or
Equipment,
(ii) Books
and
Records, or
(iii) Both

  

Interest

  

Lessor/Property

Owner/Lessee

Endologix, Inc.    2 Musick, Irvine,
County of Orange,
CA 92618 U.S.A.
   Both    Lease    The Northwestern Mutual Life Insurance Company, att: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
Endologix, Inc.    33 & 35 Hammond, Irvine, County of Orange, CA 92618 U.S.A    Inventory and/or Equipment    Lease    The Northwestern Mutual Life Insurance Company, att: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
Endologix, Inc.   

378 Commercial Street, Malden, MA 02148

165 Chubb Avenue, Lyndhurst, NJ 07071

1130 Commerce Blvd, Swedesboro, NJ 08085

2250 Outerloop Drive, Louisville, KY 40219

   Inventory
and/or
Equipment
   Third
Party
Warehouse
   UPS
Endologix, Inc.    54 Yangcheon-ro, Gangseo-gu, Seoul 07522    Inventory
and/or
Equipment (no other Collateral is located at this location)
   Third
Party
Warehouse
   TNT Express Korea
Endologix, Inc.   

10 Anson Road #21-04 & #21-04A

International Plaza

   Inventory
and/or
Equipment (no other
   Occupied    Endologix Singapore Private Limited


Grantor

  

Location

  

Specify
Whether
Location
Has
(i) Inventory
and/or
Equipment,
(ii) Books
and
Records, or
(iii) Both

  

Interest

  

Lessor/Property

Owner/Lessee

   Singapore 079903    Collateral is located at this location)      
Endologix, Inc.    A-311, M-Sate, 114 Beopwon-ro, Songpa-gu, Seoul, South Korea    Inventory
and/or
Equipment (no other
Collateral is located at this location)
   Occupied    N.A.
Endologix, Inc.    Grantor and each Guarantor’s sales representatives hold Trunk Inventory in their possession for sales calls and procedures, which Trunk Inventory is not held at a specific location or locations.    Inventory
and/or
Equipment (no other Collateral is located at this location)
   N.A.    N.A.
   Certain Inventory of the Grantor and each Guarantor is held by numerous third parties on a consignment basis at various locations.    Inventory
and/or
Equipment (no other Collateral is located at this location)
   N.A.    N.A.
CVD/RMS
Acquisition
Corp.
   2 Musick, Irvine,
County of Orange,
CA 92618 U.S.A.
   Books and Records    Occupied    The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
Nellix, Inc.    2 Musick, Irvine,
County of Orange,
CA 92618 U.S.A.
   Books and Records    Occupied    The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618


Grantor

  

Location

  

Specify
Whether
Location
Has
(i) Inventory
and/or
Equipment,
(ii) Books
and
Records, or
(iii) Both

  

Interest

  

Lessor/Property

Owner/Lessee

RMS/Endologix Sideways Merger Corp.    2 Musick, Irvine,
County of Orange,
CA 92618 U.S.A.
   Books and Records    Occupied    The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
TriVascular
Technologies,
Inc.
   3910 Brickway
Blvd., Santa Rosa,
County of Sonoma,
CA 95403 U.S.A.
   Books and Records    Occupied    Sonoma Airport
Properties LLC
TriVascular, Inc.    3910 Brickway
Blvd., Santa Rosa,
County of Sonoma,
CA 95403 U.S.A.
   Both    Lease    Sonoma Airport
Properties LLC
TriVascular Sales LLC    3910 Brickway
Blvd., Santa Rosa,
County of Sonoma,
CA 95403 U.S.A.
   Books and Records    Occupied    Sonoma Airport
Properties LLC
Endologix
Canada, LLC
   3910 Brickway
Blvd., Santa Rosa,
County of
Sonoma, CA
95403 U.S.A.
   Books and Records    Occupied    Sonoma Airport
Properties LLC


SCHEDULE 5

COMMERCIAL TORT CLAIMS

None.


SCHEDULE 6

ACCOUNTS

 

ENTITY    COUNTRY    ACCT    CURR    BANK    USE
Endologix Inc    US    XXXXX1702    USD    Bank of America    Operating account
Endologix Inc    US    XXXXX1689    USD    Bank of America    Payroll account
Endologix Inc    US    XXXXX5279    USD    Wells Fargo    Old Operating account
Endologix Inc    US    XXXXX5311    USD    Wells Fargo    Old payroll account
Endologix Inc    Us    XXXXX3910    USD    Bank of America    Lockbox account
Endologix Inc    US    XXXXX4066    USD    Bank of America    Credit Card Cash Collateral account
Trivascular Inc    US    XXXXX5539    USD    Silicon Valley Bank    Operating account
Trivascular Inc    The Netherlands    XXXXX8640    EUR    KBC Bank NV Nederland    Currency account
Trivascular Inc    UK London    XXXXX8709    GBP    National Westminster Bank    Currency account
Trivascular Sales LLC    US    XXXXX7400    USD    Silicon Valley Bank    Payroll account
Endologix Canada LLC    Canada    XXXXX7912    CAD    Bank of Montreal    Operating account


SCHEDULE 7

REAL PROPERTY

None.


SCHEDULE 8

COPYRIGHTS

None.


SCHEDULE 9

INTELLECTUAL PROPERTY LICENSES

 

1.

Inbound License Agreement, dated as of February 22, 2006, by and between Incept LLC and Nellix, Inc.

 

2.

Inbound Amendment No. 1. to License Agreement, dated as of April 30, 2012, by and between Incept LLC and Nellix, Inc.

 

3.

Inbound Amendment No. 2 to License Agreement, dated as of December 3, 2014, by and between Incept LLC and Nellix, Inc.

 

4.

Inbound Master License Agreement, dated as of May 5, 2008, by and between SurModics, Inc. and Endologix, Inc.

 

5.

Inbound Development and OEM Device Supply Agreement, dated as of August 5, 2015, by and between Bard Peripheral Vascular, Inc. and Endologix, Inc.

 

6.

Inbound License Agreement, dated as of June 22, 2011, by and between NorMedix, LLC and Endologix, Inc.

 

7.

Inbound Settlement and Patent License Agreement, dated as of March 17, 2016, by and between LifePort Sciences, LLC and Endologix, Inc.

 

8.

Inbound License Agreement, dated as of July 23, 2013, by and between Thomas L. Fogarty and Endologix, Inc.

 

9.

Inbound License Agreement, dated as of March 28, 2008, by and between Trivascular, Inc. (formerly Trivascular 2, Inc.) and Boston Scientific Scimed, Inc. and Endovascular Technologies, Inc.


SCHEDULE 10

PATENTS

See attached.


PATENT SCHEDULE

 

Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Stent graft    US9757262B2    US13943246A    2013-07-16
ENDOLOGIX INC.    US    Catheter system and methods of using same    US9700701B2    US13544426A    2012-07-09
ENDOLOGIX INC.    US    Catheter system and methods of using same    US9687374B2    US15379268A    2016-12-14
ENDOLOGIX INC.    US    Percutaneous method and device to treat dissections    US9579103B2    US12771711A    2010-04-30
ENDOLOGIX INC.    US    Catheter system and methods of using same    US9549835B2    US14462485A    2014-08-18


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Method and system for treating aneurysms    US9415195B2    US13441762A    2012-04-06
ENDOLOGIX INC.    US    Devices and methods to treat vascular dissections    US9393100B2    US13988175A    2013-05-17
ENDOLOGIX INC.    US    Method for forming materials in situ within a medical device    US9289536B2    US14201332A    2014-03-07
ENDOLOGIX INC.    US    Apparatus and method of placement of a graft or graft system    US9149381B2    US14172126A    2014-02-04
ENDOLOGIX INC.    US    Stent graft    US8821564B2    US13397952A    2012-02-16
ENDOLOGIX INC.    US    Apparatus and methods for repairing aneurysms    US8814928B2    US12616928A    2009-11-12


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Catheter system and methods of using same    US8808350B2    US13408952A    2012-02-29
ENDOLOGIX INC.    US    Graft systems having semi-permeable filling structures and methods for their use    US8801768B2    US13355705A    2012-01-23
ENDOLOGIX INC    US    Bifurcated graft deployment systems and methods    US8764812B2    US13745682A    2013-01-18
ENDOLOGIX INC.    US    Apparatus and method of placement of a graft or graft system    US8672989B2    US13546950A    2012-07-11
ENDOLOGIX INC.    US    Graft deployment system    US8568466B2    US13269332A    2011-10-07
ENDOLOGIX INC.    US    Dual concentric guidewire and methods of bifurcated graft deployment    US8523931B2    US11623022A    2007-01-12


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Stent graft    US8491646B2    US12837398A    2010-07-15
ENDOLOGIX INC.    US    Endolumenal vascular prosthesis with neointima inhibiting polymeric sleeve    US8377110B2    US10820455A    2004-04-08
ENDOLOGIX INC.    US    Bifurcated graft deployment systems and methods    US8357192B2    US13046541A    2011-03-11
ENDOLOGIX INC.    US    Bifurcated graft deployment systems and methods    US8236040B2    US12101863A    2008-04-11
ENDOLOGIX INC.    US    Catheter system and methods of using same    US8216295B2    US12496446A    2009-07-01
ENDOLOGIX INC.    US    Apparatus and method of placement of a graft or graft system    US8221494B2    US12390346A    2009-02-20


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Methods and systems for endovascular aneurysm treatment    US8182525B2    US12421297A    2009-04-09
ENDOLOGIX INC.    US    Single puncture bifurcation graft deployment system    US8167925B2    US12732095A    2010-03-25
ENDOLOGIX INC.    US    Bifurcation graft deployment catheter    US8147535B2    US11189101A    2005-07-25
ENDOLOGIX INC.    US    Material for creating multi-layered films and methods for making the same    US8133559B2    US13100483A    2011-05-04
ENDOLOGIX INC.    US    Stent graft    US8118856B2    US12844266A    2010-07-27
ENDOLOGIX INC.    US    Graft systems having filling structures supported by scaffolds and methods for their use    US8048145B2    US11413460A    2006-04-28


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Graft deployment system    US8034100B2    US10722367A    2003-11-25
ENDOLOGIX INC.    US    Material for creating multi-layered films and methods for making the same    US7951448B2    US12858274A    2010-08-17
ENDOLOGIX INC    US    Self expanding bifurcated endovascular prosthesis    US7892277B2    US11417883A    2006-05-03
ENDOLOGIX INC.    US    Material for creating multi-layered films and methods for making the same    US7790273B2    US11752750A    2007-05-23
ENDOLOGIX INC.    US    Devices for repairing aneurysms    US7682383B2    US10481386A    2004-06-14
ENDOLOGIX INC.    US    System and methods for endovascular aneurysm treatment    US7666220B2    US11482503A    2006-07-07


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Methods and systems for endovascular aneurysm treatment    US7530988B2    US11187471A    2005-07-22
ENDOLOGIX INC    US    Self expanding bifurcated endovascular prosthesis    US7520895B2    US10119525A    2002-04-08
ENDOLOGIX INC    US    Bifurcation graft deployment catheter    US6953475B2    US10675060A    2003-09-30
ENDOLOGIX INC.    US    Implantable vascular graft    US6733523B2    US09891620A    2001-06-26
ENDOLOGIX INC    US    Single puncture bifurcation graft
deployment system
   US6663665B2    US09795993A    2001-02-28
ENDOLOGIX INC.    US    Bifurcation graft deployment catheter    US6660030B2    US09747094A    2000-12-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    US    Endoluminal vascular prosthesis    US6508835B1    US09723979A    2000-11-28
ENDOLOGIX INC.    US    Bifurcation graft deployment catheter    US6500202B1    US09525778A    2000-03-15
ENDOLOGIX INC.    US    Dual wire placement catheter    US6440161B1    US09348356A    1999-07-07
ENDOLOGIX INC.    US    Single puncture bifurcation graft
deployment system
   US6261316B1    US09266661A    1999-03-11
ENDOLOGIX INC.    US    Articulating bifurcation graft    US6197049B1    US09251363A    1999-02-17
ENDOLOGIX INC.    US    Endoluminal vascular prosthesis    US6187036B1    US09210280A    1998-12-11


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Segmented stent for flexible stent delivery system    US6187034B1    US09229856A    1999-01-13
ENDOLOGIX INC.    US    Endoluminal vascular prosthesis    US6077296A    US0934689A    1998-03-04
ENDOLOGIX INC.    US    Stent delivery system featuring a flexible balloon    US6022359A    US09229519A    1999-01-13
ENDOLOGIX INC.    US    Radially expandable stent featuring accordion stops    US5931866A    US09028305A    1998-02-24
ENDOLOGIX INC.    US    DUAL INFLATABLE ARTERIAL PROSTHESIS    US20180021045A1    US15540246A    2017-06-27
ENDOLOGIX INC.    US    CATHETER SYSTEM AND METHODS OF USING SAME    US20170304098A1    US15632064A    2017-06-23


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    CATHETER SYSTEM AND METHODS OF USING SAME    US20170296791A1    US15639028A    2017-06-30
ENDOLOGIX INC    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20170266025A1    US15610242A    2017-05-31
ENDOLOGIX INC.    US    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES    US20170239035A1    US15310198A    2016-11-10
ENDOLOGIX INC.    US    METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES    US20170238937A1    US15438682A    2017-02-21
ENDOLOGIX INC    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20170128246A1    US15414499A    2017-01-24
ENDOLOGIX INC    US    METHOD AND SYSTEM FOR TREATING ANEURYSMS    US20170007263A1    US15205365A    2016-07-08


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    METHOD FOR FORMING HYDROGELS AND MATERIALS THEREFOR    US20160367731A1    US15256462A    2016-09-02
ENDOLOGIX INC.    US    DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS    US20160302798A1    US15194159A    2016-06-27
ENDOLOGIX INC.    US    SYSTEMS AND METHODS FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE    US20160030051A1    US14776385A    2015-09-14
ENDOLOGIX INC    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20150366688A1    US14840428A    2015-08-31
ENDOLOGIX INC.    US    METHOD AND SYSTEM FOR TREATING ANEURYSMS    US20150250989A1    US14717938A    2015-05-20
ENDOLOGIX INC.    US    FENESTRATED PROSTHESIS    US20150173923A1    US14581675A    2014-12-23


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Apparatus and Methods for Repairing Aneurysms    US20150012081A1    US14330812A    2014-07-14
ENDOLOGIX INC.    US    STENT GRAFT    US9907642    US14461308A    2014-08-15
ENDOLOGIX INC    US    ENDOLUMENAL VASCULAR PROSTHESIS WITH NEOINTIMA INHIBITING POLYMERIC SLEEVE    US20130253638A1    US13731908A    2012-12-31
ENDOLOGIX INC.    US    Methods and Systems for Treating Aneurysms    US20120184982A1    US13354094A    2012-01-19
ENDOLOGIX INC.    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20120109279A1    US13287907A    2011-11-02
ENDOLOGIX INC.    US    FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE    US20110276078A1    US12966852A    2010-12-13


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    US    SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS    US20110224782A1    US13027077A    2011-02-14
ENDOLOGIX INC.    US    ENDOLUMINAL VASCULAR PROSTHESIS    US20110218617A1    US13039157A    2011-03-02
ENDOLOGIX INC    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20110054587A1    US12769546A    2010-04-28
ENDOLOGIX INC    US    IMPLANTABLE VASCULAR GRAFT    US20100318174A1    US12860280A    2010-08-20
ENDOLOGIX INC    US    IMPLANTABLE VASCULAR GRAFT    US20100318181A1    US12860310A    2010-08-20
ENDOLOGIX INC.    US    UTILIZATION OF MURAL THROMBUS FOR LOCAL DRUG DELIVERY INTO VASCULAR TISSUE    US20100261662A1    US12757900A    2010-04-09


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    US    GRAFT DEPLOYMENT SYSTEM    US20100179636A1    US12726257A    2010-03-17
ENDOLOGIX INC.    US    STENT GRAFT DELIVERY SYSTEM    US20100036360A1    US12429474A    2009-04-24
ENDOLOGIX INC.    US    DOCKING APPARATUS AND METHODS OF USE    US20090319029A1    US12478208A    2009-06-04
ENDOLOGIX INC.    US    GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS    US20100004728A1    US12371087A    2009-02-13
ENDOLOGIX INC.    US    METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE    US20090155337A1    US12269677A    2008-11-12
ENDOLOGIX INC.    US    STENT    US20090105806A1    US12257149A    2008-10-23


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Multi-segmented graft deployment system    US20080071343A1    US11522292A    2006-09-15
ENDOLOGIX INC    US    IMPLANTABLE VASCULAR GRAFT    US20070299497A1    US11764715A    2007-06-18
ENDOLOGIX INC.    US    Methods and systems for aneurysm treatment using filling structures    US20070150041A1    US11444603A    2006-05-31
ENDOLOGIX INC    US    ENDOLUMINAL VASCULAR PROSTHESIS    US20070112412A1    US11623679A    2007-01-16
ENDOLOGIX INC.    US    Method and apparatus for decompressing aneurysms    US20070078506A1    US11580201A    2006-10-12
ENDOLOGIX INC.    US    Method and apparatus for decompressing aneurysms    US20050245891A1    US11104303A    2005-04-12


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Vascular stent-graft apparatus    US20040167607A1    US10787404A    2004-02-24
ENDOLOGIX INC.    US    Stent-graft with positioning anchor    US20040116997A1    US10668901A    2003-09-22
ENDOLOGIX INC.    US    Flexible vascular graft    US20010025195A1    US09728582A    2000-12-01
ENDOLOGIX INC    US    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES    US20170239035A1    US15310198A    2016-11-10
ENDOLOGIX INC    US    DUAL INFLATABLE ARTERIAL PROSTHESIS    US20180021045A1    US15540246A    2017-06-27
ENDOLOGIX INC    US    ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS       US15737223    2017-12-15


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    US    Systems and Methods with Stents and Filling Structure       62/382207    2016-08-31
ENDOLOGIX INC    US    STENTS, GRAFTS, DELIVERY SYSTEMS, AND METHODS       62/481560    2017-04-04
ENDOLOGIX INC    US    ENDOVASCULAR SYSTEMS, DEVICES, AND METHODS ALLOWING FOR BRANCH DEVICE PLACEMENT IN POCKET OF MAIN GRAFT       62/489213    2017-04-24
ENDOLOGIX INC    US    ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES       62/529669    2017-07-07
ENDOLOGIX INC    US    STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING       62/532737    2017-07-14
ENDOLOGIX INC    US    STENT GRAFT       15/911629    2018-03-05


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    US    INTERNAL ILIAC PRESERVATION DEVICES AND METHODS       15/965649    2018-04-
ENDOLOGIX INC    US   

MODULATION OF INFLAMMATORY

RESPONSE FOLLOWING
ENDOVASCULAR TREATMENT

      62/661569    2018-4-23
ENDOLOGIX INC    US    ADVANCED KINK RESISTANT STENT GRAFT       16/005269    2018-6-11
ENDOLOGIX INC    US    LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM       15/985572    2018-5-21
ENDOLOGIX INC    US    SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE       15/774511    2017-8-30
ENDOLOGIX INC    US   

LONGITUDINALLY EXTENDABLE

STENT GRAFT SYSTEMS AND
METHODS

      15/774548    2018-1-23


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    US   

GRAFT SYSTEMS HAVING FILLING

STRUCTURES SUPPORTED BY
SCAFFOLDS AND METHODS FOR THEIR USE

      16/035497    2018-7-13
ENDOLOGIX INC    US    PRE-FIXATION DEVICE FOR NELLIX AND OTHER EVAS DEVICES       62/678956    2018-5-31
ENDOLOGIX INC    US    SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE       16/066595   
ENDOLOGIX INC    US   

MODULATION OF INFLAMMATORY

RESPONSE FOLLOWING
ENDOVASCULAR TREATMENT

      62/661569    2018-4-23
ENDOLOGIX INC.    US    FENESTRATED PROSTHESIS    US8945202    12/769581    2015-2-3
ENDOLOGIX INC.    US    Fenestrated prosthesis    US8945202    12/769581    4/28/10


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX, INC.    US   

Bifurcated vascular graft deployment

device

   US6210422    09/505038    2/16/00
ENDOLOGIX, INC.    US    Method of deploying bifurcated vascular graft    US6156063    09/086247    5/28/98
ENDOLOGIX, INC.    US   

Bifurcated vascular graft deployment

device

   US6090128    08/802478    2/20/97
ENDOLOGIX, INC.    US   

Endovascular prosthesis with improved

sealing means for aneurysmal arterial
disease and method of use

   US5665117    08/620072    3/21/96
ENDOLOGIX, INC.    US    Locking assembly for coupling guidewire to delivery system       15/317905    12/9/16
Endologix, Inc. and The Cleveland Clinic Foundation    US    Fenestrated prosthesis    US8945202    US12769581    4/28/10


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Endologix, Inc.    US   

Single puncture bifurcation graft

deployment system

   US7691135    US10690227    10/21/03
Endologix, Inc.    US    Bifurcated vascular graft and method and apparatus for deploying same    US6951572    US10639255    8/12/03
Endologix, Inc.    US    Radiation delivery balloon catheter    US6699170    US09688396    10/16/00
Endologix, Inc.    US    Dual wire placement catheter    US6689157    US10035729    12/21/01
Endologix, Inc.    US    Method for delivering radiation to an intraluminal site in the body    US6685618    US09944649    8/31/01
Endologix, Inc.    US    Radiation delivery catheters and dosimetry methods    US6491619    US09648563    8/25/00


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Endologix, Inc.    US    Endoluminal vascular prosthesis    US6331190    US09483411    1/14/00
Endologix, Inc.    US   

Bifurcated vascular graft deployment

device

   US6210422    US09505038    2/16/00
Endologix, Inc.    US    Method of deploying bifurcated vascular graft    US6156063    US09086247    5/28/98
Endologix, Inc.    US   

Bifurcated vascular graft deployment

device

   US6090128    US08802478    2/20/97
Endologix, Inc.    US    Axially non-contracting flexible radially expandable stent    US6083259    US09192803    11/16/98
Endologix, Inc.    US   

Endovascular prosthesis with improved

sealing means for aneurysmal arterial
disease and method of use

   US5665117    US08620072    3/21/96


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Endologix, Inc.    US    Apparatus and method of placement of a graft or graft system       US14172126    2/4/14
Endologix, Inc. and The Cleveland Clinic Foundation    US    Apparatus and method of placement of a graft or graft system       US12769506    4/28/10
Endologix, Inc.    US    Stent graft delivery system       US12429474    4/24/09
ENDOLOGIX INC    WO    ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS    WO2016210363A1    PCT/US2016/039414    2016-06-24
ENDOLOGIX INC    JP    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES    JP2017517321A    JP2016569901    2015-05-05
ENDOLOGIX INC    CN    Endoluminal Prosthesis Systems and Methods       201680037099.X    2017-12-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    JP    DUAL INFLATABLE ARTERIAL PROSTHESIS       2017-534803    2017-06-28
ENDOLOGIX INC    US    ENDOLUMINAL DEVICE AND POLYMER       62/575827    2017-10-23
TRIVASCULAR INC    US    Advanced Endovascular Graft    US9788934B2    US14799656A    2015-07-15
ENDOLOGIX INC    WO    DUAL INFLATABLE ARTERIAL PROSTHESIS    WO2016109757A1    PCT/US2015/068204    2015-12-30
ENDOLOGIX INC    WO    SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE    WO2017117068A1    PCT/US2016/068575    2016-12-23
ENDOLOGIX INC    WO    SYSTEMS AND METHODS WITH GRAFT BODY, INFLATABLE FILL CHANNEL, AND FILLING STRUCTURE    WO2017197313A1    PCT/US2017/032490    2017-05-12


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    PCT    SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE       PCT/US2017/049482    2017-08-30
ENDOLOGIX INC    PCT    LONGITUDINALLY EXTENDABLE STENT GRAFT SYSTEMS AND METHODS       PCT/US2018/014920    2018-01-23
ENDOLOGIX INC    PCT    STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING       PCT/US2018/042158    2018-7-13
ENDOLOGIX INC    PCT   

ENDOVASCULAR SYSTEMS,

DEVICES, AND METHODS
ALLOWING FOR BRANCH DEVICE PLACEMENT IN CHANNEL OF MAIN GRAFT

      PCT/US2018/028959    2018-4-23
ENDOLOGIX INC    PCT    ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES       PCT/US2018/041152    7/6/2018


ENDOLOGIX INC    EP    DUAL CONCENTRIC GUIDEWIRE AND METHODS OF BIFURCATED GRAFT DEPLOYMENT | DOPPELTER KONZENTRISCHER FÜHRUNGSDRAHT UND VERFAHREN ZUM EINSATZ EINES VERZWEIGTEN IMPLANTATS | FIL DE GUIDAGE CONCENTRIQUE    EP2117631B1    EP2008727613A    2008-01-11


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

     

MIXTE ET PROCÉDÉS DE

DÉPLOIEMENT DE GREFFON À DEUX BRANCHES

        
ENDOLOGIX INC    EP   

DEVICES FOR REPAIRING

ANEURYSMS | VORRICHTUNG ZUM AUSBESSERN EINES ANEURYSMAS | DISPOSITIFS DE REPARATION D’ANEVRISMES

   EP1397089B1    EP2002730505A    2002-06-17
ENDOLOGIX INC    EP    CATHETER SYSTEM | Kathetersystem | Systèmes de cathéter    EP2520320B1    EP2012178965A    2009-06-30
ENDOLOGIX INC    EP   

DEVICES FOR REPAIRING

ANEURYSMS | VORRICHTUNG ZUM AUSBESSERN EINES ANEURYSMAS | PROTHÈSE POUR LE TRAITEMENT DES ANÉVRISMES

   EP2260795B1    EP201011024A    2002-06-17
ENDOLOGIX INC    EP    SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES | SYSTEME ZUR BEHANDLUNG VON ANEURYSMEN UNTER VERWENDUNG VON FÜLLSTRUKTUREN | SYSTEMES POUR LE TRAITEMENT DE L’ANEVRISME UTILISANT DES STRUCTURES DE REMPLISSAGE    EP1962722B1    EP2006850439A    2006-12-18


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS | TRANSPLANTATIONSSYSTEM MIT DURCH GERÜSTE UNTERSTÜTZTEN FÜLLSTRUKTUREN | SYSTEMES DE GREFFE PRESENTANT DES STRUCTURES DE REMPLISSAGE SOUTENUES PAR DES ECHAFAUDAGES    EP1874231B1    EP2006751879A    2006-04-28
ENDOLOGIX INC    EP    GRAFT DEPLOYMENT SYSTEM | IMPLANTAT-ABLAGESYSTEM | SYSTEME DE DEPLOIEMENT DE TUBE PROTHETIQUE    EP1572034B1    EP2003790040A    2003-11-25
ENDOLOGIX INC    EP    STENT GRAFT | STENT-IMPLANTAT | GREFFON DE STENT    EP2459127B1    EP2010806904A    2010-07-27
ENDOLOGIX INC    EP    STENT-GRAFT WITH POSITIONING ANCHOR | STENT-GRAFT MIT POSITIONIERUNGSVERANKERUNG | ENDOPROTHESE A ANCRAGE DE POSITIONNEMENT    EP1542616B1    EP2003754880A    2003-09-22
ENDOLOGIX INC    EP    Systems for endovascular aneurysm treatment | Systeme zur endovaskulären Aneurysma-Therapie | Systèmes pour le traitement d’anévrismes endovasculaires    EP2422745B1    EP2011180827A    2005-07-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    Catheter system | Kathetersystem | Système de cathéter    EP2293838B1    EP2009774381A    2009-06-30
ENDOLOGIX INC    EP    Systems for endovascular aneurysm treatment | Systeme zur Behandlung von endovaskulären Aneurysmen | Systèmes pour le traitement d’anévrisme endovasculaire    EP1778131B1    EP2005773726A    2005-07-22
ENDOLOGIX INC    EP    IMPLANTABLE VASCULAR GRAFT | IMPLANTIERBARE GEFÄSSPROTHESE | GREFFE VASCULAIRE IMPLANTABLE    EP1333787B1    EP2001990900A    2001-11-08
ENDOLOGIX INC    EP    Bifurcated vascular graft and method and apparatus for deploying same | Abzweigendes Gefässtransplantat sowie Verfahren und Gerät zu dessen Entfaltung | Implant vasculaire à deux branches, procédé et appareil pour sa mise en place    EP1009325B1    EP1998906274A    1998-02-06
ENDOLOGIX INC    EP    SINGLE PUNCTURE BIFURCATION GRAFT DEPLOYMENT SYSTEM | EINE EINZIGE PUNKTION ERFORDENDES ENTFALTUNGSSYSTEM FÜR EIN GEFÄSSIMPLANTAT MIT VERZWEIGUNG | SYSTEME DE DEPLOIEMENT D’UNE GREFFE AU NIVEAU D’UNE BIFURCATION, A L’AIDE D’UN SEUL ORIFICE    EP1159024B1    EP2000916167A    2000-03-07


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS | SELBSTEXPANDIERENDE, SICH VERZWEIGENDE, ENDOVASKULARE PROTHESE | PROTHESE ENDOVASCULAIRE BIFURQUEE A DILATATION AUTOMATIQUE    EP1087729B1    EP1999957012A    1999-05-28
ENDOLOGIX INC    EP    ENDOLUMINAL VASCULAR
PROSTHESIS | PROTHESE IM
INNEREN EINES GEFÄSSES |
PROTHESE VASCULAIRE
ENDOLUMINALE
   EP1059893B1    EP1998930137A    1998-06-15
ENDOLOGIX INC    EP    ENDOLUMINAL VASCULAR PROSTHESIS | ENDOLUMINALE VASKULÄRE PROTHESE | PROTHESE VASCULAIRE ENDOLUMINALE    EP1146833B1    EP1999973254A    1999-11-10
ENDOLOGIX INC    EP    DUAL INFLATABLE ARTERIAL PROSTHESIS | DOPPELTE AUFBLASBARE ARTERIENPROTHESE | DOUBLE PROTHÈSE ARTÉRIELLE GONFLABLE    EP3240508A1    EP2015876323A    2015-12-30
ENDOLOGIX INC    EP    FORMING HYDROGELS AND MATERIALS THEREFOR | HERSTELLUNG VON HYDROGELEN UND MATERIALIEN DAFÜR | FORMATION D’HYDROGELS ET MATÉRIAUX POUR CEUX-CI    EP3113722A4    EP2015758921A    2015-03-06


ENDOLOGIX INC    EP    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES | MODULARE STENTPROTHESENSYSTEME UND VERFAHREN MIT AUFBLASBAREN    EP3148483A4    EP2015800658A    2015-05-05


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

      FÜLLSTRUKTUREN | SYSTÈMES ET PROCÉDÉS DE GREFFE D’ENDOPROTHÈSE MODULAIRE COMPRENANT DES STRUCTURES DE REMPLISSAGE GONFLABLES         
ENDOLOGIX INC    EP    LOCKING ASSEMBLY FOR COUPLING GUIDEWIRE TO DELIVERY SYSTEM | VERRIEGELUNGSANORDNUNG ZUR KOPPLUNG EINES FÜHRUNGSDRAHTS AN EIN AUSGABESYSTEM | ENSEMBLE DE VERROUILLAGE POUR ACCOUPLER UN FIL-GUIDE À UN SYSTÈME DE DISTRIBUTION    EP3139860A1    EP2016790254A    2016-06-29
ENDOLOGIX INC    EP    FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE | FÜLLSTRUKTUR FÜR EIN PROTHESENSYSTEM UND VERWENDUNGSVERFAHREN | STRUCTURE DE REMPLISSAGE POUR UN SYSTÈME DE GREFFE ET PROCÉDÉ D’UTILISATION    EP2519191A4    EP2010841580A    2010-12-21
ENDOLOGIX INC    EP    METHOD FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE | VERFAHREN ZUR HERSTELLUNG VON MATERIALIEN IN SITU IN EINER MEDIZINISCHEN VORRICHTUNG | MÉTHODE DE FORMATION DE MATÉRIAUX IN SITU DANS UN DISPOSITIF MÉDICAL    EP2968692A1    EP2014712991A    2014-03-07


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    DOCKING APPARATUS AND METHODS OF USE | ANDOCKVORRICHTUNG UND VERWENDUNGSVERFAHREN | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION    EP2299933A4    EP2009770704A    2009-06-04
ENDOLOGIX INC    EP    SEALING APPARATUS AND METHODS OF USE | VERSCHLUSSGERÄT UND ANWENDUNGSVERFAHREN | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS    EP2299931A4    EP2009759453A    2009-06-04
ENDOLOGIX INC    EP    BIFURCATED GRAFT DEPLOYMENT SYSTEMS AND METHODS | SYSTEME UND VERFAHREN ZUR FREISETZUNG EINER BIFURKATIONSPROTHESE | SYSTÈMES DE DÉPLOIEMENT DE GREFFON À PLUSIEURS BRANCHES, ET PROCÉDÉS    EP2268227A4    EP2009730087A    2009-04-10
ENDOLOGIX INC    EP    METHOD AND SYSTEM FOR ENDOVASCULAR ANEURYSM TREATMENT | VERFAHREN UND SYSTEM ZUR ENDOVASKULÄREN BEHANDLUNG VON ANEURYSMEN | PROCÉDÉ ET SYSTÈME POUR TRAITEMENT D’ANÉVRISME ENDOVASCULAIRE    EP2693980A1    EP2012716880A    2012-04-06


ENDOLOGIX INC    EP    STENT GRAFT DELIVERY SYSTEM | STENTGRAFT-ABLAGESYSTEM | SYSTÈME DE MISE EN PLACE D ENDOPROTHÈSE VASCULAIRE    EP2278939A4    EP2009733719A    2009-04-24


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    CATHETER SYSTEM AND METHODS OF USING SAME | KATHETERSYSTEM UND VERFAHREN ZU SEINER VERWENDUNG | SYSTÈME DE CATHÉTER ET SES PROCÉDÉS D’UTILISATION    EP2680915A1    EP2012709432A    2012-02-29
ENDOLOGIX INC    EP    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | VORRICHTUNG UND VERFAHREN ZUR POSITIONIERUNG EINER GEFÄSSPROTHESE BZW. EINES GEFÄSSPROTHESENSYSTEMS | APPAREIL ET PROCÉDÉ DE DISPOSITION DE GREFFE OU DE SYSTÈME DE GREFFE    EP2635241A2    EP2011781956A    2011-11-02
ENDOLOGIX INC    EP    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | VORRICHTUNG UND VERFAHREN ZUR POSITIONIERUNG EINER GEFÄSSPROTHESE BZW. EINES GEFÄSSPROTHESENSYSTEMS | APPAREIL ET PROCÉDÉ DE PLACEMENT D’UNE GREFFE OU D’UN SYSTÈME DE GREFFE    EP2429452A1    EP2010717383A    2010-04-28
ENDOLOGIX INC    WO    SYSTEMS AND METHODS WITH GRAFT BODY, INFLATABLE FILL CHANNEL, AND FILLING STRUCTURE | SYSTÈMES ET PROCÉDÉS À CORPS DE GREFFE, CANAL DE REMPLISSAGE GONFLABLE ET STRUCTURE DE REMPLISSAGE    WO2017197313A1    PCT/US2017/32490A    2017-05-12


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    WO    SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE | SYSTÈMES ET PROCÉDÉS AVEC GREFFON FENESTRÉ ET STRUCTURE DE REMPLISSAGE    WO2017117068A1    PCT/US2016/68575A    2016-12-23
ENDOLOGIX INC    WO    LOCKING ASSEMBLY FOR COUPLING GUIDEWIRE TO DELIVERY SYSTEM | ENSEMBLE DE VERROUILLAGE POUR ACCOUPLER UN FIL-GUIDE À UN SYSTÈME DE DISTRIBUTION    WO2017004265A1    PCT/US2016/40197A    2016-06-29
ENDOLOGIX INC    WO    ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS | SYSTÈMES ET PROCÉDÉS DE PROTHÈSE ENDOLUMINALE    WO2016210363A1    PCT/US2016/39414A    2016-06-24
ENDOLOGIX INC    WO    DUAL INFLATABLE ARTERIAL PROSTHESIS | DOUBLE PROTHÈSE ARTÉRIELLE GONFLABLE    WO2016109757A1    PCT/US2015/68204A    2015-12-30
ENDOLOGIX INC    WO    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES | SYSTÈMES ET PROCÉDÉS DE GREFFE D’ENDOPROTHÈSE MODULAIRE COMPRENANT DES STRUCTURES DE REMPLISSAGE GONFLABLES    WO2015183489A1    PCT/US2015/29292A    2015-05-05


ENDOLOGIX INC    WO    FORMING HYDROGELS AND MATERIALS THEREFOR | FORMATION D’HYDROGELS ET MATÉRIAUX POUR CEUX-CI    WO2015134906A1    PCT/US2015/19251A    2015-03-06


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    WO    METHOD FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE | MÉTHODE DE FORMATION DE MATÉRIAUX IN SITU DANS UN DISPOSITIF MÉDICAL    WO2014159093A1    PCT/US2014/21928A    2014-03-07
ENDOLOGIX INC    WO    METHOD AND SYSTEM FOR ENDOVASCULAR ANEURYSM TREATMENT | PROCÉDÉ ET SYSTÈME POUR TRAITEMENT D’ANÉVRISME ENDOVASCULAIRE    WO2012139054A1    PCT/US2012/32612A    2012-04-06
ENDOLOGIX INC    WO    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | APPAREIL ET PROCÉDÉ DE DISPOSITION DE GREFFE OU DE SYSTÈME DE GREFFE    WO2012061526A3    PCT/US2011/59012A    2011-11-02
ENDOLOGIX INC    WO    CATHETER SYSTEM AND METHODS OF USING SAME | SYSTÈME DE CATHÉTER ET SES PROCÉDÉS D’UTILISATION    WO2012118901A1    PCT/US2012/27151A    2012-02-29
ENDOLOGIX INC    WO    METHODS AND SYSTEMS FOR TREATING ANEURYSMS | PROCÉDÉS ET SYSTÈMES DE TRAITEMENT D’ANÉVRISMES    WO2012100059A1    PCT/US2012/21878A    2012-01-19
ENDOLOGIX INC    WO    DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS | DISPOSITIFS ET PROCÉDÉS DE TRAITEMENT DE DISSECTIONS VASCULAIRES    WO2012068298A1    PCT/US2011/61061A    2011-11-16


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    WO    STENT GRAFT | ENDOPROTHÈSE COUVERTE    WO2011017123A3    PCT/US2010/43432A    2010-07-27
ENDOLOGIX INC    WO    STENT GRAFT | ENDOPROTHÈSE COUVERTE    WO2011008989A3    PCT/US2010/42181A    2010-07-15
ENDOLOGIX INC    WO    PERCUTANEOUS METHOD AND DEVICE TO TREAT DISSECTIONS | PROCÉDÉ ET DISPOSITIF PERCUTANÉS POUR TRAITER DES DISSECTIONS    WO2010127305A3    PCT/US2010/33274A    2010-04-30
ENDOLOGIX INC    WO    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | APPAREIL ET PROCÉDÉ DE PLACEMENT D’UNE GREFFE OU D’UN SYSTÈME DE GREFFE    WO2010127040A1    PCT/US2010/32843A    2010-04-28
ENDOLOGIX INC    WO    BIFURCATED GRAFT DEPLOYMENT SYSTEMS AND METHODS | SYSTÈMES DE DÉPLOIEMENT DE GREFFON À PLUSIEURS BRANCHES, ET PROCÉDÉS    WO2009126906A8    PCT/US2009/40239A    2009-04-10
ENDOLOGIX INC    WO    CATHETER SYSTEM | SYSTÈME DE CATHÉTER    WO2010002931A1    PCT/US2009/49316A    2009-06-30


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    WO   

DESIGN AND METHOD OF

PLACEMENT OF A GRAFT OR GRAFT SYSTEM | CONCEPTION ET PROCÉDÉ DE MISE EN PLACE D’UN GREFFON OU D’UN SYSTÈME DE GREFFONS | CONCEPTION ET PROCÉDÉ DE MISE EN PLACE D’UN GREFFON OU D’UN SYSTÈME DE GREFFONS

   WO2009105699A1    PCT/US2009/34755A    2009-02-20
ENDOLOGIX INC    WO    METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE | PROCÉDÉ ET AGENT DE STABILISATION <I>IN SITU</I> DU TISSU VASCULAIRE    WO2009064806A1    PCT/US2008/83267A    2008-11-12
ENDOLOGIX INC    WO    STENT | ENDOPROTHÈSE VASCULAIRE    WO2009055615A1    PCT/US2008/81022A    2008-10-23
ENDOLOGIX INC    DE    EINE EINZIGE PUNKTION ERFORDENDES ENTFALTUNGSSYSTEM FÜR EIN GEFÄSSIMPLANTAT MIT VERZWEIGUNG    DE60031381T2    DE60031381A    2000-03-07
ENDOLOGIX INC    DE    SELBSTEXPANDIERENDE, SICH VERZWEIGENDE, ENDOVASKULARE PROTHESE    DE69933560T2    DE69933560A    1999-05-28
ENDOLOGIX INC    DE    ENDOLUMINALE VASKULÄRE PROTHESE    DE69927055T2    DE69927055A    1999-11-10


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    AU    Bifurcated vascular graft and method and apparatus for deploying same | Bifurcated vascular graft deployment device    AU725117B2    AU199861540A    1998-02-06
ENDOLOGIX INC    AU    Implantable vascular graft    AU200230661A    AU200230661A    2001-11-08
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP1397089    EP02730505.1    2017-04-19
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP1397089    EP02730505.1    2017-04-19
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP1397089    EP02730505.1    2017-04-19
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP2260795    EP10011024.6    2016-05-25


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP2260795    EP10011024.6    2016-05-25
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP2260795    EP10011024.6    2016-05-25
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP2260795    EP10011024.6    2016-05-25
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP2260795    EP10011024.6    2016-05-25
ENDOLOGIX INC    EP    ADVANCED KINK-RESISTANT STENT GRAFT    EP2833827    13714471.3    2018-01-31
ENDOLOGIX INC    EP    ADVANCED KINK-RESISTANT STENT GRAFT    EP2833827    13714471.3    2018-01-31


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM       EP13717893.5    2014-11-06
ENDOLOGIX INC    EP    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES       EP15800658.5    2016-11-21
ENDOLOGIX INC    EP    ANEURYSM SAC ACCESS CONDUIT       15852460.3    2017-04-12
ENDOLOGIX INC    EP    DUAL INFLATABLE ARTERIAL PROSTHESIS       15876323.5    2017-07-13
ENDOLOGIX INC    EP    Endoluminal Prosthesis Systems and Methods       16815450.8    2017-12-19
ENDOLOGIX INC    CN    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES       2015800393484    2017-01-19


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    CN    DUAL INFLATABLE ARTERIAL PROSTHESIS       2015800763903    2017-08-17
ENDOLOGIX INC    JP    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES       2016-569901    2016-11-28
ENDOLOGIX INC    CN    Endoluminal Prosthesis Systems and Methods       201680037099.X    2017-12-22
ENDOLOGIX INC    JP    DUAL INFLATABLE ARTERIAL PROSTHESIS       2017-534803    2017-06-28
ENDOLOGIX INC    JP    Endoluminal Prosthesis Systems and Methods       PCT/US2016/039414    2017-12-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

NELLIX INC.    US    Stent-graft with positioning anchor    US9814612B2    US14697433A    2015-10-21
NELLIX INC.    US    System and methods for endovascular aneurysm treatment    US9737425B2    US14537749A    2014-11-10
NELLIX INC.    US    Stent graft delivery system    US9730700B2    US14586110A    2015-04-23
NELLIX INC.    US    Methods for deploying a positioning anchor with a stent-graft    US9113999B2    US11876458A    2007-10-22
NELLIX INC.    US    Sealing apparatus and methods of use    US8945199B2    US12478225A    2009-06-04
NELLIX INC.    US    Stent graft delivery system    US8926682B2    US13243941A    2011-09-23


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

NELLIX INC.    US    System and methods for endovascular aneurysm treatment    US8906084B2    US12684074A    2010-01-07
NELLIX INC.    US    Graft systems having filling structures supported by scaffolds and methods for their use    US8870941B2    US13285897A    2011-10-31
NELLIX INC.    US    STENT GRAFT DELIVERY SYSTEM    US20180028192A1    US15676869A    2017-08-14
NELLIX INC.    US    SEALING APPRATUS AND METHODS OF USE    US20150148892A1    US14612048A    2015-02-02
NELLIX INC.    US    GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE    US10022249    US14525019A    2014-10-27
NELLIX, INC.    US    System and methods of Endovascular Aneurysm Treatment       14/682414    8/21/17


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Nellix, Inc.    US    Vascular stent-graft apparatus and forming method    US6695833    US09671550    9/27/00
ENDOLOGIX INC    EP    Systems for endovascular aneurysm treatment | Systeme zur Behandlung von endovaskulären Aneurysmen | Systèmes pour le traitement d’anévrisme endovasculaire    EP1778131B1    EP2005773726A    2005-07-22
NELLIX INC.    EP    Method for forming a vascular stent-graft | Verfahren zur Herstellung eines vaskulären Stent-Grafts | Procédé de formation d’un stent-greffe vasculaire.    EP1355587B1    EP2001973590A    2001-09-26
NELLIX INC    EP    METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES | VERFAHREN UND SYSTEME ZUR BEHANDLUNG VON ANEURYSMEN UNTER VERWENDUNG VON FÜLLSTRUKTUREN | PROCEDES ET SYSTEMES POUR LE TRAITEMENT DE L’ANEVRISME UTILISANT DES STRUCTURES DE REMPLISSAGE    EP1962722A4    EP2006850439A    2006-12-18
ENDOLOGIX INC    EP    Systems for endovascular aneurysm treatment | Systeme zur endovaskulären Aneurysma-Therapie | Systèmes pour le traitement d’anévrismes endovasculaires    EP2422745A1    EP2011180827A    2005-07-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    DOCKING APPARATUS AND METHODS OF USE | ANDOCKVORRICHTUNG UND VERWENDUNGSVERFAHREN | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION    EP2299933A1    EP2009770704A    2009-06-04
ENDOLOGIX INC    EP    SEALING APPARATUS AND METHODS OF USE | VERSCHLUSSGERÄT UND ANWENDUNGSVERFAHREN | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS    EP2299931A1    EP2009759453A    2009-06-04
ENDOLOGIX INC    EP    STENT GRAFT DELIVERY SYSTEM | STENTGRAFT-ABLAGESYSTEM | SYSTÈME DE MISE EN PLACE D ENDOPROTHÈSE VASCULAIRE    EP2278939A1    EP2009733719A    2009-04-24
ENDOLOGIX INC    EP    GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS | TRANSPLANTATIONSSYSTEM MIT DURCH GERÜSTE UNTERSTÜTZTEN FÜLLSTRUKTUREN | SYSTEMES DE GREFFE PRESENTANT DES STRUCTURES DE REMPLISSAGE SOUTENUES PAR DES ECHAFAUDAGES    EP1874231A2    EP2006751879A    2006-04-28
ENDOLOGIX INC    EP    STENT-GRAFT WITH POSITIONING ANCHOR | STENT-GRAFT MIT POSITIONIERUNGSVERANKERUNG | ENDOPROTHESE A ANCRAGE DE POSITIONNEMENT    EP1542616A2    EP2003754880A    2003-09-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

NELLIX INC.    WO    FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE | STRUCTURE DE REMPLISSAGE POUR UN SYSTÈME DE GREFFE ET PROCÉDÉ D’UTILISATION    WO2011082040A1    PCT/US2010/061621    2010-12-21
NELLIX INC.    WO    DOCKING APPARATUS AND METHODS OF USE | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION    WO2009158170A1    PCT/US2009/046308    2009-06-04
NELLIX INC.    WO    SEALING APPARATUS AND METHODS OF USE | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS    WO2009149294A1    PCT/US2009/046310    2009-06-04
NELLIX INC.    WO    STENT GRAFT DELIVERY SYSTEM | SYSTÈME DE MISE EN PLACE D’ENDOPROTHÈSE VASCULAIRE | SYSTÈME DE MISE EN PLACE D’ENDOPROTHÈSE VASCULAIRE    WO2009132309A1    PCT/US2009/041718    2009-04-24
NELLIX INC.    WO    GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS | ENDOCADRE DE GREFFE AYANT DES CARACTÉRISTIQUES VARIABLES AXIALEMENT    WO2009103011A1    PCT/US2009/034136    2009-02-13
TRIVASCULAR INC.    US    Endovascular graft    US9867727B2    US14320773A    2014-07-01


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Advanced endovascular graft    US9788934B2    US14799656A    2015-07-15
TRIVASCULAR INC.    US    Endovascular graft for aneurysms involving major branch vessels    US9724186B2    US14050835A    2013-10-10
TRIVASCULAR INC.    US    System and method of pivoted stent deployment    US9713523B2    US14452343A    2014-08-05
TRIVASCULAR INC.    US    Systems and methods for guidewire crossover for bifurcated prostheses    US9655754B2    US14323059A    2014-07-03
TRIVASCULAR INC.    US    Bifurcated endovascular prosthesis having tethered contralateral leg    US9585774B2    US14823076A    2015-08-11
TRIVASCULAR INC.    US    PTFE layers and methods of
manufacturing
   US9549829B2    US14458349A    2014-08-13


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Delivery catheter for endovascular device    US9498363B2    US13835491A    2013-03-15
TRIVASCULAR INC    US    Low profile stent and delivery system    US9463101B2    US14923477A    2015-10-27
TRIVASCULAR INC.    US    PTFE layers and methods of
manufacturing
   US9446553B2    US14230318A    2014-03-31
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US9351858B2    US14704013A    2015-05-05
TRIVASCULAR INC.    US    Non-degradable, low swelling, water soluble radiopaque hydrogel polymer    US9308301B2    US13089960A    2011-04-19
TRIVASCULAR INC.    US    Endovascular delivery system with an improved radiopaque marker scheme    US9233015B2    US13803050A    2013-03-14


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Low profile stent graft and delivery system    US9192462B2    US13803037A    2013-03-14
TRIVASCULAR INC.    US    Fenestrated inflatable graft    US9144486B2    US13652471A    2012-10-15
TRIVASCULAR INC.    US    Bifurcated endovascular prosthesis having tethered contralateral leg    US9132025B2    US13803067A    2013-03-14
TRIVASCULAR INC.    US    Endovascular delivery system with flexible and torqueable hypotube    US9066828B2    US13803062A    2013-03-14
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US9050754B2    US12729182A    2010-03-22
TRIVASCULAR INC.    US    Durable stent graft with tapered struts and stable delivery methods and devices    US8992595B2    US13799207A    2013-03-13


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    In vitro testing of endovascular device    US8978448B2    US13649066A    2012-10-10
TRIVASCULAR INC.    US    Advanced endovascular graft delivery system and method of treatment    US8900288B2    US12566104A    2009-09-24
TRIVASCULAR INC.    US    Method of delivering advanced endovascular graft and system    US8864814B2    US13246651A    2011-09-27
TRIVASCULAR INC.    US    PTFE layers and methods of
manufacturing
   US8840824B2    US12910281A    2010-10-22
TRIVASCULAR INC.    US    Endovascular graft    US8801769B2    US13737351A    2013-01-09
TRIVASCULAR INC.    US    Apparatus for manufacturing an endovascular graft section    US8783316B2    US12697504A    2010-02-01


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    PTFE layers and methods of
manufacturing
   US8728372B2    US12915636A    2010-10-29
TRIVASCULAR INC.    US    Advanced endovascular graft    US8709065B2    US12491336A    2009-06-25
TRIVASCULAR INC.    US    Virtual prototyping and testing for medical device development    US8666714B2    US13523765A    2012-06-14
TRIVASCULAR INC.    US    Asymmetric stent apparatus and method    US8663309B2    US11861828A    2007-09-26
TRIVASCULAR INC.    US    Endovascular graft    US8361136B2    US12566793A    2009-09-25
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US8348989B2    US11429735A    2006-05-08


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Delivery system and method for bifurcated graft    US8328861B2    US11941434A    2007-11-16
TRIVASCULAR INC.    US    Endovascular graft and method of delivery    US8241346B2    US13246643A    2011-09-27
TRIVASCULAR INC.    US    Inflatable porous implants and methods for drug delivery    US8267989B2    US12860364A    2010-08-20
TRIVASCULAR INC.    US    Inflatable intraluminal graft    US8226708B1    US10168053A    2002-06-14
TRIVASCULAR INC.    US    Stent and delivery system for deployment thereof    US8226701B2    US11861756A    2007-09-26
TRIVASCULAR INC.    US    Virtual prototyping and testing for medical device development    US8224632B2    US12904994A    2010-10-14


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Dual chamber cuff structure    US8216297B2    US11504434A    2006-08-14
TRIVASCULAR INC.    US    Barbed radially expandable stent    US8167927B2    US13245661A    2011-09-26
TRIVASCULAR INC.    US    Securement assembly and method for expandable endovascular device    US8083789B2    US11941450A    2007-11-16
TRIVASCULAR INC.    US    System and method of pivoted stent deployment    US8066755B2    US11861716A    2007-09-26
TRIVASCULAR INC.    US    Constant force material delivery system and method    US7971751B2    US12724068A    2010-03-15
TRIVASCULAR INC.    US    Passive hemostatic sheath valve    US7901379B2    US11298285A    2005-12-09


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Virtual prototyping and testing for medical device development    US7840393B1    US09679725A    2000-10-04
TRIVASCULAR INC.    US    Inflatable porous implants and methods for drug delivery    US7803178B2    US10769532A    2004-01-30
TRIVASCULAR INC.    US    Advanced endovascular graft    US7766954B2    US11333595A    2006-01-17
TRIVASCULAR INC.    US    Constant force material delivery system and method    US7708163B2    US11360077A    2006-02-23
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US7682475B2    US11870748A    2007-10-11
TRIVASCULAR INC.    US    Method for manufacturing an endovascular graft section    US7678217B2    US11522490A    2006-09-15


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Inflatable implant    US7632291B2    US10461853A    2003-06-13
TRIVASCULAR INC.    US    Endovascular graft    US7615071B2    US11390732A    2006-03-28
TRIVASCULAR INC.    US    Delivery system and method for
expandable intracorporeal device
   US7338518B2    US11201028A    2005-08-10
TRIVASCULAR INC.    US    Passive hemostatic sheath valve    US7241276B2    US10636871A    2003-08-06
TRIVASCULAR INC.    US    Advanced endovascular graft    US7147660B2    US10327711A    2002-12-20
TRIVASCULAR INC.    US    Kink resistant endovascular graft    US7150758B2    US10384103A    2003-03-06


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Radially expandable stent    US7147661B2    US10029559A    2001-12-20
TRIVASCULAR INC.    US    Method and apparatus for shape forming endovascular graft material    US7147455B2    US10868292A    2004-06-14
TRIVASCULAR INC.    US    Method for manufacturing an endovascular graft section    US7125464B2    US10029557A    2001-12-20
TRIVASCULAR INC.    US    Endovascular graft    US7081129B2    US10132754A    2002-04-24
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US7090693B1    US10029584A    2001-12-20
TRIVASCULAR INC.    US    Delivery system and method for
expandable intracorporeal device
   US7066951B2    US10419312A    2003-04-17


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Method and apparatus for shape forming endovascular graft material    US6776604B1    US10029570A    2001-12-20
TRIVASCULAR INC.    US    Delivery system and method for bifurcated endovascular graft    US6761733B2    US09917371A    2001-07-27
TRIVASCULAR INC.    US    Delivery system and method for endovascular graft    US6733521B2    US09834278A    2001-04-11
TRIVASCULAR INC.    US    Delivery system and method for
expandable intracorporeal device
   US6602280B2    US09774733A    2001-01-31
TRIVASCULAR INC.    US    Endovascular graft    US6395019B2    US09133978A    1998-08-14
TRIVASCULAR INC    US    ENDOVASCULAR GRAFT    US20170348125A1    US15686214A    2017-08-25


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    US    ADVANCED ENDOVASCULAR GRAFT    US20170348087A1    US15686218A    2017-08-25
TRIVASCULAR INC    US    ENDOVASCUALR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS    US20170296327A1    US15638559A    2017-06-30
TRIVASCULAR INC    US    SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES    US20170216064A1    US15491074A    2017-04-19
TRIVASCULAR INC    US    Low Profile Stent Graft and Delivery System    US9987123    US15263469A    2016-09-13
TRIVASCULAR INC    US    BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG    US20170035549A1    US15299542A    2016-10-21
TRIVASCULAR INC.    US    DELIVERY CATHETER FOR ENDOVASCULAR DEVICE    US20170035590A1    US15298166A    2016-10-19


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    US    PTFE LAYERS AND METHODS OF MANUFACTURING    US20160367354A1    US15251011A    2016-08-30
TRIVASCULAR INC    US    ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME    US10034787    US14970621A    2015-12-16
TRIVASCULAR INC    US    NON-DEGRADABLE, LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGEL POLYMER    US20160193392A1    US15068415A    2016-03-11
TRIVASCULAR INC.    US    INTERNAL ILIAC PRESERVATION DEVICES AND METHODS    US9956101    US14958085A    2015-12-03
TRIVASCULAR INC.    US    STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT    US20160113796A1    US14920828A    2015-10-22
TRIVASCULAR INC.    US    ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE    US20150265446A1    US14717080A    2015-05-20


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS    US20150250481A1    US14643217A    2015-03-10
TRIVASCULAR INC.    US    ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM    US20150164667A1    US14631818A    2015-02-25
TRIVASCULAR INC.    US    DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES    US20150157479A1    US14615337A    2015-02-05
TRIVASCULAR INC.    US    TANDEM MODULAR ENDOGRAFT    US20150088244A1    US14492674A    2014-09-22
TRIVASCULAR INC.    US    ENDOLEAK ISOLATION SLEEVES AND METHODS OF USE    US20150073523A1    US14481834A    2014-09-09
TRIVASCULAR INC.    US    GATE WIRE FOR CONTRALATERAL LEG ACCESS    US20140194970A1    US14151373A    2014-01-09


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    SAC LINER FOR ANEURYSM REPAIR    US20140194973A1    US14151195A    2014-01-09
TRIVASCULAR INC.    US    ASYMMETRIC STENT APPARATUS AND METHOD    US20140135899A1    US14157350A    2014-01-16
TRIVASCULAR INC.    US    LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM    US20130268056A1    US13803033A    2013-03-14
TRIVASCULAR INC.    US    ADVANCED KINK RESISTANT STENT GRAFT    US9993328    US13803046A    2013-03-14
TRIVASCULAR INC.    US    VASCULAR GRAFT HAVING
LIMITED END STRUCTURE
   US20130096665A1    US13650705A    2012-10-12
TRIVASCULAR INC.    US    INFLATABLE INTRALUMINAL GRAFT    US20120265290A1    US13532887A    2012-06-26


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM    US20120191174A1    US13297219A    2011-11-15
TRIVASCULAR INC.    US    SYSTEM AND METHOD OF PIVOTED STENT DEPLOYMENT    US20120083870A1    US13277117A    2011-10-19
TRIVASCULAR INC.    US    BARBED RADIALLY EXPANDABLE STENT WITH SLOTTED STRUTS    US20120016457A1    US13245652A    2011-09-26
TRIVASCULAR INC.    US    FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT    US20110218609A1    US13024255A    2011-02-09
TRIVASCULAR INC.    US    HINGED ENDOVASCULAR DEVICE    US20100331958A1    US12747499A    2010-09-07
TRIVASCULAR INC.    US    Inflatable Implant    US20100076481A1    US12628623A    2009-12-01


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    METHOD OF DELIVERING ADVANCED ENDOVASCULAR GRAFT    US20100016943A1    US12566808A    2009-09-25
TRIVASCULAR INC.    US    MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY    US20090099649A1    US12245620A    2008-10-03
TRIVASCULAR INC.    US    ALIGNMENT STENT APPARATUS AND METHOD    US20090082845A1    US11861746A    2007-09-26
TRIVASCULAR INC.    US    SYSTEM AND METHOD OF
SECURING STENT BARBS
   US20090082847A1    US11861731A    2007-09-26
TRIVASCULAR INC.    US    APPARATUS FOR SECURING STENT BARBS    US20090082841A1    US11861739A    2007-09-26
TRIVASCULAR INC.    US    PTFE LAYERS AND METHODS OF MANUFACTURING    US20090036971A1    US12250915A    2008-10-14


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    PTFE LAYERS AND METHODS OF MANUFACTURING    US20090036973A1    US12250946A    2008-10-14
TRIVASCULAR INC.    US    Non-degradable, low swelling, water soluble radiopaque hydrogel polymer    US20060222596A1    US11097467A    2005-04-01
TRIVASCULAR INC.    US    Hybrid modular endovascular graft    US20060224232A1    US11097718A    2005-04-01
TRIVASCULAR INC.    US    Delivery system and method for bifurcated graft    US20060009833A1    US11205793A    2005-08-15
TRIVASCULAR INC.    US    Methods, compositions and devices for embolizing body lumens    US20050158272A1    US11031311A    2005-01-07
TRIVASCULAR INC.    US    Endoluminal prosthesis endoleak management    US20050090804A1    US10691849A    2003-10-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US20050027347A1    US10640368A    2003-08-13
TRIVASCULAR INC.    US    Layered endovascular graft    US20040220664A1    US10803153A    2004-03-17
TRIVASCULAR INC.    US    Delivery system and method for bifurcated graft    US20040138734A1    US10686863A    2003-10-16
TRIVASCULAR INC.    US    Endovascular graft    US20030216802A1    US10289136A    2002-11-05
TRIVASCULAR INC.    US    Inflatable intraluminal graft    US20030225453A1    US10289137A    2002-11-05
TRIVASCULAR INC.    US    Advanced endovascular graft    US20030120338A1    US10091641A    2002-03-05


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Delivery system and method for bifurcated graft    US20030004560A1    US10122474A    2002-04-11
TRIVASCULAR INC.    US    Layered endovascular graft    US20020010508A1    US09970576A    2001-10-04
TRIVASCULAR, INC.    US    Stent-graft with improved flexibility       15/568834    10/24/17
Trivascular, Inc.    US    Passive hemostatic sheath valve    US7901379    US11298285    12/9/05
Trivascular, Inc.    US    Fluid mixing apparatus and method    US7178978    US10658074    9/8/03
Trivascular, Inc.    US   

Delivery system and method for

expandable intracorporeal device

   US6602280    US09774733    1/31/01


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Endovascular graft    US6395019    US09133978    8/14/98
Trivascular, Inc.    US    Layered endovascular graft    US6331191    US09200317    11/25/98
Trivascular, Inc.    US    Endovascular graft having longitudinally displaceable sections    US6132457    US09177295    10/22/98
Trivascular, Inc.    US    Low profile stent graft and delivery system       US15263469    9/13/16
Trivascular, Inc.    US    Delivery catheter for endovascular device       US15298166    10/19/16
Trivascular, Inc.    US    Bifurcated endovascular prosthesis having tethered contralateral leg       US15299542    10/21/16


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US15251011    8/30/16
Trivascular, Inc.    US    Endovascular delivery system with an improved radiopaque marker scheme       US14970621    12/16/15
Trivascular, Inc.    US   

Non-degradable, low swelling, water

soluble radiopaque hydrogel polymer

      US15068415    3/11/16
Trivascular, Inc.    US   

Internal iliac preservation devices and

methods

      US14958085    12/3/15
Trivascular, Inc.    US    Stent graft delivery system with access conduit       US14920828    10/22/15
Trivascular, Inc.    US    Bifurcated endovascular prosthesis having tethered contralateral leg       US14823076    8/11/15


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Low profile stent and delivery system       US14923477    10/27/15
Trivascular, Inc.    US    Endovascular delivery system with flexible and torqueable hypotube       US14717080    5/20/15
Trivascular, Inc.    US    Inflatable occlusion wire-balloon for aortic applications       US14643217    3/10/15
Trivascular, Inc.    US    Advanced endovascular graft and delivery system       US14631818    2/25/15
Trivascular, Inc.    US    Durable stent graft with tapered struts and stable delivery methods and devices       US14615337    2/5/15
Trivascular, Inc.    US    Tandem modular endograft       US14492674    9/22/14


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Endoleak isolation sleeves and methods of use       US14481834    9/9/14
Trivascular, Inc.    US    Sac liner for aneurysm repair       US14151195    1/9/14
Trivascular, Inc.    US    Gate wire for contralateral leg access       US14151373    1/9/14
Trivascular, Inc.    US    Asymmetric stent apparatus and method       US14157350    1/16/14
Trivascular, Inc.    US    Low profile stent graft and delivery system       US13803033    3/14/13
Trivascular, Inc.    US    Advanced kink resistant stent graft       US13803046    3/14/13


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Vascular graft having limited end structure       US13650705    10/12/12
Trivascular, Inc.    US    Inflatable intraluminal graft       US13532887    6/26/12
Trivascular, Inc.    US    Advanced endovascular graft and delivery system       US13297219    11/15/01
Trivascular, Inc.    US   

System and method of pivoted stent

deployment

      US13277117    10/19/11
Trivascular, Inc.    US   

Barbed radially expandable stent with

slotted struts

      US13245652    9/26/11
Trivascular, Inc.    US    Fill tube manifold and delivery methods for endovascular graft       US13024255    2/9/11


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Hinged endovascular device       US12747499    9/7/10
Trivascular, Inc.    US    Inflatable implant       US12628623    12/1/09
Trivascular, Inc.    US   

Method of delivering advanced

endovascular graft

      US12566808    9/25/09
Trivascular, Inc.    US    Modular vascular graft for low profile percutaneous delivery       US12245620    10/3/08
Trivascular, Inc.    US    System and method of securing stent barbs       US11861731    9/26/07
Trivascular, Inc.    US    Alignment stent apparatus and method       US11861746    9/26/07


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Apparatus for securing stent barbs       US11861739    9/26/07
Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US12250946    10/14/08
Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US12250915    10/14/08
Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US11106150    4/13/05
Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US11106131    4/13/05
Trivascular, Inc.    US    Hybrid modular endovascular graft       US11097718    4/1/05


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US   

Non-degradable low swelling, water

soluble radiopaque hydrogel polymer

      US11097467    4/1/05
Trivascular, Inc.    US    Delivery system and method for bifurcated graft       US11205793    8/15/05
Trivascular, Inc.    US    Modular endovascular graft       US11077938    3/11/05
Trivascular, Inc.    US    Methods, compositions and devices for embolizing body lumens       US11031311    1/7/05
Trivascular, Inc.    US   

Endoluminal prosthesis endoleak

management

      US10691849    10/22/03
Trivascular, Inc.    US    Endovascular graft joint and method for manufacture       US10640368    8/13/03


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Layered endovascular graft       US10803153    3/17/04
Trivascular, Inc.    US    Delivery system and method for bifurcated graft       US10686863    10/16/03
Trivascular, Inc.    US    Inflatable intraluminal graft       US10289137    11/5/02
Trivascular, Inc.    US    Endovascular graft       US10289136    11/5/02
Trivascular, Inc.    US    Advanced endovascular graft       US10091641    3/5/02
Trivascular, Inc.    US    Delivery system and method for bifurcated graft       US10122474    4/11/02


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Layered endovascular graft       US09970576    10/3/01
TRIVASCULAR INC.    EP    ADVANCED KINK-RESISTANT STENT GRAFT | HOCHENTWICKELTES KNICKBESTÄNDIGES STENTTRANSPLANTAT | ENDOPROTHÈSE ÉVOLUÉE RÉSISTANT AU PLIAGE    EP2833827B1    EP2013714471A    2013-03-21
TRIVASCULAR INC.    EP    INFLATABLE IMPLANT | AUFBLASBARES IMPLANTAT | IMPLANT GONFLABLE    EP1635738B1    EP2004776568A    2004-06-14
TRIVASCULAR INC.    EP   

ENDOVASCULAR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS | ENDOVASKULÄRES

TRANSPLANTAT FÜR ANEURYSMEN MIT BETEILIGUNG VON GROSSEN VERZWEIGTEN GEFÄSSEN | GREFFON ENDOVASCULAIRE POUR ANÉVRISMES METTANT EN JEU DES VAISSEAUX RAMIFIÉS PRINCIPAUX

   EP2906144B1    EP2013780282A    2013-10-10


TRIVASCULAR INC.    EP    ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM | FORTSCHRITTLICHES ENDOVASKULÄRES TRANSPLANTAT UND SYSTEM ZU SEINER VERABREICHUNG | GREFFE ENDOVASCULAIRE AVANCÉE ET    EP2640319B1    EP2011841183A    2011-11-15


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

      SYSTÈME DE POSE ASSOCIÉ         
TRIVASCULAR INC.    EP    DELIVERY CATHETER FOR ENDOVASCULAR DEVICE | EINFÜHRKATHETER FÜR EINE ENDOVASKULÄRE VORRICHTUNG | CATHÉTER DE DÉLIVRANCE POUR DISPOSITIF ENDOVASCULAIRE    EP2833845B1    EP2013771941A    2013-04-01
TRIVASCULAR INC.    EP    Endovascular graft | Endovaskuläres Gewebe | Greffe endovasculaire    EP1464301B1    EP200475832A    1999-02-09
TRIVASCULAR INC.    EP    PTFE LAYERS AND METHODS OF MANUFACTURING | PTFE-LAGEN UND HERSTELLUNGSVERFAHREN | COUCHES DE PTFE ET PROCEDES DE FABRICATION    EP1888318B1    EP2006740124A    2006-03-30
TRIVASCULAR INC.    EP    ADVANCED ENDOVASCULAR GRAFT | FORTSCHRITTLICHES ENDOVASKULÄRES TRANSPLANTAT | GREFFON ENDOVASCULAIRE EVOLUE    EP1467679B1    EP2002796047A    2002-12-20


TRIVASCULAR INC.    EP    Non-degradable low swelling, water soluble radiopaque hydrogels | Nicht abbaubares, schwach anschwellendes, wasserlösliches röntgendichtes Hydrogelpolymer | Polymère absorbant l’eau, radiopaque, soluble dans l’eau, à faible gonflement et non dégradable    EP2332590B1    EP2010194236A    2006-03-28


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    EP    Endovascular graft | Endovaskuläres Transplantat | Greffe endovasculaire    EP2147658B1    EP200913660A    1999-02-09
TRIVASCULAR INC.    EP    Kink resistant endovascular graft | Knickbeständiges Stentimplantat | Stent à greffer resistant au pliage    EP2319456B1    EP2010183146A    2004-03-05
TRIVASCULAR INC.    EP    Delivery system for graft | Abgabesystem für Graft | Système de mise en place pour prothèse    EP2145607B1    EP2009175398A    2004-10-15
TRIVASCULAR INC.    EP    DELIVERY SYSTEM FOR BIFURCATED GRAFT | VORRICHTUNG ZUR PLATZIERUNG VON ZWEIGETEILTEN ENDOPROTHESEN | SYSTEME DE MISE EN PLACE D’UN GREFFON A BIFURCATION    EP1377234B1    EP2002725639A    2002-04-11
TRIVASCULAR INC.    EP    Advanced endovascular graft | Erweitertes endovaskuläres Transplantat | Greffe endovasculaire évoluée    EP2135583B1    EP20099090A    2002-12-20
TRIVASCULAR INC.    EP    KINK RESISTANT ENDOVASCULAR GRAFT | KNICKFESTES ENDOVASKULÄRES IMPLANTAT | IMPLANT ENDOVASCULAIRE RÉSISTANT A LA DÉFORMATION    EP1601314B1    EP2004718097A    2004-03-05


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    EP    NON-DEGRADABLE LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGELS | NICHT-ABBAUBARE WENIG QUELLENDE WASSERLÖSLICHE RÖNTGENDICHTE HYDROGELS | HYDROGEL RADIOPAQUE, SOLUBLE DANS L’EAU, NON DEGRADABLE ET A FAIBLE GONFLEMENT    EP1874370B1    EP2006739747A    2006-03-28
TRIVASCULAR INC.    EP    INFLATABLE INTRALUMINAL GRAFT | AUFBLASBARER INTRALUMINALER PFROPFEN | GREFFON INTRALUMINAL GONFLABLE    EP1176926B1    EP2000907760A    2000-03-03
TRIVASCULAR INC.    EP    ENDOVASCULAR GRAFT | ENDOVASKULÄRES IMPLANTAT | GREFFON ENDOVASCULAIRE    EP1054648B1    EP1999906812A    1999-02-09
TRIVASCULAR INC.    EP    STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT | STENTGRAFTEINFÜHRUNGSSYSTEM MIT ZUGANGSKANAL | SYSTEME DE POSE DE GREFFE ET PROTHESE ENDOVASCULAIRE AVEC CONDUIT D’ACCES    EP3209249A1    EP2015852460A    2015-10-22


TRIVASCULAR INC.    EP    INTERNAL ILIAC PRESERVATION DEVICES AND METHODS | VORRICHTUNGEN UND VERFAHREN ZUR INTERNEN BECKENKONSERVIERUNG | DISPOSITIFS ET PROCÉDÉS DE PRÉSERVATION DE L’ILIAQUE INTERNE    EP3226814A1    EP2015816618A    2015-12-03


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    EP    INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS | AUFBLASBARER OKKLUSIONSDRAHTBALLON FÜR ANWENDUNGEN IN DER AORTA | BALLONNET DE FIL D’OCCLUSION GONFLABLE POUR APPLICATIONS AORTIQUES    EP3116439A1    EP2015711020A    2015-03-10
TRIVASCULAR INC.    EP    SYSTEMS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES | SYSTEME FÜR FÜHRUNGSDRAHTÜBERGANG FÜR VERZWEIGTE PROTHESEN | SYSTÈMES POUR UN CROISEMENT DE FIL-GUIDE POUR DES PROTHÈSES BIFURQUÉES    EP3091944A1    EP2014752969A    2014-07-30
TRIVASCULAR INC.    Germany   

SYSTEMS FOR GUIDEWIRE

CROSSOVER FOR BIFURCATED
PROSTHESES

   3091944    14752969.7    7/18/2018
TRIVASCULAR INC.    UK   

SYSTEMS FOR GUIDEWIRE

CROSSOVER FOR BIFURCATED
PROSTHESES

   3091944    14752969.7    7/18/2018
TRIVASCULAR INC.    IT   

SYSTEMS FOR GUIDEWIRE

CROSSOVER FOR BIFURCATED
PROSTHESES

   3091944    14752969.7    7/18/2018


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    EP    TANDEM MODULAR ENDOGRAFT | MODULARES TANDEM-ENDOGRAFT | ENDOGREFFE MODULAIRE EN TANDEM    EP3049021A1    EP2014782021A    2014-09-23
TRIVASCULAR INC.    EP    DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES | DAUERHAFTES STENTIMPLANTAT MIT KONISCHEN STREBEN UND STABILE FREISETZUNGSVERFAHREN SOWIE VORRICHTUNGEN | ENDOPROTHÈSE VASCULAIRE DURABLE AVEC ENTRETOISES CONIQUES ET PROCÉDÉS ET DISPOSITIFS DE DÉLIVRANCE STABLES    EP2833830A4    EP2013772199A    2013-03-29
TRIVASCULAR INC.    EP    ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME | ENDOVASKULÄRES FREISETZUNGSSYSTEM MIT VERBESSERTEM RÖNTGENMARKERSCHEMA | SYSTÈME DE POSE ENDOVASCULAIRE AYANT UNE TECHNIQUE DE MARQUEUR RADIO-OPAQUE AMÉLIORÉE    EP2861189A1    EP2013733113A    2013-05-31


TRIVASCULAR INC.    EP    BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG | GEGABELTE ENDOVASKULÄRE PROTHESE MIT ANGEBUNDENEM KONTRALATERALEM BEIN | PROTHÈSE ENDOVASCULAIRE    EP2861183A1    EP2013733115A    2013-05-31


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

      BIFURQUÉE POSSÉDANT UNE JAMBE CONTROLATÉRALE AVEC ATTACHE         
TRIVASCULAR INC.    EP    LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM | FLACHES STENTTRANSPLANTAT UND FREISETZUNGSSYSTEM | ENDOPROTHÈSE VASCULAIRE À PROFIL BAS ET SYSTÈME DE DÉLIVRANCE    EP2833829A1    EP2013717893A    2013-03-21
TRIVASCULAR INC    EP    ALIGNMENT STENT APPARATUS AND METHOD | VORRICHTUNG UND VERFAHREN ZUR STENTAUSRICHTUNG | APPAREIL D’ENDOPROTHÈSE D’ALIGNEMENT ET PROCÉDÉ    EP2194919A4    EP2008834027A    2008-09-25
TRIVASCULAR INC    EP    MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY | MODULARER GEFÄSSERSATZ FÜR PERKUTANE FREISETZUNG MIT NIEDRIGEM PROFIL | GREFFON VASCULAIRE MODULAIRE POUR ADMINISTRATION PERCUTANÉE À PROFIL RÉDUIT    EP2194921A4    EP2008835032A    2008-10-03


TRIVASCULAR INC    EP    METHOD AND APPARATUS FOR MANUFACTURING AN ENDOVASCULAR GRAFT SECTION | VERFAHREN UND VORRICHTUNG ZUR HERSTELLUNG EINES ENDOVASKULÄREN TRANSPLANTATABSCHNITTS | PROCEDE ET APPAREIL DE    EP1465685A4    EP2002805657A    2002-12-20


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

      FABRICATION D’UNE SECTION DE GREFFON ENDOCORONAIRE         
TRIVASCULAR INC    WO    ENDOLUMINAL PROSTHESIS DEPLOYMENT DEVICES AND METHODS | DISPOSITIFS ET PROCÉDÉS DE DÉPLOIEMENT DE PROTHÈSE ENDOLUMINALE    WO2017019913A1    WO2016US44583A    2016-07-28
TRIVASCULAR INC    WO    STENT-GRAFT WITH IMPROVED FLEXIBILITY | GREFFON DE STENT À FLEXIBILITÉ AMÉLIORÉE    WO2016183128A1    WO2016US31728A    2016-05-11
TRIVASCULAR INC    WO    BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT | DÉPLOIEMENT DE PROTHÈSE ENDOLUMINALE ASSISTÉ PAR BALLONNET    WO2016191602A1    WO2016US34427A    2016-05-26
TRIVASCULAR INC    WO    INTERNAL ILIAC PRESERVATION DEVICES AND METHODS | DISPOSITIFS ET PROCÉDÉS DE PRÉSERVATION DE L’ILIAQUE INTERNE    WO2016090112A1    WO2015US63686A    2015-12-03
TRIVASCULAR INC    WO    STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT | SYSTEME DE POSE DE GREFFE ET PROTHESE ENDOVASCULAIRE AVEC CONDUIT D’ACCES    WO2016065208A1    WO2015US57016A    2015-10-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    WO    INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS | BALLONNET DE FIL D’OCCLUSION GONFLABLE POUR APPLICATIONS AORTIQUES    WO2015138402A1    WO2015US19626A    2015-03-10
TRIVASCULAR INC    WO    SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES | SYSTÈMES ET PROCÉDÉS POUR UN CROISEMENT DE FIL-GUIDE POUR DES PROTHÈSES BIFURQUÉES    WO2015105530A1    WO2014US48769A    2014-07-30
TRIVASCULAR INC    WO    TANDEM MODULAR ENDOGRAFT | ENDOGREFFE MODULAIRE EN TANDEM    WO2015048004A1    WO2014US56953A    2014-09-23
TRIVASCULAR INC    WO    ENDOVASCULAR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS | GREFFON ENDOVASCULAIRE POUR ANÉVRISMES METTANT EN JEU DES VAISSEAUX RAMIFIÉS PRINCIPAUX    WO2014059114A3    WO2013US64290A    2013-10-10
TRIVASCULAR INC    WO    SAC LINER FOR ANEURYSM REPAIR | REVÊTEMENT SAC POUR RÉPARATION D’ANÉVRISME    WO2014110231A3    WO2014US10828A    2014-01-09
TRIVASCULAR INC    WO    GATE WIRE FOR CONTRALATERAL LEG ACCESS | FIL GUIDE POUR PERMETTRE UN ACCÈS À UN JAMBAGE CONTROLATÉRAL    WO2014110254A1    WO2014US10870A    2014-01-09


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    WO    BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG | PROTHÈSE ENDOVASCULAIRE BIFURQUÉE POSSÉDANT UNE JAMBE CONTROLATÉRALE AVEC ATTACHE    WO2013188134A1    WO2013US43630A    2013-05-31
TRIVASCULAR INC    WO    ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME | SYSTÈME DE POSE ENDOVASCULAIRE AYANT UNE TECHNIQUE DE MARQUEUR RADIO-OPAQUE AMÉLIORÉE    WO2013188132A1    WO2013US43615A    2013-05-31
TRIVASCULAR INC    WO    ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE | SYSTÈME DE POSE ENDOVASCULAIRE POURVU D’UN HYPOTUBE FLEXIBLE ET POUVANT ÊTRE SOUMIS À UN COUPLE DE TORSION    WO2013188133A1    WO2013US43623A    2013-05-31
TRIVASCULAR INC    WO    DELIVERY CATHETER FOR ENDOVASCULAR DEVICE | CATHÉTER DE DÉLIVRANCE POUR DISPOSITIF ENDOVASCULAIRE    WO2013151924A1    WO2013US34787A    2013-04-01


TRIVASCULAR INC    WO    DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES | ENDOPROTHÈSE VASCULAIRE DURABLE AVEC ENTRETOISES CONIQUES ET PROCÉDÉS ET DISPOSITIFS DE DÉLIVRANCE STABLES    WO2013151896A1    WO2013US34654A    2013-03-29


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    WO    LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM | ENDOPROTHÈSE VASCULAIRE À PROFIL BAS ET SYSTÈME DE DÉLIVRANCE    WO2013151793A1    WO2013US33250A    2013-03-21
TRIVASCULAR INC    WO    ADVANCED KINK-RESISTANT STENT GRAFT | ENDOPROTHÈSE ÉVOLUÉE RÉSISTANT AU PLIAGE    WO2013151794A3    WO2013US33252A    2013-03-21
TRIVASCULAR INC    WO    ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM | GREFFE ENDOVASCULAIRE AVANCÉE ET SYSTÈME DE POSE ASSOCIÉ    WO2012068175A3    WO2011US60873A    2011-11-15
TRIVASCULAR INC    WO    FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT | COLLECTEUR DE TUBE DE REMPLISSAGE ET PROCÉDÉS DE POSE DE GREFFON ENDOVASCULAIRE    WO2011100367A3    WO2011US24248A    2011-02-09
TRIVASCULAR INC    DE    ENDOVASKULÄRES IMPLANTAT    DE69918272T2    DE69918272A    1999-02-09


TRIVASCULAR INC    CA    VIRTUAL PROTOTYPING AND TESTING FOR MEDICAL DEVICE DEVELOPMENT | ESSAI ET PROTOTYPAGE VIRTUELS DE MISE AU POINT DE DISPOSITIFS MEDICAUX    CA2424252C    CA2424252A    2001-09-28


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    CA    DELIVERY SYSTEM AND METHOD FOR BIFURCATED GRAFT | METHODE ET SYSTEME DE MISE EN PLACE D’UN GREFFON A BIFURCATION    CA2443104C    CA2443104A    2002-04-11
TRIVASCULAR INC    CA    ENDOVASCULAR GRAFT | GREFFON ENDOVASCULAIRE    CA2501892C    CA2501892A    1999-02-09
TRIVASCULAR INC    CA    INFLATABLE INTRALUMINAL GRAFT | GREFFON INTRALUMINAL GONFLABLE    CA2640263C    CA2640263A    2000-03-03
TRIVASCULAR INC    CA    INFLATABLE INTRALUMINAL GRAFT | GREFFON INTRALUMINAL GONFLABLE    CA2376253C    CA2376253A    2000-03-03
TRIVASCULAR INC    CA    ENDOVASCULAR GRAFT | GREFFON ENDOVASCULAIRE    CA2319052C    CA2319052A    1999-02-09
TRIVASCULAR INC    AU    Modular vascular graft for low profile percutaneous delivery    AU2008308474B2    AU2008308474A    2008-10-03
TRIVASCULAR INC    AU    Advanced endovascular graft    AU2009230748B2    AU2009230748A    2009-10-26
TRIVASCULAR INC    AU    Advanced endovascular graft    AU2009201682B2    AU2009201682A    2009-04-28
TRIVASCULAR INC    AU    Method and apparatus for manufacturing an endovascular graft section    AU2008258148B2    AU2008258148A    2008-12-17
TRIVASCULAR INC    AU    Advanced endovascular graft    AU2002360765C1    AU2002360765A    2002-12-20


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    AU    Method and apparatus for manufacturing an endovascular graft section    AU2002366805B8    AU2002366805A    2002-12-20
TRIVASCULAR INC    AU    Virtual prototyping and testing for medical device development    AU2001293179A1    AU2001293179A    2001-09-28
TRIVASCULAR INC    AU    Delivery system and method for
expandable intracorporeal device
   AU200133250A    AU200133250A    2001-02-01
TRIVASCULAR INC    JP    ADVANCED KINK-RESISTANT STENT GRAFT    6297023    2015-504610    3/2/2018
TRIVASCULAR INC    UK   

INFLATABLEOCCLUSIONWIRE-

BALLOON FOR AORTIC
APPLICATIONS

   15711020.6    3116439    2/7/2018
TRIVASCULAR INC    UK   

PASSIVE HEMOSTATIC SHEATH

VALVE

   04780128.7    1651135    2/28/2018
TRIVASCULAR INC    CN    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES       201810370663.0    2015-5-5
ENDOLOGIX, INC.    CN    CATHETER SYSTEM AND METHODS OF USING SAME    ZL201510649289.4    201510649289.4    2018-6-8
ENDOLOGIX, INC.    JP    CATHETER SYSTEM AND METHODS OF USING SAME    6294669    2013-556828    2018-2-23
TRIVASCULAR INC    Germany   

PASSIVE HEMOSTATIC SHEATH

VALVE

   1651135    04780128.7    2018-2-28
ENDOLOGIX, INC.    JP    BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT       2017-560952    5/26/2016


ENDOLOGIX, Inc.    EP    SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE       16882476.1    12/23/2016


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX, Inc.    JP    SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE       2018-534852    12/23/2016
ENDOLOGIX INC.    US   

STENT GRAFT SYSTEMS WITH

RESTRAINTS IN CIRCUMFERENTIAL

CHANNELS AND METHODS
THEREOF

      62/678961    5/31/2018
ENDOLOGIX INC.    US   

PERCUTANEOUS METHOD AND

DEVICE TO TREAT DISSECTIONS

      15/429090    2/9/2017
NELLIX, INC.    US   

SYSTEM AND METHODS FOR

ENDOVASCULAR ANEURYSM
TREATMENT

   2018-0064566    15/682414    8/21/2017
TRIVASCULAR INC.    US   

ENDOVASCULAR DELIVERY

SYSTEM WITH AN IMPROVED
RADIOPAQUE MARKER SCHEME

      16/049560    7/30/2018
ENDOLOGIX INC.    PCT    SINGLE PUNCTURE BIFURCATION GRAFT DEPLOYMENT SYSTEM    WO2000053251    PCT/US2000/006070    3/7/2000
ENDOLOGIX INC.    PCT    GRAFT DEPLOYMENT SYSTEM    WO2004047885    PCT/US2003/37685    11/25/2003
ENDOLOGIX INC.    PCT   

DUAL CONCENTRIC GUIDEWIRE

AND METHODS OF BIFURCATED GRAFT DEPLOYMENT

   WO2008089097    PCT/US2008/050915    1/11/2008
ENDOLOGIX INC.    PCT   

ENDOLUMENAL VASCULAR

PROSTHESIS WITH NEOINTIMA
INHIBITING POLYMERIC SLEEVE

   WO2005096997    PCT/US2005/11522    4/6/2005
ENDOLOGIX INC.    PCT    IMPLANTABLE VASCULAR GRAFT    WO2002039888    PCT/US2001/47028    11/8/2001
ENDOLOGIX INC.    PCT    DUAL WIRE PLACEMENT CATHETER    WO2001003762    PCT/US2000/016352    6/14/2000
ENDOLOGIX INC.    PCT   

MULTI-SEGMENTED GRAFT

DEPLOYMENT SYSTEM

   WO2008034106    PCT/US2007/78565    9/14/2007


ENDOLOGIX INC.    PCT    METHOD AND APPARATUS FOR DECOMPRESSING ANEURYSMS    WO2005099807    PCT/US2005/12306    4/12/2005


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    EP   

ENDOLUMINAL PROSTHESIS

DEPLOYMENT DEVICES AND
METHODS

   3328326    16831382.3    7/28/2016
TRIVASCULAR INC.    EP    BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT    3302356    16800744.1    5/26/2016
TRIVASCULAR INC.    EP   

STENT-GRAFT WITH IMPROVED

FLEXIBILITY

   3294210    16793394.4    5/11/2016
TRIVASCULAR INC.    EP    PTFE LAYERS AND METHODS OF MANUFACTURING    3095585    16171681.6    3/30/2006


SCHEDULE 11

TRADEMARKS

See attached.


Trademarks

 

Grantor

  

Country

  

Mark

  

Application No.

  

Application Date

  

Registration No.

  

Registration Date

Endologix, Inc.    U.S.    LOGO    86/854470    12/18/15      
Endologix, Inc.    U.S.    ACTIVESEAL    85/518,608    01/17/12    5396605    02/06/18
Endologix, Inc.    U.S.    AFX    85/069,068    06/22/10    4214460    09/25/12
Endologix, Inc.    U.S.    ANGIOTIP    85/767055    10/30/12    5205176    05/16/17
Endologix, Inc.    U.S.    DURAPLY    86/362822    08/11/14    5433696    3/27/18
Endologix, Inc.    U.S.    ENDOLOGIX    75/323,314    07/11/97    2257799    06/29/99
Endologix, Inc.    U.S.    EVAS FORWARD    86/116940    11/12/13    5306786    10/10/17
Endologix, Inc.    U.S.    INNOVATION
TAKING SHAPE
   85/369,728    07/12/11    4220343    10/09/12
Endologix, Inc.    U.S.    INNOVATION
THAT EMPOWERS
   85/514516    01/11/12    4841631    10/27/15
Endologix, Inc.    U.S.    INTELIX    86/316249    06/20/14    5059968    10/11/16
Endologix, Inc.    U.S.    INTUITRAK    77/494,729    06/09/08    3649757    07/07/09
Endologix, Inc.    U.S.    INTUITRAK
DELIVERY
SYSTEM
   77/520,529    07/11/08    3649866   

07/07/09


Endologix, Inc.    U.S.    NELLIX    77/090544    01/24/07    3880178   

11/23/10


Endologix, Inc.    U.S.    POWERLINK    75/658,969    03/12/99    2456038   

05/29/01

Endologix, Inc.    U.S.    POWERLINK XL    78/718,728    09/22/05    3573999   

02/10/09

Endologix, Inc.    U.S.    SUREPASS    78/965,443    08/31/06    3593259   

03/17/09

Endologix, Inc.    U.S.    VELA    85/857988    02/22/13    5296578   

09/26/17

Endologix, Inc.    U.S.    XPAND    85/126,464    09/09/10    4168563   

07/03/12

Endologix, Inc.    Argentina    LOGO    3514846    06/16/16    2888199   

05/19/17

Endologix, Inc.    Argentina    LOGO    3514844    06/16/16    2888198   

05/19/17

Endologix, Inc.    Argentina    LOGO    3514844    06/16/16      
Endologix, Inc.    Argentina    LOGO    3514842    06/16/16    2888196   

05/19/17

Endologix, Inc.    Argentina    AFX    3064304    01/27/11    2496722   

04/04/12

Endologix, Inc.    Argentina    DURAPLY    3386456    02/11/15    2773735   

12/09/15

Endologix, Inc.    Argentina    INTELIX    3375648    12/19/14    2766285   

12/04/15

Endologix, Inc.    Argentina    INTELIX    3375649    12/19/14    2766286   

11/04/15


Endologix, Inc.    Argentina    INTELIX    3375650    12/19/14    2766287    11/04/15
Endologix, Inc.    Argentina    NELLIX    3243024    05/02/13    2658594    06/26/14
Endologix, Inc.    Argentina    VELA    3271551    08/22/13    2808433    06/03/16
Endologix, Inc.    Argentina    XPAND    3072929    03/16/11    2506706    06/01/12
Endologix, Inc.    Australia    LOGO    1326557    06/14/16    1326557    04/24/17
Endologix, Inc.    Australia    DURAPLY    1710503    02/10/15    1710503    11/04/15
Endologix, Inc.    Australia    INTELIX    1247823    12/19/14    1247823    11/25/16
Endologix, Inc.    Brazil    LOGO    911.201.521    06/17/16      
Endologix, Inc.    Brazil    LOGO    911.201.572    06/17/16      
Endologix, Inc.    Brazil    LOGO    911.201.599    06/17/16      
Endologix, Inc.    Brazil    LOGO    911.201.602    06/17/16      


Endologix, Inc.    Brazil    ACTIVESEAL    909861684    08/20/15      


Endologix, Inc.    Brazil    AFX    830891226    12/21/10      
Endologix, Inc.    Brazil    AFX    912186283    01/19/17      
Endologix, Inc.    Brazil    DURAPLY    909861722    08/20/15      
Endologix, Inc.    Brazil    INTELIX    909861749    08/20/15      
Endologix, Inc.    Brazil    INTELIX    909861765    08/20/15      
Endologix, Inc.    Brazil    INTELIX    909861773    08/20/15      
Endologix, Inc.    Brazil    NELLIX    840506538    05/06/13    840506538    02/16/16
Endologix, Inc.    Brazil    VELA    840618530    08/22/13      
Endologix, Inc.    Canada    DURAPLY    1714718    02/10/15      
Endologix, Inc.    Canada    INTELIX    1707569    12/17/14      
Endologix, Inc.    Canada    VELA    1640416    08/21/13      
Endologix, Inc.    Chile    XPAND    1137099    12/30/14    1187135    11/27/15
Endologix, Inc.    China    LOGO    1326551    06/14/16      
Endologix, Inc.    China    DURAPLY    1257411    02/10/15    1257411    02/10/15
Endologix, Inc.    China    INTELIX    1247823    12/19/14    1247823    12/19/14
Endologix, Inc.    Colombia    AFX    16-133051    05/11/26    582446    11/17/17
Endologix, Inc.    Colombia    ENDOLOGIX    16-121402    05/11/16    582446    11/17/17


Endologix, Inc.    Colombia    XPAND    1246435    12/26/14    1246435    12/26/14


Endologix, Inc.    European
Community
   AFX    009609884    12/20/10    009609884    12/01/11
Endologix, Inc.    European
Community
   ANGIOTIP    011780129    04/30/13    011780129    09/24/13
Endologix, Inc.    European
Community
   CLASSICAL
REMODELING
   4598728    08/19/05    4598728    08/02/06
Endologix, Inc.    European
Community
   DURAPLY    1257411    02/10/15    1257411    02/10/15
Endologix, Inc.    European
Community
   ENDOLOGIX, INC.    720649    01/12/98    720649    01/12/98
Endologix, Inc.    European
Community
   INTELIX    13361399    10/15/14      
Endologix, Inc.    European
Community
   INTUITRAK    7453401    11/28/08    7453401    09/21/09
Endologix, Inc.    European
Community
   INTUITRAK
DELIVERY
SYSTEM
   7513302    12/23/08    7513302    07/21/09
Endologix, Inc.    European
Community
   NELLIX    011771011    04/26/13    011771011    09/18/13
Endologix, Inc.    European
Community
   POWERLINK XL    5002977    03/22/06    5002977    04/11/07
Endologix, Inc.    European
Community
   VISIFLEX
DELIVERY
SYSTEM
   5075528    04/24/06    5075528    04/16/07


Endologix, Inc.    European
Community
   VISIFLEX SURE
PASS
   5749338    02/28/07    5749338    01/31/08


Endologix, Inc.    European Union    LOGO    1326551    06/14/16    1326551    06/12/17
Endologix, Inc.    France    POWERLINK    043299490    09/13/99    043299490    12/31/04
Endologix, Inc.    Hong Kong    DURAPLY    303301280    02/15/15    303301280    10/05/15
Endologix, Inc.    Hong Kong    INTELIX    303240954    12/18/14    303240954    09/07/16
Endologix, Inc.    Italy    POWERLINK    001724    09/13/99    0001376420    02/27/08
Endologix, Inc.    Japan    LOGO    1326551    06/14/16    1326551    05/02/17
Endologix, Inc.    Japan    ACTIVESEAL    2015-078597    08/17/15    5857166    06/10/16
Endologix, Inc.    Japan    AFX    2015-078596    08/17/15    5824704    02/05/16
Endologix, Inc.    Japan    DURAPLY    1257411    02/10/15    1257411    01/19/16
Endologix, Inc.    Japan    ENDOLOGIX, INC.    1155/1998    01/12/98    4352035    01/14/00
Endologix, Inc.    Japan    INTELIX    1247823    12/19/14    1247823    10/27/15
Endologix, Inc.    Japan    NELLIX    2013-031634    04/25/13    5613989    09/06/13
Endologix, Inc.    Japan    VELA    2013-6/4901    08/21/13      
Endologix, Inc.    Japan    VISIFLEX
DELIVERY
SYSTEM
   2006-035170    04/17/06    4974084    07/28/06


Endologix, Inc.    Japan    VISIFLEX
SUREPASS
   2007-017236    02/28/07    5066349    07/27/07


Endologix, Inc.    Korea    DURAPLY    1257411    02/10/15    1257411    02/10/15
Endologix, Inc.    Korea    INTELIX    1247823    12/19/14    1247823    06/13/16
Endologix, Inc.    Malaysia    DURAPLY    2015052019    02/11/15    2015052019    12/29/16
Endologix, Inc.    Malaysia    INTELIX    2014069128    12/18/14    2014069128    04/22/16
Endologix, Inc.    Malaysia    INTELIX    2014069135    12/18/14    2014069135    05/10/16
Endologix, Inc.    Mexico    XPAND    1246435    12/26/14    1246435    07/26/16
Endologix, Inc.    New Zealand    DURAPLY    1024501    02/10/15    1024501    12/02/15
Endologix, Inc.    New Zealand    INTELIX    1247823    12/19/14    1019974    09/27/16
Endologix, Inc.    Peru    XPAND    601318    12/29/14    00223114    04/22/15
Endologix, Inc.    Singapore    DURAPLY    40201513229    02/10/15    40201513229    01/06/16
Endologix, Inc.    Singapore    INTELIX    40201508694    12/19/14    40201508694    11/11/15
Endologix, Inc.    Taiwan    DURAPLY    104008448    02/11/15    1764288    04/16/16
Endologix, Inc.    Taiwan    INTELIX    103072703    12/18/14    1740066    11/16/15
Endologix, Inc.    Thailand    DURAPLY    973443    02/11/15    171110590    09/28/17
Endologix, Inc.    Thailand    INTELIX    966979    12/19/14      
Endologix, Inc.    Thailand    INTELIX    966980    12/19/14      
Endologix, Inc.    United Kingdom    POWERLINK    2369587    09/13/99    2369587    12/09/05
Endologix, Inc.    Venezuela    XPAND    20754-14    12/30/14    P352404    06/07/16
Endologix, Inc.    Vietnam    DURAPLY    1257411    02/10/15    1257411    11/03/16


Endologix, Inc.    Vietnam    INTELIX    1247823    12/19/14    1247823    05/21/15
Endologix, Inc.    U.S.    ALTO    87/906,099    5/3/2018      
Endologix, Inc.    U.S.    VERTA    87/116,482    7/26/2016      
TriVascular, Inc.    U.S.    ALLEGRO    86/758,465    9/16/2015      
TriVascular, Inc.    U.S.    CUSTOMSEAL    86/047,875    8/26/2013    4,732,342    5/5/2015
TriVascular, Inc.    U.S.    OVATION    77/941,535    2/22/2010    4,440,468    11/26/2013
TriVascular, Inc.    U.S.    OVATION ALTO    86/047,894    8/26/2013    5,195,890    5/2/2017
TriVascular, Inc.    U.S.    OVATION PRIME    85/900,037    4/10/2013    4,452,625    12/17/2013
TriVascular, Inc.    U.S.    LOGO    85/832,445    1/25/2013    4,449,077    12/10/2013
TriVascular, Inc.    U.S.    TRIVASCULAR    75/879,907    12/21/1999    2,867,015    7/27/2004
TriVascular, Inc.    U.S.    LOGO    85/831,355    1/24/2013    4,395,789    9/3/2013
TriVascular, Inc.    Australia    CUSTOMSEAL    1608471    2/27/2014    1608471    1/21/2015
TriVascular, Inc.    Australia    OVATION    1379343    8/20/2010    1379343    1/10/2011
TriVascular, Inc.    Australia    OVATION ALTO    1608211    2/26/2014    1608211    5/28/2014
TriVascular, Inc.    Australia    OVATION PRIME    1583683    10/2/2013    1583683    1/7/2014
TriVascular, Inc.    Australia    LOGO    1537921    1/29/2013    1537921    7/31/2013
TriVascular, Inc.    Australia    TRIVASCULAR    888603    9/7/2001    888603    9/7/2001


TriVascular, Inc.    Australia    LOGO    983475    12/30/2003    983475    8/16/2004


TriVascular, Inc.    Brazil    CUSTOMSEAL    840.803.346    2/26/2014    840803346    10/18/2016
TriVascular, Inc.    Brazil    OVATION    830727035    8/20/2010    830727035    1/6/2015
TriVascular, Inc.    Brazil    OVATION ALTO    840.803.419    2/26/2014      
TriVascular, Inc.    Brazil    OVATION PRIME    840.666.152    10/4/2013    840666152    8/23/2016
TriVascular, Inc.    Brazil    LOGO    830854487    11/24/2010    830854487    6/3/2014
TriVascular, Inc.    Canada    CUSTOMSEAL    1,665,277    2/25/2014      
TriVascular, Inc.    Canada    OVATION    1493184    8/20/2010    TMA858,759    8/28/2013
TriVascular, Inc.    Canada    OVATION ALTO    1,665,276    2/25/2014      
TriVascular, Inc.    Canada    OVATION PRIME    1,645,991    10/2/2013      
TriVascular, Inc.    Canada    LOGO    1,611,335    1/25/2013    TMA934,553    4/12/2016
TriVascular, Inc.    Canada    TRIVASCULAR    1,612,136    1/31/2013    TMA882,992    7/29/2014
TriVascular, Inc.    Canada    LOGO    1200748    12/30/2003    TMA825955    6/8/2012
TriVascular, Inc.    China    CUSTOMSEAL    14075157    2/26/2014    14075157    4/28/2015
TriVascular, Inc.    China    OVATION    8598413    8/23/2010    8598413    11/7/2011
TriVascular, Inc.    China    OVATION ALTO    14075158    2/26/2014    14075158    4/28/2015
TriVascular, Inc.    China    OVATION PRIME    13321289    10/8/2013    13321289    6/21/2015


TriVascular, Inc.    China    LOGO    8898103    11/30/2010    8898103    12/14/2011


TriVascular, Inc.    EUTM    OVATION    009325234    8/20/2010    009325234    2/3/2011
TriVascular, Inc.    EUTM    OVATION ALTO    012636908    2/25/2014    012636908    7/16/2014
TriVascular, Inc.    EUTM    OVATION PRIME    012189148    10/2/2013    012189148    2/26/2014
TriVascular, Inc.    EUTM    LOGO    011523305    1/28/2013    011523305    6/24/2013
TriVascular, Inc.    EUTM    TRIVASCULAR    002374593    9/13/2001    002374593    3/12/2003
TriVascular, Inc.    EUTM    LOGO    003598836    12/31/2003    003598836    4/29/2005
TriVascular, Inc.    EUTM    TRIVASCULAR2 &
Design
   007457344    11/27/2008    007457344    6/16/2009
TriVascular, Inc.    India    OVATION    2012141    8/20/2010    2012141    8/23/2016
TriVascular, Inc.    India    LOGO    2060383    11/29/2010    2060383    11/29/2010
TriVascular, Inc.    Japan    CUSTOMSEAL    2014-14237    2/26/2014    5672406    5/23/2014
TriVascular, Inc.    Japan    OVATION    2010-065871    8/20/2010    5614976    9/13/2013
TriVascular, Inc.    Japan    OVATION ALTO    2014-14238    2/26/2014    5672407    5/23/2014
TriVascular, Inc.    Japan    OVATION PRIME    2013-024875    4/4/2013    5613251    9/6/2013
TriVascular, Inc.    Japan    LOGO    2013-5504    1/30/2013    5643434    1/17/2014
TriVascular, Inc.    Japan    TRIVASCULAR    2001-115594    12/27/2001    4731627    12/5/2003
TriVascular, Inc.    Japan    LOGO    2004-030615    3/18/2004    4778040    6/11/2004


TriVascular, Inc.    Mexico    OVATION    1113689    8/20/2010    1235645    8/20/2010
TriVascular, Inc.    Mexico    LOGO    1139285    12/2/2010    1213946    4/27/2011